open-data

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by sex, age group, and jurisdiction of occurrence.

Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html).

Deaths involving coronavirus disease 2019 (COVID-19) with a focus on ages 0-18 years in the United States.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

The following apply to all three datasets: Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.Some data cells are suppressed to protect individual privacy.The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.Datasets are updated monthly.Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and aut

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This dataset shows health conditions and contributing causes mentioned in conjunction with deaths involving coronavirus disease 2019 (COVID-19) by age group and jurisdiction of occurrence.

2022 and 2023 data are provisional. Estimates for 2020 and 2021 are based on final data.

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Pfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hgg

Moderna Vaccine Data- https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Provisional counts of deaths by the week the deaths occurred, by state of occurrence, and by select underlying causes of death for 2020-2023. The dataset also includes weekly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

NOTE: death counts are presented with a one week lag.

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Moderna Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

HHS is providing support to healthcare providers fighting the coronavirus disease 2019 (COVID-19) pandemic through the bipartisan Coronavirus Aid, Relief, & Economic Security (CARES) Act; the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act, which provide a total of $178 billion for relief funds to hospitals and other healthcare providers on the front lines of the COVID-19 response. This funding supports healthcare-related expenses or lost revenue attributable to COVID-19 and ensures uninsured Americans can get treatment for COVID-19. HHS is distributing this Provider Relief Fund (PRF) money and these payments do not need to be repaid.

The Department allocated $50 billion in PRF payments for general distribution to Medicare facilities and providers impacted by COVID-19, based on eligible providers' net reimbursement. HHS has made other PRF distributions to a wide array of health care providers and more information on those distributions can be found here: https://www.hhs.gov/coronavirus/cares-act-provider-relief-fund/data/index.html

Effective September 27, 2023, this dataset will be updated weekly on Thursdays.

Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by week ending date and by state

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

This archived public use dataset has 11 data elements reflecting United States COVID-19 community levels for all available counties.

The COVID-19 community levels were developed using a combination of three metrics — new COVID-19 admissions per 100,000 population in the past 7 days, the percent of staffed inpatient beds occupied by COVID-19 patients, and total new COVID-19 cases per 100,000 population in the past 7 days. The COVID-19 community level was determined by the higher of the new admissions and inpatient beds metrics, based on the current level of new cases per 100,000 population in the past 7 days. New COVID-19 admissions and the percent of staffed inpatient beds occupied represent the current potential for strain on the health system. Data on new cases acts as an early warning indicator of potential increases in health system strain in the event of a COVID-19 surge.

Using these data, the COVID-19 community level was classified as low, medium, or high.

COVID-19 Community Levels were used to help communities and individuals make decisions based on their local context and their unique needs. Community vaccination coverage and other local information, like early alerts from surveillance, such as through wastewater or the number of emergency department visits for COVID-19, when available, can also inform decision making for health officials and individuals.

For the most accurate and up-to-date data for any county or state, visit the relevant health department website. COVID Data Tracker may display data that differ from state and local websites. This can be due to differences in how data were collected, how metrics were calculated, or the timing of web updates.

Archived Data Notes:

This dataset was renamed from "United States COVID-19 Community Levels by County as Originally Posted" to "United States COVID-19 Community Levels by County" on March 31, 2022.

March 31, 2022: Column name for county population was changed to “county_population”. No change was made to the data points previous released.

March 31, 2022: New column, “health_service_area_population”, was added to the dataset to denote the total population in the designated Health Service Area based on 2019 Census estimate.

March 31, 2022: FIPS codes for territories American Samoa, Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands were re-formatted to 5-digit numeric for records released on 3/3/2022 to be consistent with other records in the dataset.

March 31, 2022: Changes were made to the text fields in variables “county”, “state”, and “health_service_area” so the formats are consistent across releases.

March 31, 2022: The “%” sign was removed from the text field in column “covid_inpatient_bed_utilization”. No change was made to the data. As indicated in the column description, values in this column represent the percentage of staffed inpatient beds occupied by COVID-19 patients (7-day average).

March 31, 2022: Data values for columns, “county_population”, “health_service_area_number”, and “health_service_area” were backfilled for records released on 2/24/2022. These columns were added since the week of 3/3/2022, thus the values were previously missing for records released the week prior.

April 7, 2022: Updates made to data released on 3/24/2022 for Guam, Commonwealth of the Northern Mariana Islands, and United States Virgin Islands to correct a data mapping error.

April 21, 2022: COVID-19 Community Level (CCL) data released for counties in Nebraska for the week of April 21, 2022 have 3 counties identified in the high category and 37 in the medium category. CDC has been working with state officials t

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Pfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hgg

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Overall US COVID-19 Vaccine administration and vaccine equity data at county level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Because inventory reporting is no longer required, Vaccines.gov information will not be updated on this site after July 2024.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 19 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors.

Currently, CDC provides the public with three versions of COVID-19 case surveillance line-listed data: this 19 data element dataset with geography, a 12 data element public use dataset, and a 33 data element restricted access dataset.

The following apply to the public use datasets and the restricted access dataset: Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.Some data are suppressed to protect individual privacy.Datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensure that time-dependent outcome data are accurately captured.Datasets are updated monthly.Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (<a href="https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/positionstatement2020/Interim-20-ID-01_COVID

Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html).

Deaths involving COVID-19 reported to NCHS by sex and age group and week ending date.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Estimates of excess deaths can provide information about the burden of mortality potentially related to COVID-19, beyond the number of deaths that are directly attributed to COVID-19. Excess deaths are typically defined as the difference between observed numbers of deaths and expected numbers. This visualization provides weekly data on excess deaths by jurisdiction of occurrence. Counts of deaths in more recent weeks are compared with historical trends to determine whether the number of deaths is significantly higher than expected.

Estimates of excess deaths can be calculated in a variety of ways, and will vary depending on the methodology and assumptions about how many deaths are expected to occur. Estimates of excess deaths presented in this webpage were calculated using Farrington surveillance algorithms (1). For each jurisdiction, a model is used to generate a set of expected counts, and the upper bound of the 95% Confidence Intervals (95% CI) of these expected counts is used as a threshold to estimate excess deaths. Observed counts are compared to these upper bound estimates to determine whether a significant increase in deaths has occurred. Provisional counts are weighted to account for potential underreporting in the most recent weeks. However, data for the most recent week(s) are still likely to be incomplete. Only about 60% of deaths are reported within 10 days of the date of death, and there is considerable variation by jurisdiction. More detail about the methods, weighting, data, and limitations can be found in the Technical Notes.

Overall US COVID-19 Vaccine deliveries and administration data at national and jurisdiction level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

This dataset provides a complete time history of metrics calculated using SARS-CoV-2 concentrations in wastewater.

Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html)

Provisional count of deaths involving COVID-19 by county of occurrence, in the United States, 2020-2023.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Provisional counts of deaths by the month the death occurred and by select causes of death for 2020-2023.

The COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program provides reimbursements on a rolling basis directly to eligible health care entities for claims that are attributed to the testing, treatment, and or vaccine administration of COVID-19 for uninsured individuals. The program funding information is as follow:

TESTING The American Rescue Plan Act (ARP) which provided $4.8 billion to reimburse providers for testing the uninsured; the Families First Coronavirus Response Act (FFCRA) Relief Fund, which includes funds received from the Public Health and Social Services Emergency Fund, as appropriated in the FFCRCA (P.L. 116-127) and the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) (PPPHCEA), which each appropriated $1 billion to reimburse health care entities for conducting COVID-19 testing for the uninsured.

TREATMENT & VACCINATION The Provider Relief Fund, which includes funds received from the Public Health and Social Services Emergency Fund, as appropriated in the Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136), provided $100 billion in relief funds. The PPPHCEA appropriated an additional $75 billion in relief funds and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act (P.L. 116-260) appropriated another $3 billion. Within the Provider Relief Fund, a portion of the funding from these sources will be used to support healthcare-related expenses attributable to the treatment of uninsured individuals with COVID-19 and vaccination of uninsured individuals. To learn more about the program, visit: https://www.hrsa.gov/CovidUninsuredClaim

This dataset represents the list of health care entities who have agreed to the Terms and Conditions and received claims reimbursement for COVID-19 testing of uninsured individuals, vaccine administration and treatment for uninsured individuals with a COVID-19 diagnosis.

For Provider Relief Fund Data - https://data.cdc.gov/Administrative/HHS-Provider-Relief-Fund/kh8y-3es6

After October 13, 2022, this dataset will no longer be updated as the related CDC COVID Data Tracker site was retired on October 13, 2022. This dataset contains historical trends in vaccinations and cases by age group, at the US national level. Data is stratified by at least one dose and fully vaccinated. Data also represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This data file contains the following indicators that can be used to illustrate potential differences in the burden of deaths due to COVID-19 according to race and ethnicity: count of COVID-19 deaths, distribution of COVID-19 deaths, unweighted distribution of population, and weighted distribution of population.

Related data CDC has been providing the public with two versions of COVID-19 county-level community transmission level data: this dataset with the daily values as originally posted on the COVID Data Tracker, and an historical dataset with daily data as well as the updates and corrections from state and local health departments. Similar to this dataset, the original historical dataset is archived on 10/20/2022. It will continue to be publicly available but will no longer be updated. A new dataset containing historical community transmission data by county is now published weekly and can be found at: Weekly COVID-19 County Level of Community Transmission Historical Changes | Data | Centers for Disease Control and Prevention (cdc.gov).

This public use dataset has 7 data elements reflecting community transmission levels for all available counties and jurisdictions. It contains reported daily transmission levels at the county level with the same values used to display transmission maps on the COVID Data Tracker. Each day, the dataset is appended to contain the most recent day's data. Transmission level is set to low, moderate, substantial, or high using the calculation rules below.

Methods for calculating county level of community transmission indicator The County Level of Community Transmission indicator uses two metrics: (1) total new COVID-19 cases per 100,000 persons in the last 7 days and (2) percentage of positive SARS-CoV-2 diagnostic nucleic acid amplification tests (NAAT) in the last 7 days. For each of these metrics, CDC classifies transmission values as low, moderate, substantial, or high (below and here). If the values for each of these two metrics differ (e.g., one indicates moderate and the other low), then the higher of the two should be used for decision-making.

CDC core metrics of and thresholds for community transmission levels of SARS-CoV-2

Total New Case Rate Metric: "New cases per 100,000 persons in the past 7 days" is calculated by adding the number of new cases in the county (or other administrative level) in the last 7 days divided by the population in the county (or other administrative level) and multiplying by 100,000. "New cases per 100,000 persons in the past 7 days" is considered to have a transmission level of Low (0-9.99); Moderate (10.00-49.99); Substantial (50.00-99.99); and High (greater than or equal to 100.00).

Test Percent Positivity Metric: "Percentage of positive NAAT in the past 7 days" is calculated by dividing the number of positive tests in the county (or other administrative level) during the last 7 days by the total number of tests conducted over the last 7 days. "Percentage of positive NAAT in the past 7 days" is considered to have a transmission level of Low (less than 5.00); Moderate (5.00-7.99); Substantial (8.00-9.99); and High (greater than or equal to 10.00).

If

Overall Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States at national level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

The bipartisan CARES Act; the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act provided $178 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response. The Department of Health and Human Services through the Health Resources and Services Administration is distributing two rounds of payments to hospitals in High Impact areas for positive COVID-19 admissions. In the first round of the High Impact Allocation, $12 billion was distributed to nearly 400 hospitals who provided inpatient care for 100 or more COVID-19 patients through April 10, 2020. $2 billion of these payments was distributed to these hospitals based on their Medicare disproportionate share and uncompensated care payments. In the second round of funding, $10 billion will be distributed to hospitals having over 161 COVID-19 admissions between January 1 and June 10, 2020.

Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html).

Cumulative deaths involving COVID-19 reported to NCHS by sex and age in years, in the United States.

Final counts of deaths by the week the deaths occurred, by state of occurrence, and by select causes of death for 2014-2019. Death counts in this dataset were derived from the National Vital Statistics System database that provides the most timely access to the data. Therefore, counts may differ slightly from final data due to differences in processing, recoding, and imputation.

Because inventory reporting is no longer required, Vaccines.gov information will not be updated on this site after July 2024.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Rate of deaths by age/sex (per 100,000 population) for motor vehicle occupants killed in crashes, 2012 & 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Safety Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.

Updated on April 28, 2025, to comply with the President’s Executive Order 14168.

Rate of deaths by age/sex (per 100,000 population) for people killed in crashes involving a driver with BAC =>0.08%, 2012. 2012 Source: Fatality Analysis Reporting System (FARS)Note: Blank cells indicate data are suppressed. 2014 Source: Source: National Highway Traffic Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File. Fatality rates based on fewer than 20 deaths are suppressed.

Updated on April 28, 2025, to comply with the President’s Executive Order 14168.

Rate of deaths by age/sex (per 100,000 population) for motor vehicle occupants killed in crashes, 2012 & 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Safety Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.

Updated on April 28, 2025, to comply with the President’s Executive Order 14168.

Effective June 28, 2023, this dataset will no longer be updated. Data deaths by place of death are available in this dataset https://data.cdc.gov/NCHS/d/4va6-ph5s.

Deaths involving COVID-19, pneumonia and influenza reported to NCHS by place of death and state, United States.

Reporting of new Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.

Aggregate Data Collection Process Since the start of the COVID-19 pandemic, data have been gathered through a robust process with the following steps: A CDC data team reviews and validates the information obtained from jurisdictions’ state and local websites via an overnight data review process. If more than one official county data source exists, CDC uses a comprehensive data selection process comparing each official county data source, and takes the highest case and death counts respectively, unless otherwise specified by the state. CDC compiles these data and posts the finalized information on COVID Data Tracker. County level data is aggregated to obtain state and territory specific totals. This process is collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provide the most up-to-date numbers on cases and deaths by report date. CDC may retrospectively update counts to correct data quality issues.

Methodology Changes Several differences exist between the current, weekly-updated dataset and the archived version: Source: The current Weekly-Updated Version is based on county-level aggregate count data, while the Archived Version is based on State-level aggregate count data. Confirmed/Probable Cases/Death breakdown:  While the probable cases and deaths are included in the total case and total death counts in both versions (if applicable), they were reported separately from the confirmed cases and deaths by jurisdiction in the Archived Version.  In the current Weekly-Updated Version, the counts by jurisdiction are not reported by confirmed or probable status (See Confirmed and Probable Counts section for more detail). Time Series Frequency: The current Weekly-Updated Version contains weekly time series data (i.e., one record per week per jurisdiction), while the Archived Version contains daily time series data (i.e., one record per day per jurisdiction). Update Frequency: The current Weekly-Updated Version is updated weekly, while the Archived Version was updated twice daily up to October 20, 2022. Important note: The counts reflected during a given time period in this dataset may not match the counts reflected for the same time period in the archived dataset noted above. Discrepancies may exist due to differences between county and state COVID-19 case surveillance and reconciliation efforts.

Confirmed and Probable Counts In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions report probable cases and deaths to CDC.* Confirmed and probable case definition criteria are described here:

Council of State and Territorial Epidemiologists (ymaws.com).

Deaths CDC reports death data on other sections of the website: CDC COVID Data Tracker: Home, CDC COVID Data Tracker: Cases, Deaths, and Testing, and NCHS Provisional Death Counts. Information presented on the COVID Data Tracker pages is based on the same source (to

This dataset includes data on adult's diet, physical activity, and weight status from Behavioral Risk Factor Surveillance System. This data is used for DNPAO's Data, Trends, and Maps database, which provides national and state specific data on obesity, nutrition, physical activity, and breastfeeding.

Overall Trends in Number of COVID-19 Vaccinations in the US at national and jurisdictional levels. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

This dataset presents the age-adjusted death rates for the 10 leading causes of death in the United States beginning in 1999.

Data are based on information from all resident death certificates filed in the 50 states and the District of Columbia using demographic and medical characteristics. Age-adjusted death rates (per 100,000 population) are based on the 2000 U.S. standard population. Populations used for computing death rates after 2010 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for non-census years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Causes of death classified by the International Classification of Diseases, Tenth Revision (ICD–10) are ranked according to the number of deaths assigned to rankable causes. Cause of death statistics are based on the underlying cause of death.

SOURCES CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.

2. Murphy SL, Xu JQ, Kochanek KD, Curtin SC, and Arias E. Deaths: Final data for 2015. National vital statistics reports; vol 66. no. 6. Hyattsville, MD: National Center for Health Statistics. 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19, pneumonia, and influenza reported to NCHS by race, age, and jurisdiction of occurrence.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This visualization provides weekly data on the number of deaths from all causes by jurisdiction of occurrence and age group. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This visualization provides weekly data on the number of deaths by jurisdiction of occurrence and cause of death. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected. Selected causes of death are shown, based on analyses of the most prevalent comorbid conditions reported on death certificates where COVID-19 was listed as a cause of death (see https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#Comorbidities). Cause of death counts are based on the underlying cause of death, and presented for Respiratory diseases, Circulatory diseases, Malignant neoplasms, and Alzheimer disease and dementia. Estimated numbers of deaths due to these other causes of death could represent misclassified COVID-19 deaths, or potentially could be indirectly related to COVID-19 (e.g., deaths from other causes occurring in the context of health care shortages or overburdened health care systems). Deaths with an underlying cause of death of COVID-19 are not included in these estimates of deaths due to other causes. Deaths due to external causes (i.e. injuries) or unknown causes are excluded. For more detail, see the Technical Notes.

This dataset is no longer updated. Please see the following datasets for recent data:

Provisional COVID-19 Deaths by Week (https://data.cdc.gov/dataset/Provisional-COVID-19-Death-Counts-by-Week-Ending-D/r8kw-7aab/)

Provisional COVID-19 Deaths by Sex, Age, and State (https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku)

2011 to present. BRFSS combined land line and cell phone prevalence data. BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. Data will be updated annually as it becomes available. Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf Glossary: https://data.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct

Source for 2012 national data: National Occupant Protection Use Survey (NOPUS), 2012. Source for 2014 national data: National Occupant Protection Use Survey (NOPUS), 2014. Source for 2012 state data: State Observational Survey of Seat Belt Use, 2012. Source for 2014 state data: Seat Belt Use in 2014- Use Rates in the States and Territories

This data presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. Counts for the most recent final annual data are provided for comparison. National provisional counts include deaths occurring within the 50 states and the District of Columbia as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts. To address this, methods were developed to adjust provisional counts for reporting delays by generating a set of predicted provisional counts.

Several data quality metrics, including the percent completeness in overall death reporting, percentage of deaths with cause of death pending further investigation, and the percentage of drug overdose deaths with specific drugs or drug classes reported are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts. Reporting of the specific drugs and drug classes involved in drug overdose deaths varies by jurisdiction, and comparisons of death rates involving specific drugs across selected jurisdictions should not be made. Provisional data presented will be updated on a monthly basis as additional records are received.

For more information please visit: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

The U.S. Department of Health and Human Services (HHS) via the Health Resources and Services Administration (HRSA) is releasing American Rescue Plan payments to providers and suppliers who have served rural Medicaid, Children's Health Insurance Program (CHIP), and Medicare beneficiaries from January 1, 2019 through September 30, 2020. The dataset will be updated as additional payments are released. Data does not reflect recipients’ attestation status, returned payments, or unclaimed funds.

This dataset contains model-based county estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. This dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related social needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2022 county population estimate data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

This is the complete dataset for the 500 Cities project 2019 release. This dataset includes 2017, 2016 model-based small area estimates for 27 measures of chronic disease related to unhealthy behaviors (5), health outcomes (13), and use of preventive services (9). Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. It represents a first-of-its kind effort to release information on a large scale for cities and for small areas within those cities. It includes estimates for the 500 largest US cities and approximately 28,000 census tracts within these cities. These estimates can be used to identify emerging health problems and to inform development and implementation of effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these measures include Behavioral Risk Factor Surveillance System (BRFSS) data (2017, 2016), Census Bureau 2010 census population data, and American Community Survey (ACS) 2013-2017, 2012-2016 estimates. Because some questions are only asked every other year in the BRFSS, there are 7 measures (all teeth lost, dental visits, mammograms, pap tests, colorectal cancer screening, core preventive services among older adults, and sleep less than 7 hours) from the 2016 BRFSS that are the same in the 2019 release as the previous 2018 release. More information about the methodology can be found at www.cdc.gov/500cities.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation—Youth Access. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to restrictions, enforcement and penalties associated with the sale of e-cigarettes to youth through retail sales and vending machines.

Provisional estimates of death rates. Estimates are presented for each of the 15 leading causes of death plus estimates for deaths attributed to drug overdose, falls (for persons aged 65 and over), human immunodeficiency virus (HIV) disease, homicide, and firearms-related deaths.

Related data CDC has been providing the public with two versions of COVID-19 county-level community transmission level data: this historical dataset with the daily county-level transmission data from January 22, 2020, and a dataset with the daily values as originally posted on the COVID Data Tracker. Similar to this dataset, the original dataset with daily data as posted is archived on 10/20/2022. It will continue to be publicly available but will no longer be updated. A new dataset containing community transmission data by county as originally posted is now published weekly and can be found at: Weekly COVID-19 County Level of Community Transmission as Originally Posted | Data | Centers for Disease Control and Prevention (cdc.gov).

This public use dataset has 7 data elements reflecting historical data for community transmission levels for all available counties and jurisdictions. It contains historical data for the county level of community transmission and includes updated data submitted by states and jurisdictions. Each day, the dataset was updated to include the most recent days’ data and incorporate any historical changes made by jurisdictions. This dataset includes data since January 22, 2020. Transmission level is set to low, moderate, substantial, or high using the calculation rules below.

Methods for calculating county level of community transmission indicator The County Level of Community Transmission indicator uses two metrics: (1) total new COVID-19 cases per 100,000 persons in the last 7 days and (2) percentage of positive SARS-CoV-2 diagnostic nucleic acid amplification tests (NAAT) in the last 7 days. For each of these metrics, CDC classifies transmission values as low, moderate, substantial, or high (below and here). If the values for each of these two metrics differ (e.g., one indicates moderate and the other low), then the higher of the two should be used for decision-making.

CDC core metrics of and thresholds for community transmission levels of SARS-CoV-2

Total New Case Rate Metric: "New cases per 100,000 persons in the past 7 days" is calculated by adding the number of new cases in the county (or other administrative level) in the last 7 days divided by the population in the county (or other administrative level) and multiplying by 100,000. "New cases per 100,000 persons in the past 7 days" is considered to have transmission level of Low (0-9.99); Moderate (10.00-49.99); Substantial (50.00-99.99); and High (greater than or equal to 100.00).

Test Percent Positivity Metric: "Percentage of positive NAAT in the past 7 days" is calculated by dividing the number of positive tests in the county (or other administrative level) during the last 7 days by the total number of tests resulted over the last 7 days. "Percentage of positive NAAT in the past 7 days" is considered to have transmission level of Low (less than 5.00); Moderate (5.00-7.99); Substa

The U.S. Census Bureau, in collaboration with five federal agencies, launched the Household Pulse Survey to produce data on the social and economic impacts of Covid-19 on American households. The Household Pulse Survey was designed to gauge the impact of the pandemic on employment status, consumer spending, food security, housing, education disruptions, and dimensions of physical and mental wellness.

The survey was designed to meet the goal of accurate and timely weekly estimates. It was conducted by an internet questionnaire, with invitations to participate sent by email and text message. The sample frame is the Census Bureau Master Address File Data. Housing units linked to one or more email addresses or cell phone numbers were randomly selected to participate, and one respondent from each housing unit was selected to respond for him or herself. Estimates are weighted to adjust for nonresponse and to match Census Bureau estimates of the population by age, sex, race and ethnicity, and educational attainment. All estimates shown meet the NCHS Data Presentation Standards for Proportions,

To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC's national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. Viral genomic sequences are analyzed and classified as a particular variant. The proportions of variants in a population are estimated nationally, by HHS region, and by jurisdiction. The thousands of sequences analyzed every week through CDC’s national genomic sequencing and bioinformatics efforts fuel this comprehensive and population-based U.S. surveillance system established to identify and monitor the spread of variants.

These data appear on the CDC COVID Data Tracker at the following URL: https://covid.cdc.gov/covid-data-tracker/#variant-proportions

For more information on how these data are generated and used to provide estimates of variant proportions, please see the following references:

Paul P, France AM, Aoki Y, et al. Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021. MMWR Morb Mortal Wkly Rep 2021;70:846–850. DOI: http://dx.doi.org/10.15585/mmwr.mm7023a3 Lambrou AS, Shirk P, Steele MK, et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:206–211. DOI: http://dx.doi.org/10.15585/mmwr.mm7106a4

1970-2019. Orzechowski and Walker. Tax Burden on Tobacco. Tax burden data was obtained from the annual compendium on tobacco revenue and industry statistics, The Tax Burden on Tobacco. Data are reported on an annual basis; Data include federal and state-level information regarding taxes applied to the price of a pack of cigarettes.

Percentages are weighted to population characteristics. Data are not available if it did not meet BRFSS stability requirements.For more information on these requirements, as well as risk factors and calculated variables, see the Technical Documents and Survey Data for a specific year - http://www.cdc.gov/brfss/annual_data/annual_data.htm.Recommended citation: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [appropriate year].

This dataset of U.S. mortality trends since 1900 highlights the differences in age-adjusted death rates and life expectancy at birth by race and sex.

Age-adjusted death rates (deaths per 100,000) after 1998 are calculated based on the 2000 U.S. standard population. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years between 2000 and 2010 are revised using updated intercensal population estimates and may differ from rates previously published. Data on age-adjusted death rates prior to 1999 are taken from historical data (see References below).

Life expectancy data are available up to 2017. Due to changes in categories of race used in publications, data are not available for the black population consistently before 1968, and not at all before 1960. More information on historical data on age-adjusted death rates is available at https://www.cdc.gov/nchs/nvss/mortality/hist293.htm.

SOURCES

CDC/NCHS, National Vital Statistics System, historical data, 1900-1998 (see https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm); CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. National Center for Health Statistics, Data Warehouse. Comparability of cause-of-death between ICD revisions. 2008. Available from: http://www.cdc.gov/nchs/nvss/mortality/comparability_icd.htm.

2. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.

3. Kochanek KD, Murphy SL, Xu JQ, Arias E. Deaths: Final data for 2017. National Vital Statistics Reports; vol 68 no 9. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf.

4. Arias E, Xu JQ. United States life tables, 2017. National Vital Statistics Reports; vol 68 no 7. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07-508.pdf.

5. National Center for Health Statistics. Historical Data, 1900-1998. 2009. Available from: https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

NNDSS - In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes: • These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/infectious-disease/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data.

• Notices, errata, and other notes are available in the Notice To Data Users page https://www.cdc.gov/nndss/infectious-disease/notice-to-data-users.html.

• The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes: *Case counts for reporting years 2024 and 2025 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). • Please refer to the Stacks publication for weekly updates to the footnote for influenza-associated pediatric mortality. U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

Deaths counts for influenza, pneumonia, and COVID-19 reported to NCHS by week ending date, by state and HHS region, and age group.

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

Weekly COVID-19 Community Levels (CCLs) have been replaced with levels of COVID-19 hospital admission rates (low, medium, or high) which demonstrate >99% concordance by county during February 2022–March 2023. For more information on the latest COVID-19 status levels in your area and hospital admission rates, visit United States COVID-19 Hospitalizations, Deaths, and Emergency Visits by Geographic Area.

This archived public use dataset contains historical case and percent positivity data updated weekly for all available counties and jurisdictions. Each week, the dataset was refreshed to capture any historical updates. Please note, percent positivity data may be incomplete for the most recent time period.

This archived public use dataset contains weekly community transmission levels data for all available counties and jurisdictions since October 20, 2022. The dataset was appended to contain the most recent week's data as originally posted on COVID Data Tracker. Historical corrections are not made to these data if new case or testing information become available. A separate archived file is made available here (: Weekly COVID-19 County Level of Community Transmission Historical Changes) if historically updated data are desired.

Related data CDC provides the public with two active versions of COVID-19 county-level community transmission level data: this dataset with the levels as originally posted (Weekly Originally Posted dataset), updated weekly with the most recent week’s data since October 20, 2022, and a historical dataset with the county-level transmission data from January 22, 2020 (Weekly Historical Changes dataset).

Methods for calculating county level of community transmission indicator The County Level of Community Transmission indicator uses two metrics: (1) total new COVID-19 cases per 100,000 persons in the last 7 days and (2) percentage of positive SARS-CoV-2 diagnostic nucleic acid amplification tests (NAAT) in the last 7 days. For each of these metrics, CDC classifies transmission values as low, moderate, substantial, or high (below and here). If the values for each of these two metrics differ (e.g., one indicates moderate and the other low), then the higher of the two should be used for decision-making.

CDC core metrics of and thresholds for community transmission levels of SARS-CoV-2 Total New Case Rate Metric: "New cases per 100,000 persons in the past 7 days" is calculated by adding the number of new cases in the county (or other administrative level) in the last 7 days divided by the population in the county (or other administrative level) and multiplying by 100,000. "New cases per 100,000 persons in the past 7 days" is considered to have a transmission level of Low (0-9.99); Moderate (10.00-49.99); Substantial (50.00-99.99); and High (greater than or equal to 100.00).

Test Percent Positivity Metric: "Percentage of positive NAAT in the past 7 days" is calculated by dividing the number of positive tests in the county (or other administrative level) during the last 7 days by the total number of tests conducted

The bipartisan CARES Act; and the Paycheck Protection Program and Health Care Enhancement Act (PPPHCEA); and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act provided $178 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response. The Department of Health and Human Services through the Health Resources and Services Administration is allocating $2 billion in incentive payments to nursing home facilities that reduce both COVID-19 infection rates relative to their county and mortality rates against a national benchmark.

2015-2022. This data set contains data from BRFSS.

The Public Health Emergency (PHE) declaration for COVID-19 expired on May 11, 2023. As a result, the Aggregate Case and Death Surveillance System will be discontinued. Although these data will continue to be publicly available, this dataset will no longer be updated.

On October 20, 2022, CDC began retrieving aggregate case and death data from jurisdictional and state partners weekly instead of daily.

This dataset includes the URLs that were used by the aggregate county data collection process that compiled aggregate case and death counts by county. Within this file, each of the states (plus select jurisdictions and territories) are listed along with the county web sources which were used for pulling these numbers. Some states had a single statewide source for collecting the county data, while other states and local health jurisdictions may have had standalone sources for individual counties. In the cases where both local and state web sources were listed, a composite approach was taken so that the maximum value reported for a location from either source was used. The initial raw data were sourced from these links and ingested into the CDC aggregate county dataset before being published on the COVID Data Tracker.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

County data on race and Hispanic origin is available for counties with more than 100 COVID-19 deaths. Deaths are cumulative from the week ending January 4, 2020 to the most recent reporting week, and based on county of occurrence. Data is provisional.

Urban-rural classification is based on the 2013 National Center for Health Statistics Urban-Rural Classification Scheme for Counties (https://www.cdc.gov/nchs/data_access/urban_rural.htm).

This dataset provides a complete time history of SARS-CoV-2 concentrations in wastewater for each sampling location.

This dataset includes crude birth rates and general fertility rates in the United States since 1909.

The number of states in the reporting area differ historically. In 1915 (when the birth registration area was established), 10 states and the District of Columbia reported births; by 1933, 48 states and the District of Columbia were reporting births, with the last two states, Alaska and Hawaii, added to the registration area in 1959 and 1960, when these regions gained statehood. Reporting area information is detailed in references 1 and 2 below. Trend lines for 1909–1958 are based on live births adjusted for under-registration; beginning with 1959, trend lines are based on registered live births.

NOTES: Figures include all revisions received from the states and, therefore, may differ from those previously published. Data are provisional and are subject to monthly reporting variation. National data are calculated by summing the number of events reported by state of residence; counts are rounded to the nearest thousand (births and deaths) or hundred (infant deaths). Provisional counts may differ by approximately 2% from final counts, due to rounding and reporting variation. Additionally, the accuracy of the provisional counts may change over time. Data are estimates by state of residence. For discussion of the nature, source, and limitations of the data, see "Technical Notes" of the report, Births, Marriages, Divorces, and Deaths: Provisional Data for 2009. Available from URL: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_25.htm. Final counts of births, deaths, and infant deaths for previous years can be obtained from http://wonder.cdc.gov.

SOURCE: Provisional data from the National Vital Statistics System, National Center for Health Statistics, CDC.

Disability and Health Data System (DHDS) is an online source of state-level data on adults with disabilities. Users can access information on six functional disability types: cognitive (serious difficulty concentrating, remembering or making decisions), hearing (serious difficulty hearing or deaf), mobility (serious difficulty walking or climbing stairs), vision (serious difficulty seeing), self-care (difficulty dressing or bathing) and independent living (difficulty doing errands alone).

This dataset contains model-based census tract estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related social needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

2011 to present. BRFSS SMART MMSA Prevalence combined land line and cell phone data. The Selected Metropolitan Area Risk Trends (SMART) project uses the Behavioral Risk Factor Surveillance System (BRFSS) to analyze the data of selected metropolitan statistical areas (MMSAs) with 500 or more respondents. BRFSS data can be used to identify emerging health problems, establish and track health objectives, and develop and evaluate public health policies and programs. BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. Data will be updated annually as it becomes available. Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf Glossary: https://data.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy.

To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates (https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data.

We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS) (https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates at the Public Use Microdata Areas (PUMA) level using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center(https://mcdc.missouri.edu/applications/geocorr2014.html). PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations.

The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31..

PUMA COVID-19 Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-Public-Use-Microdat/djj9-kh3p

Note: After May 3, 2024, this dataset will no longer be updated because hospitals are no longer required to report data on COVID-19 hospital admissions, hospital capacity, or occupancy data to HHS through CDC’s National Healthcare Safety Network (NHSN). The related CDC COVID Data Tracker site was revised or retired on May 10, 2023.

Note: May 3,2024: Due to incomplete or missing hospital data received for the April 21,2024 through April 27, 2024 reporting period, the COVID-19 Hospital Admissions Level could not be calculated for CNMI and will be reported as “NA” or “Not Available” in the COVID-19 Hospital Admissions Level data released on May 3, 2024.

This dataset represents COVID-19 hospitalization data and metrics aggregated to county or county-equivalent, for all counties or county-equivalents (including territories) in the United States. COVID-19 hospitalization data are reported to CDC’s National Healthcare Safety Network, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN and included in this dataset represent aggregated counts and include metrics capturing information specific to COVID-19 hospital admissions, and inpatient and ICU bed capacity occupancy.

Reporting information:As of December 15, 2022, COVID-19 hospital data are required to be reported to NHSN, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN represent aggregated counts and include metrics capturing information specific to hospital capacity, occupancy, hospitalizations, and admissions. Prior to December 15, 2022, hospitals reported data directly to the U.S. Department of Health and Human Services (HHS) or via a state submission for collection in the HHS Unified Hospital Data Surveillance System (UHDSS). While CDC reviews these data for errors and corrects those found, some reporting errors might still exist within the data. To minimize errors and inconsistencies in data reported, CDC removes outliers before calculating the metrics. CDC and partners work with reporters to correct these errors and update the data in subsequent weeks.Many hospital subtypes, including acute care and critical access hospitals, as well as Veterans Administration, Defense Health Agency, and Indian Health Service hospitals, are included in the metric calculations provided in this report. Psychiatric, rehabilitation, and religious non-medical hospital types are excluded from calculations. Data are aggregated and displayed for hospitals with the same Centers for Medicare and Medicaid Services (CMS) Certification Number (CCN), which are assigned by CMS to counties based on the CMS Provider of Services files. Full details on COVID-19 hospital data reporting guidance can be found here: https://www.hhs.gov/sites/default/files/covid-19-faqs-hospitals-hospital-laboratory-acute-care-facility-data-reporting.pdf Calculation of county-level hospital metrics:County-level hospital data are derived using calculations performed at the Health Service Area (HSA) level. An HSA is defined by CDC’s National Center for Health Statistics as a geographic area containing at least one county which is self-contained with respect to the population’s provision of routine hospital care. Every county in the United States is assigned to an HSA, and each HSA must contain at least one hospital. Therefore, use of HSAs in the calculation of local hospital metrics allows for more accurate characterization of the relationship between health care utilization and health status at the local level. Data presented at the county-level represent admissions, hospital inpatient and ICU bed capacity and occupancy among hosp

This file contains COVID-19 death counts, death rates, and percent of total deaths by jurisdiction of residence. The data is grouped by different time periods including 3-month period, weekly, and total (cumulative since January 1, 2020). United States death counts and rates include the 50 states, plus the District of Columbia and New York City. New York state estimates exclude New York City. Puerto Rico is included in HHS Region 2 estimates.

Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file.

Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death.

Death counts should not be compared across states. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly.

The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City, Puerto Rico; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.

Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf).

Rates are based on deaths occurring in the specified week/month and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly/monthly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly/monthly) rate prevailed for a full year.

Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).

2017, 2016. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census tract-level data in GIS-friendly format can be joined with census tract spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-Boundaries/x7zy-2xmx) in a geographic information system (GIS) to produce maps of 27 measures at the census tract level. There are 7 measures (all teeth lost, dental visits, mammograms, Pap tests, colorectal cancer screening, core preventive services among older adults, and sleep less than 7 hours) in this 2019 release from the 2016 BRFSS that were the same as the 2018 release.

1965, 1966, 1970, 1974-2015, 2017. Centers for Disease Control and Prevention (CDC). Office on Smoking and Health (OSH). Survey Questions (Tobacco Use). The QIT is a compilation of more than 7,000 historical tobacco-related survey questions from various state, national and international surveys.

2005-2009. SAMMEC - Smoking-Attributable Mortality, Morbidity, and Economic Costs. Smoking-attributable expenditures (SAEs) are excess health care expenditures attributable to cigarette smoking by type of service among adults ages 19 years of age and older.

We are releasing data that compares the HHS Provider Relief Fund and the CMS Accelerated and Advance Payments by State and provider as of May 15, 2020. This data is already available on other websites, but this chart brings the information together into one view for comparison. You can find additional information on the Accelerated and Advance Payments at the following links:

Fact Sheet: https://www.cms.gov/files/document/Accelerated-and-Advanced-Payments-Fact-Sheet.pdf;

Zip file on providers in each state: https://www.cms.gov/files/zip/accelerated-payment-provider-details-state.zip

Medicare Accelerated and Advance Payments State-by-State information and by Provider Type: https://www.cms.gov/files/document/covid-accelerated-and-advance-payments-state.pdf.

This file was assembled by HHS via CMS, HRSA and reviewed by leadership and compares the HHS Provider Relief Fund and the CMS Accelerated and Advance Payments by State and provider as of December 4, 2020.

HHS Provider Relief Fund President Trump is providing support to healthcare providers fighting the coronavirus disease 2019 (COVID-19) pandemic through the bipartisan Coronavirus Aid, Relief, & Economic Security Act and the Paycheck Protection Program and Health Care Enhancement Act, which provide a total of $175 billion for relief funds to hospitals and other healthcare providers on the front lines of the COVID-19 response. This funding supports healthcare-related expenses or lost revenue attributable to COVID-19 and ensures uninsured Americans can get treatment for COVID-19. HHS is distributing this Provider Relief Fund money and these payments do not need to be repaid. The Department allocated $50 billion of the Provider Relief Fund for general distribution to Medicare facilities and providers impacted by COVID-19, based on eligible providers' net reimbursement. It allocated another $22 billion to providers in areas particularly impacted by the COVID-19 outbreak, rural providers, and providers who serve low-income populations and uninsured Americans. HHS will be allocating the remaining funds in the near future.

As part of the Provider Relief Fund distribution, all providers have 45 days to attest that they meet certain criteria to keep the funding they received, including public disclosure. As of May 15, 2020, there has been a total of $34 billion in attested payments. The chart only includes those providers that have attested to the payments by that date. We will continue to update this information and add the additional providers and payments once their attestation is complete.

CMS Accelerated and Advance Payments Program On March 28, 2020, to increase cash flow to providers of services and suppliers impacted by the coronavirus disease 2019 (COVID-19) pandemic, the Centers for Medicare & Medicaid Services (CMS) expanded the Accelerated and Advance Payment Program to a broader group of Medicare Part A providers and Part B suppliers. Beginning on April 26, 2020, CMS stopped accepting new applications for the Advance Payment Program, and CMS began reevaluating all pending and new applications for Accelerated Payments in light of the availability of direct payments made through HHS’s Provider Relief Fund.

Since expanding the AAP program on March 28, 2020, CMS approved over 21,000 applications totaling $59.6 billion in payments to Part A providers, which includes hospitals, through May 18, 2020. For Part B suppliers—including doctors, non-physician practitioners and durable medical equipment suppliers— during the same time period, CMS approved almost 24,000 applications advancing $40.4 billion in payments. The AAP program is not a grant, and providers and suppliers are required to repay the loan.

CMS has published AAP data, as required by the Continuing Appropriations and Other Extensions Act of 2021, on this website: https://www.cms.gov/files/document/covid-medicare-accelerated-and-advance-payments-program-covid-19-public-health-emergency-payment.pdf

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation – Smokefree Campuses. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include state smokefree indoor air policies in areas such as: Smokefree campuses for private and public colleges and schools (K-12).

NSSP Emergency Department (ED) Visit Trajectories by State and Sub-State Regions- COVID-19, Flu, RSV, Combined. This dataset provides the percentage of emergency department patient visits for the specified pathogen of all ED patient visits for the specified geographic part of the country that were observed for the given week from data submitted to the National Syndromic Surveillance Program (NSSP). In addition, the trend over time is characterized as increasing, decreasing or no change, with exceptions for when there are no data available, the data are too sparse, or there are not enough data to compute a trend. These data are to provide awareness of how the weekly trend is changing for the given geographic region. 

Note that the reported sub-state trends are from Health Service Areas (HSA) and the data reported from the health care facilities located within the given HSA. Health Service Areas are regions of one or more counties that align to patterns of care seeking. The HSA level data are reported for each county in the HSA.

More information on HSAs is available here.

For the emergency department time series, trajectory classifications reported on for sub-state (HSA) emergency department time series, trajectory classifications are based on approximations of the first derivative (slope) of trends that are smoothed using generalized additive models (GAMs). To determine time intervals in which the slope is sufficiently changing (i.e., rate of change distinguishable from 0), 95% confidence intervals for the slope approximations are calculated and assessed. Weeks with a 95% confidence interval not containing 0 are classified as increasing if the slope estimate is positive and decreasing if the slope estimate is negative. Weeks with a 95% confidence interval containing 0 are classified as stable. In the scenario that an HSA's time series is determined to be too sparse (i.e., many weeks with percentages of 0%), a model is not fit, and the HSA is classified as “sparse”.

For additional information, please see: Companion Guide: NSSP Emergency Department Data on Respiratory Illness

Updated once per week on Fridays. 

This dataset includes birth rates for unmarried women by age group, race, and Hispanic origin in the United States since 1970.

Methods for collecting information on marital status changed over the reporting period and have been documented in:

• Ventura SJ, Bachrach CA. Nonmarital childbearing in the United States, 1940–99. National vital statistics reports; vol 48 no 16. Hyattsville, Maryland: National Center for Health Statistics. 2000. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr48/nvs48_16.pdf. • National Center for Health Statistics. User guide to the 2013 natality public use file. Hyattsville, Maryland: National Center for Health Statistics. 2014. Available from: http://www.cdc.gov/nchs/data_access/VitalStatsOnline.htm.

National data on births by Hispanics origin exclude data for Louisiana, New Hampshire, and Oklahoma in 1989; for New Hampshire and Oklahoma in 1990; for New Hampshire in 1991 and 1992. Information on reporting Hispanic origin is detailed in the Technical Appendix for the 1999 public-use natality data file (see (ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/Nat1999doc.pdf.)

All birth data by race before 1980 are based on race of the child. Starting in 1980, birth data by race are based on race of the mother.

For more information about the Pregnancy Risk Assessment Monitoring System please visit http://www.cdc.gov/prams/. See http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6107a1.htm?s_cid=mm6107a1_e for the MMWR article.

This dataset describes drug poisoning deaths at the county level by selected demographic characteristics and includes age-adjusted death rates for drug poisoning from 1999 to 2015.

Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are defined as having ICD–10 underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent).

Estimates are based on the National Vital Statistics System multiple cause-of-death mortality files (1). Age-adjusted death rates (deaths per 100,000 U.S. standard population for 2000) are calculated using the direct method. Populations used for computing death rates for 2011–2015 are postcensal estimates based on the 2010 U.S. census. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Estimate does not meet standards of reliability or precision. Death rates are flagged as “Unreliable” in the chart when the rate is calculated with a numerator of 20 or less.

Death rates for some states and years may be low due to a high number of unresolved pending cases or misclassification of ICD–10 codes for unintentional poisoning as R99, “Other ill-defined and unspecified causes of mortality” (2). For example, this issue is known to affect New Jersey in 2009 and West Virginia in 2005 and 2009 but also may affect other years and other states. Estimates should be interpreted with caution.

Smoothed county age-adjusted death rates (deaths per 100,000 population) were obtained according to methods described elsewhere (3–5). Briefly, two-stage hierarchical models were used to generate empirical Bayes estimates of county age-adjusted death rates due to drug poisoning for each year during 1999–2015. These annual county-level estimates “borrow strength” across counties to generate stable estimates of death rates where data are sparse due to small population size (3,5). Estimates are unavailable for Broomfield County, Colo., and Denali County, Alaska, before 2003 (6,7). Additionally, Bedford City, Virginia was added to Bedford County in 2015 and no longer appears in the mortality file in 2015. County boundaries are consistent with the vintage 2005-2007 bridged-race population file geographies (6).

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19, influenza, and pneumonia reported to NCHS by jurisdiction of occurrence, place of death, and age group.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

TABLE III. Deaths in 122 U.S. cities – 2016. 122 Cities Mortality Reporting System — Each week, the vital statistics offices of 122 cities across the United States report the total number of death certificates processed and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group (Under 28 days, 28 days –1 year, 1-14 years, 15-24 years, 25-44 years, 45-64 years, 65-74 years, 75-84 years, and ≥ 85 years).

FOOTNOTE: U: Unavailable. —: No reported cases.

• Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

† Pneumonia and influenza.

§ Total includes unknown ages.

In general, total combined rates for traumatic brain injury (TBI)-related emergency department (ED) visits, hospitalizations and deaths have increased over the past decade. Total combined rates of TBI-related hospitalizations, ED visits, and deaths climbed slowly from a rate of 521.0 per 100,000 in 2001 to 615.7 per 100,000 in 2005. The rates then dipped to 595.1 per 100,000 in 2006 and 566.7 per 100,000 in 2007. The rates then spiked sharply in 2008 and continued to climb through 2010 to a rate of 823.7 per 100,000. Total combined rates of TBI-related hospitalizations, ED visits, and deaths are driven in large part by the relatively high number of TBI-related ED visits. In comparison to ED visits, the overall rates of TBI-related hospitalizations remained relatively stable changing from 82.7 per 100,000 in 2001 to 91.7 per 100,000 in 2010. TBI-related deaths also decreased slightly over time from 18.5 per 100,000 in 2001 to 17.1 per 100,000 in 2010. Note that the axis scale for TBI-related deaths appears to the right of the chart and differs from TBI-related hospitalizations and ED visits.Go to http://www.cdc.gov/traumaticbraininjury/data/index.html to view more TBI data & statistics.

Weekly data on the number of deaths from all causes by sex, age group, and race/Hispanic origin group for the United States. Counts of deaths in more recent weeks can be compared with counts from earlier years (2015-2019) to determine if the number is higher than expected.

This dataset includes select data from the U.S. Census Bureau's American Community Survey (ACS) on the percent of adults who bike or walk to work. This data is used for DNPAO's Data, Trends, and Maps database, which provides national and state specific data on obesity, nutrition, physical activity, and breastfeeding. For more information about ACS visit https://www.census.gov/programs-surveys/acs/.

This site provides data for select demographic characteristics (age, sex, and age by sex) of people receiving COVID-19 vaccinations in the United States at the national and jurisdictional levels. For national race/ethnicity data, please visit COVID-19 Vaccination Demographics in the United States,National. For jurisdictional race/ethnicity data, please visit the relevant health department website if available.

Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities. 

This dataset includes data on weight status for children aged 3 months to 4 years old from Women, Infant, and Children Participant and Program Characteristics (WIC-PC). This data is used for DNPAO's Data, Trends, and Maps database, which provides national and state specific data on obesity, nutrition, physical activity, and breastfeeding. For more information about WIC-PC visit https://www.fns.usda.gov/wic/national-survey-wic-participants.

This dataset contains information on the number of deaths and age-adjusted death rates for the five leading causes of death in 1900, 1950, and 2000.

Age-adjusted death rates (deaths per 100,000) after 1998 are calculated based on the 2000 U.S. standard population. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years between 2000 and 2010 are revised using updated intercensal population estimates and may differ from rates previously published. Data on age-adjusted death rates prior to 1999 are taken from historical data (see References below).

SOURCES

CDC/NCHS, National Vital Statistics System, historical data, 1900-1998 (see https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm); CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. National Center for Health Statistics, Data Warehouse. Comparability of cause-of-death between ICD revisions. 2008. Available from: http://www.cdc.gov/nchs/nvss/mortality/comparability_icd.htm.

2. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.

3. Kochanek KD, Murphy SL, Xu JQ, Arias E. Deaths: Final data for 2017. National Vital Statistics Reports; vol 68 no 9. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf.

4. Arias E, Xu JQ. United States life tables, 2017. National Vital Statistics Reports; vol 68 no 7. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07-508.pdf.

5. National Center for Health Statistics. Historical Data, 1900-1998. 2009. Available from: https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm.

Provisional counts of deaths by the month the deaths occurred, by age group and HHS region, for select underlying causes of death for 2019-2020. The dataset also includes monthly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This visualization provides data that can be used to illustrate potential differences in the burden of deaths due to COVID-19 by race and ethnicity.

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

This visualization provides weekly data on the number of deaths from all causes by jurisdiction of occurrence and race and Hispanic origin. Numbers of deaths are also shown for all causes excluding COVID-19, and for COVID-19. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected.

Note: After November 1, 2024, this dataset will no longer be updated due to a transition in NHSN Hospital Respiratory Data reporting that occurred on Friday, November 1, 2024. For more information on NHSN Hospital Respiratory Data reporting, please visit https://www.cdc.gov/nhsn/psc/hospital-respiratory-reporting.html.

Due to a recent update in voluntary NHSN Hospital Respiratory Data reporting that occurred on Wednesday, October 9, 2024, reporting levels and other data displayed on this page may fluctuate week-over-week beginning Friday, October 18, 2024. For more information on NHSN Hospital Respiratory Data reporting, please visit https://www.cdc.gov/nhsn/psc/hospital-respiratory-reporting.html. Find more information about the updated CMS requirements: https://www.federalregister.gov/documents/2024/08/28/2024-17021/medicare-and-medicaid-programs-and-the-childrens-health-insurance-program-hospital-inpatient. 

This dataset represents weekly respiratory virus-related hospitalization data and metrics aggregated to national and state/territory levels reported during two periods: 1) data for collection dates from August 1, 2020 to April 30, 2024, represent data reported by hospitals during a mandated reporting period as specified by the HHS Secretary; and 2) data for collection dates beginning May 1, 2024, represent data reported voluntarily by hospitals to CDC’s National Healthcare Safety Network (NHSN). NHSN monitors national and local trends in healthcare system stress and capacity for up to approximately 6,000 hospitals in the United States. Data reported represent aggregated counts and include metrics capturing information specific to COVID-19- and influenza-related hospitalizations, hospital occupancy, and hospital capacity. Find more information about reporting to NHSN at: https://www.cdc.gov/nhsn/psc/hospital-respiratory-reporting.html.

Source: COVID-19 hospitalization data reported to CDC’s National Healthcare Safety Network (NHSN). Data source description (updated October 18, 2024): As of October 9, 2024, Hospital Respiratory Data (HRD; formerly Respiratory Pathogen, Hospital Capacity, and Supply data or ‘COVID-19 hospital data’) are reported to HHS through CDC’s National Healthcare Safety Network based on updated requirements from the Centers for Medicare and Medicaid Services (CMS). These data are voluntarily reported to NHSN as of May 1, 2024 until November 1, 2024, at which time CMS will require acute care and critical access hospitals to electronically report information via NHSN about COVID-19, Influenza, and RSV, hospital bed census and capacity, and limited patient demographic information, including age. Data for collection dates prior to May 1, 2024, represent data reported during a previously mandated reporting period as specified by the HHS Secretary. Data for collection dates May 1, 2024, and onwards represent data reported voluntarily to NHSN; as such, data included represents reporting hospitals only for a given week and might not be complete or representative of all hospitals. NHSN monitors national and local trends in healthcare system stress and capacity for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN represent aggregated counts and include metrics capturing information specific to hospital capacity, occupancy, hospitalizations, and admissions. Find more information about reporting to NHSN: https://www.cdc.gov/nhsn/psc/hospital-respiratory-reporting.html. Find more information about the updated CMS requirements: https://www.federalregister.gov/documents/2024/08/28/2024-17021/medicare-and-medicaid-programs-and-the-childrens-health-insurance-program-hospital-inpatient.  Data quality: While CDC reviews reported data for completeness and errors and corrects those found, some reporting errors might still exist within the data. CDC and partners work with reporters to correct these errors and update the data in subse

As part of an ongoing partnership with the Census Bureau, the National Center for Health Statistics (NCHS) recently added questions to assess the prevalence of post-COVID-19 conditions (long COVID), on the experimental Household Pulse Survey. This 20-minute online survey was designed to complement the ability of the federal statistical system to rapidly respond and provide relevant information about the impact of the coronavirus pandemic in the U.S. Data collection began on April 23, 2020. Beginning in Phase 3.5 (on June 1, 2022), NCHS included questions about the presence of symptoms of COVID that lasted three months or longer. Phase 3.5 will continue with a two-weeks on, two-weeks off collection and dissemination approach.

Estimates on this page are derived from the Household Pulse Survey and show the percentage of adults aged 18 and over who a) as a proportion of the U.S. population, the percentage of adults who EVER experienced post-COVID conditions (long COVID). These adults had COVID and had some symptoms that lasted three months or longer; b) as a proportion of adults who said they ever had COVID, the percentage who EVER experienced post-COVID conditions; c) as a proportion of the U.S. population, the percentage of adults who are CURRENTLY experiencing post-COVID conditions. These adults had COVID, had long-term symptoms, and are still experiencing symptoms; d) as a proportion of adults who said they ever had COVID, the percentage who are CURRENTLY experiencing post-COVID conditions; and e) as a proportion of the U.S. population, the percentage of adults who said they ever had COVID.

2008-2024. American Lung Association. Cessation Coverage. Medicaid data compiled by the Centers for Disease Control and Prevention’s Office on Smoking and Health were obtained from the State Tobacco Cessation Coverage Database, developed and administered by the American Lung Association. Data from 2008-2012 are reported on an annual basis; beginning in 2013 data are reported on a quarterly basis. Data include state-level information on Medicaid coverage of approved medications by the Food and Drug Administration (FDA) for tobacco cessation treatment; types of counseling recommended by the Public Health Service (PHS) and barriers to accessing cessation treatment. Note: Section 2502 of the Patient Protection and Affordable Care Act requires all state Medicaid programs to cover all FDA-approved tobacco cessation medications as of January 1, 2014. However, states are currently in the process of modifying their coverage to come into compliance with this requirement. Data in the STATE System on Medicaid coverage of tobacco cessation medications reflect evidence of coverage that is found in documentable sources, and may not yet reflect medications covered under this requirement.

This dataset includes birth rates for females by age group in the United States since 1940.

The number of states in the reporting area differ historically. In 1915 (when the birth registration area was established), 10 states and the District of Columbia reported births; by 1933, 48 states and the District of Columbia were reporting births, with the last two states, Alaska and Hawaii, added to the registration area in 1959 and 1960, when these regions gained statehood. Reporting area information is detailed in references 1 and 2 below. Trend lines for 1909–1958 are based on live births adjusted for under-registration; beginning with 1959, trend lines are based on registered live births.

The National Hospital Care Survey (NHCS) collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States. Settings currently include inpatient and emergency departments (ED). Additionally, the NHCS contributes data that may inform public health emergencies as the survey is designed to capture emerging diseases and viruses that require hospitalizations, including COVID-19 encounters. The 2020 - 2023 NHCS are not yet fully operational so it is important to note that these data are not nationally representative.

The data are from 26 hospitals submitting inpatient and 26 hospitals submitting ED Uniform Bill (UB)-04 administrative claims from March 18, 2020-December 26, 2023. Even though the data are not nationally representative, they can provide insight on the impact of COVID-19 on various types of hospitals throughout the country. This information is not available in other hospital reporting systems. The NHCS data from these hospitals can show results by a combination of indicators related to COVID-19, such as length of inpatient stay, in-hospital mortality, comorbidities, and intubation or ventilator use. NHCS data allow for reporting on patient conditions and treatments within the hospital over time.

This dataset of U.S. mortality trends since 1900 highlights trends in age-adjusted death rates for five selected major causes of death.

Age-adjusted death rates (deaths per 100,000) after 1998 are calculated based on the 2000 U.S. standard population. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years between 2000 and 2010 are revised using updated intercensal population estimates and may differ from rates previously published. Data on age-adjusted death rates prior to 1999 are taken from historical data (see References below).

Revisions to the International Classification of Diseases (ICD) over time may result in discontinuities in cause-of-death trends.

SOURCES

CDC/NCHS, National Vital Statistics System, historical data, 1900-1998 (see https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm); CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. National Center for Health Statistics, Data Warehouse. Comparability of cause-of-death between ICD revisions. 2008. Available from: http://www.cdc.gov/nchs/nvss/mortality/comparability_icd.htm.

2. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.

3. Kochanek KD, Murphy SL, Xu JQ, Arias E. Deaths: Final data for 2017. National Vital Statistics Reports; vol 68 no 9. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf.

4. Arias E, Xu JQ. United States life tables, 2017. National Vital Statistics Reports; vol 68 no 7. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07-508.pdf.

5. National Center for Health Statistics. Historical Data, 1900-1998. 2009. Available from: https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm.

Vaccination Coverage among Young Children (0-35 Months)

• National, regional, state, and selected local area vaccination coverage estimates for 2-year-old children by birth year and birth year cohorts from the National Immunization Survey-Child.

• Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/index.html

Final counts of deaths by the month the deaths occurred and by select causes of death for 2014-2019.

Vaccination Coverage among Pregnant Women

• Data on influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination coverage at the state level from the Pregnancy Risk Assessment Monitoring System (PRAMS) for women who had a recent live birth by age and race/ethnicity.

• Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/index.html and https://www.cdc.gov/flu/fluvaxview/index.htm

Provisional estimates of selected reproductive indicators. Estimates are presented for: general fertility rates, age-specific birth rates, total and low risk cesarean delivery rates, preterm birth rates and other gestational age categories.

Changes in the rates of TBI-related deaths vary depending on age. For persons 44 years of age and younger, TBI-related deaths decreased between the periods of 2001-2002 and 2009-2010. Rates for age groups 45-64 years of age remained stable for this same ten-year period. For persons 65 years and older, rates of TBI-related deaths increased during this time period, from 41.2 to 45.2 deaths per 100,000.Go to http://www.cdc.gov/traumaticbraininjury/data/index.html to view more TBI data & statistics.Source: http://www.cdc.gov/traumaticbraininjury/data/rates_deaths_byage.html

Influenza Vaccination Coverage for All Ages (6+ Months)

• Data on influenza vaccination coverage from the National Immunization Survey-Flu (NIS-Flu) and the Behavioral Risk Factor Surveillance System (BRFSS) for the general population at the national, regional, and state levels by age group and race/ethnicity.

• Additional information available at https://www.cdc.gov/flu/fluvaxview/index.htm

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation – Smokefree Indoor Air. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to state legislation on smokefree indoor air in areas such as: Bars, Commercial Day Care Centers, Government Multi-Unit Housing, Government Worksites, Home-Based Day Care Centers, Hotels and Motels, Personal Vehicles, Private Multi-Unit Housing, Private Worksites, Restaurants, Bingo Halls, Casinos, Enclosed Arenas, Grocery Stores, Hospitals, Hospital Campuses, Malls, Mental Health Outpatient and Residential Facilities, Prisons, Public Transportation, Racetrack Casinos, Substance Abuse Outpatient and Residential Facilities.

Interactive Summary Health Statistics for Adults provide annual estimates of selected health topics for adults aged 18 years and over based on final data from the National Health Interview Survey.

This data table provides a collection of information from peer-reviewed autism prevalence studies. Information reported from each study includes the autism prevalence estimate and additional study characteristics (e.g., case ascertainment and criteria). A PubMed search was conducted to identify studies published at any time through September 2020 using the search terms: autism (title/abstract) OR autistic (title/abstract) AND prevalence (title/abstract). Data were abstracted and included if the study fulfilled the following criteria: • The study was published in English; • The study produced at least one autism prevalence estimate; and • The study was population-based (any age range) within a defined geographic area.

Percentages are weighted to population characteristics. Data are not available if it did not meet BRFSS stability requirements. For more information on these requirements, as well as risk factors and calculated variables, see the Technical Documents and Survey Data for a specific year - http://www.cdc.gov/brfss/annual_data/annual_data.htm. Recommended citation: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [appropriate year].

NNDSS - Table I. infrequently reported notifiable diseases - 2017. In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnote: —: No reported cases. N: Not reportable. NA: Not available. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts.

• Case counts for reporting year 2017 are provisional and subject to change. Data for years 2012 through 2016 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf.

† This table does not include cases from the U.S. territories. Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

§ Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf.

¶ Updated weekly reports from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.

** Not reportable in all jurisdictions. Data from states where the condition is not reportable are excluded from this table, except for the arboviral diseases and influenza-associated pediatric mortality. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html.

†† Data for Haemophilus influenzae (all ages, all serotypes) are available in Table II.

§§ In 2016, the nationally notifiable condition ‘Hepatitis B Perinatal Infection’ was renamed to ‘Perinatal Hepatitis B Virus Infection’ and reflects updates in the 2016 CSTE position statement for Perinatal Hepatitis B Virus Infection.

¶¶ Please refer to the MMWR publication for weekly updates to the footnote for this condition.

*** Please refer to the MMWR publication for weekly updates to the footnote for this condition.

††† Data for meningococcal disease (all serogroups) are available in Table II.

§§§ Novel influenza A virus infections are human infections with influenza A viruses that are different from currently circulating human seasonal influenza viruses. With the exception of one avian lineage influenza A (H7N2) virus, all novel influenza A virus infections reported to CDC since 2011 have been variant influenza viruses. Total case counts are provided by the Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD).

¶¶¶ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

** Prior to 2015, CDC's National Notifiable Diseases Surveillance System (NNDSS) did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead data were collected in aggregate as "viral hemorrhagic fevers". Beginning in 2015, NNDSS has been updated to receive data for each of

This dataset contains model-based census tract level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. These data can be joined with the Census tract 2022 boundary file in a GIS system to produce maps for 40 measures at the census tract level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7

Overall rates of TBI climbed slowly from 2001 through 2007, then spiked sharply in 2008 and continued to climb through 2010. The increase in TBI rates in 2008 was much sharper for men (nearly 40% increase) than for women (20% increase). In 2007, overall rates of TBI were 26% higher in men compared to women. In 2008, that gap began to widen, reaching 61% in 2009 before narrowing to 29% in 2010. Rates of overall TBI are largely driven by rates of TBI-related ED visits.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation—Licensure. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to requirements, restrictions and penalties associated with holding a retail license to sell tobacco products over-the-counter and through vending machines.

NNDSS - Table II. Giardiasis to Haemophilus influenza - 2014. In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (≥ 1,000 and ≤ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Data for H. influenzae (age <5 yrs serotype b, nonserotype b, and unknown serotype) are available in Table I.

More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

This dataset contains model-based ZIP Code Tabulation Area (ZCTA) level estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related scocial needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

CDC is working with commercial laboratories to conduct large-scale geographic seroprevalence surveys to estimate the percentage of people who were previously infected with SARS-CoV-2, the virus that causes COVID-19 disease. The strategy involves working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States using serology (antibody) testing for surveillance (“seroprevalence surveys” or “serosurveys”). For the surveys, de-identified clinical blood samples are tested for antibodies to SARS-CoV-2.

This dataset contains the data used to by the Nationwide Commercial Laboratory Seroprevalence Survey interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#national-lab.

Additional information is available at https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html.

2011 to 2012. BRFSS SMART County Prevalence combined land line and cell phone data. The Selected Metropolitan Area Risk Trends (SMART) project uses the Behavioral Risk Factor Surveillance System (BRFSS) to analyze the data of selected counties with 500 or more respondents. BRFSS data can be used to identify emerging health problems, establish and track health objectives, and develop and evaluate public health policies and programs. BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. Data will be updated annually as it becomes available. Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf Glossary: https://chronicdata.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19 reported to NCHS by time-period, HHS region, race and Hispanic origin, and age group.

United States death counts include the 50 states, plus the District of Columbia and New York City. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City, Puerto Rico; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation-Tax. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include state taxes on combustible (cigarettes, cigars, little cigars, pipe tobacco, and roll-your-own tobacco) tobacco products, non-combustible (snus, moist snuff, dry snuff, chewing tobacco) tobacco products, and tax stamps.

Interactive visualization: http://www.cdc.gov/chikungunya/modeling/index.html. This dataset contains monthly predictions for the spread of chikungunya virus transmission. A full description of the methods is available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0104915.

NNDSS - TABLE 1CC. Rabies, Animal to Rabies, Human - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

The U.S. Census Bureau, in collaboration with five federal agencies, launched the Household Pulse Survey to produce data on the social and economic impacts of Covid-19 on American households. The Household Pulse Survey was designed to gauge the impact of the pandemic on employment status, consumer spending, food security, housing, education disruptions, and dimensions of physical and mental wellness.

The survey was designed to meet the goal of accurate and timely weekly estimates. It was conducted by an internet questionnaire, with invitations to participate sent by email and text message. The sample frame is the Census Bureau Master Address File Data. Housing units linked to one or more email addresses or cell phone numbers were randomly selected to participate, and one respondent from each housing unit was selected to respond for him or herself. Estimates are weighted to adjust for nonresponse and to match Census Bureau estimates of the population by age, sex, race and ethnicity, and educational attainment. All estimates shown meet the NCHS Data Presentation Standards for Proportions.

Updated on 3/31/2025 to comply with the President’s Executive Order 14168.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

This dataset includes estimates of U.S. life expectancy at birth by state and census tract for the period 2010-2015 (1). Estimates were produced for 65,662 census tracts, covering the District of Columbia (D.C.) and all states, excluding Maine and Wisconsin, representing 88.7% of all U.S. census tracts (see notes). These estimates are the result of the collaborative project, “U.S. Small-area Life Expectancy Estimates Project (USALEEP),” between the National Center for Health Statistics (NCHS), the National Association for Public Health Statistics and Information Systems (NAPHSIS), and the Robert Wood Johnson Foundation (RWJF) (2).

The Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET) is a network that conducts active, population-based surveillance for laboratory-confirmed RSV-associated hospitalizations in children younger than 18 years of age and adults. RSV-NET, along with the Coronavirus Disease 2019 (COVID-19) Hospitalization Surveillance Network (COVID-NET) an the Influenza Hospitalization Surveillance network (FluSuv-NET), comprise the Respiratory Virus Hospitalization Surveillance Network (RESP-NET). The RESP-NET platforms have overlapping surveillance areas and use similar methods to collect data. Because the surveillance areas and age groups included in surveillance have changed over time, trends should be interpreted with caution. RSV-NET is CDC’s source for important data on rates of hospitalizations associated with RSV. Hospitalization rates show how many people in the surveillance area are hospitalized with RSV, compared to the total number of people residing in that area.

Data are preliminary and subject to change as more data become available. Data will be updated weekly.

NNDSS - TABLE 1PP. Viral hemorrhagic fevers, Sabia virus to Zika virus disease, non-congenital – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

Vaccination Coverage among Adolescents (13-17 Years)

• Data on adolescent vaccination coverage and selected sociodemographic characteristics by State, HHS Region, and the United States from the National Immunization Survey-Teen (NIS-Teen).

• Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/index.html

The Federal Pharmacy Partnership for Long-Term Care (LTC) Program was a partnership between CDC and CVS, Walgreens, and Managed Health Care Associates, Inc. The program offered on-site COVID-19 vaccination services for residents of nursing homes and assisted living facilities. The Federal Pharmacy Partnership for LTC Program was in effect after vaccines became available to April 23, 2021. This is the historical archived data related to the LTC Program and represents data that was shown on COVID Data Tracker through September 30, 2021. Twelve variables that provided data on residents and staff vaccinated through the program were removed from the COVID-19 Vaccinations in the United States,Jurisdiction dataset. LTC was removed as an option from the location variable in the following datasets: COVID-19 Vaccinations in the United States,Jurisdiction and COVID-19 Vaccination Trends in the United States,National and Jurisdictional.

NNDSS - Table II. Invasive Pneumococcal to Legionellosis - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as < 5 years. Since 2010, case notifications for this condition were consolidated under one event code for Invasive pneumococcal disease.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

NNDSS - TABLE 1JJ. Tuberculosis to Tularemia – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

NNDSS - TABLE 1MM. Viral hemorrhagic fevers, Chapare virus to Ebola virus – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

2005-2009. SAMMEC - Smoking-Attributable Mortality, Morbidity, and Economic Costs. Smoking-attributable mortality (SAM) is the number of deaths caused by cigarette smoking based on diseases for which the U.S. Surgeon General has determined that cigarette smoking is a causal factor.

This dataset describes drug poisoning deaths at the U.S. and state level by selected demographic characteristics, and includes age-adjusted death rates for drug poisoning.

Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are defined as having ICD–10 underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent).

Estimates are based on the National Vital Statistics System multiple cause-of-death mortality files (1). Age-adjusted death rates (deaths per 100,000 U.S. standard population for 2000) are calculated using the direct method. Populations used for computing death rates for 2011–2016 are postcensal estimates based on the 2010 U.S. census. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Death rates for some states and years may be low due to a high number of unresolved pending cases or misclassification of ICD–10 codes for unintentional poisoning as R99, “Other ill-defined and unspecified causes of mortality” (2). For example, this issue is known to affect New Jersey in 2009 and West Virginia in 2005 and 2009 but also may affect other years and other states. Drug poisoning death rates may be underestimated in those instances.

REFERENCES

1. National Center for Health Statistics. National Vital Statistics System: Mortality data. Available from: http://www.cdc.gov/nchs/deaths.htm.

2. CDC. CDC Wonder: Underlying cause of death 1999–2016. Available from: http://wonder.cdc.gov/wonder/help/ucd.html.

NNDSS - Table I. infrequently reported notifiable diseases - 2014.In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnote:-: No reported cases N: Not reportable NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. * Case counts for reporting year 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. ��� Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. �� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the Arboviral diseases, STD data, TB data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/document/SRCA_FINAL_REPORT_2006-2012_final.xlsx. �� Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Data for H. influenzae (all ages, all serotypes) are available in Table II. ��ʉ�� Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Please refer to the MMWR publication for weekly updates to the footnote for this condition. ���� Please refer to the MMWR publication for weekly updates to the footnote for this condition. ���� Data for meningococcal disease (all serogroups) are available in Table II. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition. ��ʉ�ʉ�� Please refer to the MMWR publication for weekly updates to the footnote for this condition. ������ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. ������ Please refer to the MMWR publication for weekly updates to the footnote for this condition. See Table II for Dengue Hemorrhagic Fever.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

NNDSS - TABLE 1II. Tetanus to Trichinellosis – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

NNDSS - TABLE 1KK. Vancomycin-intermediate Staphylococcus aureus to Varicella morbidity – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

NNDSS - TABLE 1OO. Viral hemorrhagic fevers, Lujo virus to Viral hemorrhagic fevers, Marburg virus – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents..

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

NNDSS - TABLE 1NN. Viral hemorrhagic fevers, Guanarito virus to Viral hemorrhagic fevers, Lassa virus – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

NNDSS - TABLE 1LL. Vibriosis, Confirmed to Vibriosis, Probable – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

• These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation—Smokefree Indoor Air. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to state legislation on smokefree indoor air in areas such as: Bars, Commercial Day Care Centers, Government Multi-Unit Housing, Government Worksites, Home-Based Day Care Centers, Hotels and Motels, Personal Vehicles, Private Multi-Unit Housing, Private Worksites, Restaurants, Bingo Halls, Casinos, Enclosed Arenas, Grocery Stores, Hospitals, Hospital Campuses, Malls, Mental Health Outpatient and Residential Facilities, Prisons, Public Transportation, Racetrack Casinos, Substance Abuse Outpatient and Residential Facilities.

The Environmental Protection Agency (EPA) provides air pollution data about ozone and particulate matter (PM2.5) to CDC for the Tracking Network. The EPA maintains a database called the Air Quality System (AQS) which contains data from approximately 4,000 monitoring stations around the country, mainly in urban areas. Data from the AQS is considered the "gold standard" for determining outdoor air pollution. However, AQS data are limited because the monitoring stations are usually in urban areas or cities and because they only take air samples for some air pollutants every three days or during times of the year when air pollution is very high. CDC and EPA have worked together to develop a statistical model (Downscaler) to make modeled predictions available for environmental public health tracking purposes in areas of the country that do not have monitors and to fill in the time gaps when monitors may not be recording data. This data does not include "Percent of population in counties exceeding NAAQS (vs. population in counties that either meet the standard or do not monitor PM2.5)". Please visit the Tracking homepage for this information.View additional information for indicator definitions and documentation by selecting Content Area "Air Quality" and the respective indicator at the following website: http://ephtracking.cdc.gov/showIndicatorsData.action

Respiratory illness activity is monitored using the acute respiratory illness (ARI) metric. ARI captures a broad range of diagnoses from emergency department visits for respiratory illnesses, from the common cold to severe infections like influenza, RSV and COVID-19. It captures illnesses that may not present with fever, offering a more complete picture than the previous influenza-like illness (ILI) metric.

Updated once per week on Fridays.

Rates are infants (under 1 year) and neonatal (under 28 days) deaths per 1,000 live births.

https://www.cdc.gov/nchs/data-visualization/mortality-trends/

Quarterly data on the number of deaths from all causes by state (of occurrence), sex, age group, and race/Hispanic origin group for the United States. Counts of deaths in more recent time periods can be compared with counts from earlier years (2015-2019) to determine if the number is higher than expected. Annual and cumulative counts (from Quarter 2, 2020 through the most recent quarter) are also shown.

2017, 2016. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project city-level data in GIS-friendly format can be joined with city spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-City-Boundaries/n44h-hy2j) in a geographic information system (GIS) to produce maps of 27 measures at the city-level. There are 7 measures (all teeth lost, dental visits, mammograms, Pap tests, colorectal cancer screening, core preventive services among older adults, and sleep less than 7 hours) in this 2019 release from the 2016 BRFSS that were the same as the 2018 release.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation—Preemption. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to statutory state preemption of more stringent local laws on advertising, smokefree indoor air, youth access and licensure.

2012-2020 (even years). Data from BRFSS for indicators of adult oral health for even years from 2012 through 2020. National estimates are represented by the median prevalence among 50 states and the District of Columbia data. Estimates are prepared from the BRFSS public use data sets. Estimates in this file are not age adjusted, and may differ slightly from estimates available from the BRFSS web site or Chronic Disease Indicators due to small differences in definition, age adjustment or rounding. For more information, see: https://www.cdc.gov/oralhealthdata/overview/Adult-Indicators.html.

TABLE III. Deaths in 122 U.S. cities - 2015122 Cities Mortality Reporting System ��� Each week, the vital statistics offices of 122 cities across the United States report the total number of death certificates processed and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group (Under 28 days, 28 days ���1 year, 1-14 years, 15-24 years, 25-44 years, 45-64 years, 65-74 years, 75-84 years, and ��� 85 years).FOOTNOTE:U: Unavailable -: No reported cases * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. ** Totals include unknown ages. *** Partial counts for this city.

The COVID-19 Coverage Assistance Fund provides reimbursements on a rolling basis directly to eligible health care entities for costs associated with administering COVID-19 vaccines to underinsured individuals, who are defined for this purpose as having a health plan that either does not include COVID-19 vaccine administration as a covered benefit or covers COVID-19 vaccine administration but with cost-sharing.

The program funding information is as follows: The Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136), appropriated $100 billion to reimburse eligible health care providers for health care related expenses or lost revenues that are attributable to coronavirus. The Paycheck Protection Program and Health Care Enhancement Act or PPPHCEA (P.L. 116-139) appropriated an additional $75 billion for relief funds, and the Coronavirus Response and Relief Supplemental Appropriations (CRRSA) Act appropriated an additional $3 billion. HRSA established the Provider Relief Fund (PRF) to administer payments to eligible providers. A portion of the PRF funds are being used to provide reimbursement to providers for administering Food and Drug Administration (FDA) authorized COVID-19 vaccines under an Emergency Use Authorization (EUA) or FDA-licensed COVID-19 vaccines under a Biologics License Application (BLA) to underinsured individuals. To learn more about the program, visit: https://www.hrsa.gov/covid19-coverage-assistance

This dataset represents the list of health care entities who have agreed to the Terms and Conditions and received claims reimbursement for costs associated with administering COVID-19 vaccines to underinsured individuals.

For Provider Relief Fund Data - https://data.cdc.gov/Administrative/HHS-Provider-Relief-Fund/kh8y-3es6

Alcohol-Impaired Driving Fatalities 2005-2014; All persons killed in crashes involving a driver with BAC >= .08 g/dL. Occupant Fatalities 2005-2014; All occupants killed where body type = 1-79. Source: National Highway Traffic Safety Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2005-2013 Final Reports and 2014 Annual Report File

This site provides historical data beginning June 14, 2023, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Percent of Total Population Who Are Up to Date with COVID-19 Vaccines”

Definition for Up to Date: For surveillance purposes people are ‘Upto Date’ with COVID-19 vaccines based on the following criteria:

People ages 6 years and older: Are up to date if they received 1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine.

Children ages 6 months to 5 years who received the Pfizer-BioNTech COVID-19 vaccine: Are up to date if: At ages 6 months to 4 years, they received 3 COVID-19 vaccine doses, including at least 1 updated COVID-19 dose; at age 5 years, they received at least 1 updated COVID-19 vaccine dose.

Children ages 6 months to 5 years who received the Moderna COVID-19 vaccine: Are up to date if they received 2 Moderna COVID-19 vaccine doses, including at least 1 updated COVID-19 vaccine dose.

People who are unable or choose not to get a recommended mRNA vaccine: Are up to date if they receive the Novavax COVID-19 vaccine doses approved for their age group.

CDC uses US Census estimates for the total populations within each specified demographic group regardless of prior vaccination status as denominators.

Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

2023 Respiratory Virus Response - NSSP Emergency Department Visits - COVID-19, Flu, RSV, Combined

For additional information, please see: Companion Guide: NSSP Emergency Department Data on Respiratory Illness

NNDSS - Table II. Lyme disease to Meningococcal - 2014In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

The Respiratory Virus Hospitalization Surveillance Network (RESP-NET) is a network that conducts, active, population-based surveillance for laboratory confirmed hospitalizations associated with Influenza, COVID-19, and RSV. The RESP-NET platforms have overlapping surveillance areas and use similar methods to collect data. Hospitalization rates show how many people in the surveillance area are hospitalized with influenza, COVID-19, and RSV compared to the total number of people residing in that area.

Data will be updated weekly. Data are preliminary and subject to change as more data become available.

Provisional counts of deaths by the month the deaths occurred, by age group, sex, and race/ethnicity, for select underlying causes of death for 2020-2021. Final data are provided for 2019. The dataset also includes monthly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

Vaccination Coverage and Exemptions among Kindergartners

• Data on school vaccination coverage and exemptions from the School Vaccination Assessment Program for kindergartners at the national and state levels.

• Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/schoolvaxview/index.html

Provisional counts of deaths in the United States by educational attainment, race, sex, and age group. The dataset includes cumulative provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

More than 450 public health, clinical, and commercial laboratories located throughout the United States voluntarily participate in surveillance for respiratory syncytial virus (RSV) through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS) (https://www.cdc.gov/surveillance/nrevss/labs/index.html). The data contain weekly, aggregate counts of RSV tests performed and RSV detections as reported to NREVSS since April 11, 2020.

NREVSS data are reported weekly at the national and 10 HHS regional levels (https://www.hhs.gov/about/agencies/iea/regional-offices/index.html). The presented data are RSV Nucleic Acid Amplification Test (NAAT) results, which include reverse transcription-polymerase chain reaction (RT-PCR) tests. These data exclude antigen, antibody, and at-home test results. Less than 5% of RSV tests reported to NREVSS are from antigen tests. All data are provisional and subject to change. Reporting is less complete for the most recent weeks, but relatively complete (>90%) for the period up to 2 weeks earlier.

Percent positivity is a surveillance metric used to monitor RSV activity over time and by geographic area. Participating laboratories send weekly reports of the total number of RSV tests performed that week, and the number of those tests that were positive. In the table and upon hovering on the map, the total test counts reflect the latest data reported to NREVSS and may differ from data presented by public health jurisdictions. Public health jurisdictions may have additional data not reported to NREVSS and may use a different reporting cadence. The RSV trend graphs display the weekly average percent of tests positive for RSV among all the tests performed. Each point on the regional table displays the average number of RSV tests that were performed, and the average percent of those that were positive during a 3-week period (i.e., the specified week, and the weeks immediately preceding and following it). This is also known as a centered, 3-week moving average. The RSV detections displayed are the 5-week moving average (average of the 4 previous and current weeks) in accordance with the recommendations for assessing RSV trends by detections (https://academic.oup.com/jid/article/216/3/345/3860464).

NREVSS strives to present precise estimates of respiratory viral trends and minimize reporting burden for participating laboratories. However, there are several limitations to this surveillance system. NREVSS is a laboratory-based surveillance system that does not have patient-specific data; multiple tests from a single patient may be included. In addition, NREVSS does not collect demographic or clinical data (i.e., hospitalizations or deaths). Testing practices may vary regionally, and the number of participating laboratories may change from year to year. Laboratories from all 50 states report data weekly, but reporting is voluntary and may not be representative of local RSV activity. The data do not include all test results within a jurisdiction and therefore do not reflect all RSV NAATs administered regionally or nationally. Participating laboratories vary in size, testing capabilities, and areas and populations served. Geographic results from clinical laboratories are based on testing location and laboratories may test samples from across one or more states. For more information on NREVSS and RSV surveillance please visit: https://www.cdc.gov/surveillance/nrevss.

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when members of the public in states and territories were subject to state and territorial executive orders, administrative orders, resolutions, and proclamations for COVID-19 that require them to wear masks in public. “Members of the public” are defined as individuals operating in a personal capacity. “In public” is defined to mean either (1) anywhere outside the home or (2) both in retail businesses and in restaurants/food establishments. Data consists exclusively of state and territorial orders, many of which apply to specific counties within their respective state or territory; therefore, data is broken down to the county level.

These data are derived from publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly require individuals to wear masks in public found by the CDC, COVID-19 Community Intervention & Critical Populations Task Force, Monitoring & Evaluation Team, Mitigation Policy Analysis Unit, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program, and Max Gakh, Assistant Professor, School of Public Health, University of Nevada, Las Vegas from April 10, 2020 through August 15, 2021. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. Effective and expiration dates were coded using only the dates provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not include data on counties that have opted out of their state mask mandate pursuant to state law. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.

NNDSS - Table II. Chlamydia to Coccidioidomycosis - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

This file contains COVID-19 death counts and rates by month and year of death, jurisdiction of residence (U.S., HHS Region) and demographic characteristics (sex, age, race and Hispanic origin, and age/race and Hispanic origin). United States death counts and rates include the 50 states, plus the District of Columbia.

Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file.

Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death.

Death counts should not be compared across jurisdictions. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly.

The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.

Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf).

Rate are based on deaths occurring in the specified week and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly) rate prevailed for a full year.

Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).

CDC's Division of Population Health provides a cross-cutting set of 115 indicators developed by consensus among CDC, the Council of State and Territorial Epidemiologists, and the National Association of Chronic Disease Directors. These indicators allow states and territories to uniformly define, collect, and report chronic disease data that are important to public health practice in their area. In addition to providing access to state-specific indicator data, the CDI web site serves as a gateway to additional information and data resources.

The National Outbreak Reporting System (NORS) is a web-based platform designed to support reporting to CDC by local, state, and territorial health departments in the United States of all waterborne disease outbreaks and enteric disease outbreaks transmitted by food, contact with environmental sources, infected persons or animals, or unknown modes of transmission.

2002-2010. BRFSS SMART MMSA Prevalence land line only data. The Selected Metropolitan Area Risk Trends (SMART) project uses the Behavioral Risk Factor Surveillance System (BRFSS) to analyze the data of selected metropolitan statistical areas (MMSAs) with 500 or more respondents. BRFSS data can be used to identify emerging health problems, establish and track health objectives, and develop and evaluate public health policies and programs. BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. Data will be updated annually as it becomes available. Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf Glossary: https://chronicdata.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct/data

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Provisional COVID-19 deaths by urbanicity and week. Deaths are based on the county of occurrence in the United States. Urbanicity is defined as metropolitan and non-metropolitan, based on the 2013 National Center for Health Statistics (NCHS) Urban-Rural Classification Scheme for Counties. Counties are classified as “metropolitan” if they are large central metro, large fringe metro, medium metro or small metro; and “non-metropolitan” if micropolitan or non-core.

This dataset contains model-based county-level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. Project was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2022 county population estimates, and American Community Survey (ACS) 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. These data can be joined with the census 2022 county boundary file in a GIS system to produce maps for 40 measures at the county level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7

2000 to Present. Adult Tobacco Consumption in the U.S. This dataset highlights critical trends in adult total and per capita consumption of both combustible (cigarettes, little cigars, small cigars, pipe tobacco, roll-your-own tobacco) tobacco products and smokeless (chewing tobacco and snuff) tobacco from 2000 to present. To view the CDC MMWR report, please visit https://www.cdc.gov/mmwr/volumes/65/wr/mm6548a1.htm.

Percentages are weighted to population characteristics. Data are not available if it did not meet BRFSS stability requirements.For more information on these requirements, as well as risk factors and calculated variables, see the Technical Documents and Survey Data for a specific year - http://www.cdc.gov/brfss/annual_data/annual_data.htm.Recommended citation: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [appropriate year].

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy.

To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates(https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data.

We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS)(https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). Public Use Microdata Areas (PUMA) level – PUMAs are geographic areas within each state that contain no fewer than 100,000 people. PUMAs can consist of part of a single densely populated county or can combine parts or all of multiple counties that are less densely populated.

The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.

County and State Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-County-and-local-es/q9mh-h2tw

NNDSS - Table II. Hepatitis (viral, acute) - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

This dataset includes data on adolescent's diet, physical activity, and weight status from Youth Risk Behavior Surveillance System (YRBSS). This data is used for DNPAO's Data, Trends, and Maps database, which provides national and state specific data on obesity, nutrition, physical activity, and breastfeeding. For more information about YRBSS visit https://www.cdc.gov/healthyyouth/data/yrbs/index.htm.

Data on drug overdose death rates, by drug type and selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Vital Statistics System, numerator data from annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics.2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Success Rates dataset contains success rates for ART cycles started during the year indicated. Since ART success depends on whether patients are using their own eggs or donor eggs, success rates are included separately for these two groups. Success rates for patients using their own eggs are shown per intended retrieval, per actual retrieval, and per transfer. These success rates are reported as cumulative success rates, which take into account transfers that occur within 1 year after an egg retrieval. Since ART success depends on whether patients are using ART for the first time or had prior ART cycles, users can examine success rates for all “Patients using their own eggs” or for “Patients with no prior ART using their own eggs.” For new patients using ART for the first time, the success rates are also shown after 1, 2, or all intended egg retrievals during the reporting year. In addition, the average number of transfers per intended retrieval and the average number of intended retrievals per live-birth delivery are shown. Success rates for ART cycles that involve the transfer of embryos created from donor eggs or donated embryos are shown and are not cumulative. They are based on donor cycles started in the year indicated that had embryo transfers, regardless of when the donor eggs were retrieved. Success rates in this section are not presented by patient age group because previous data show that an intended parent’s age does not substantially affect success when using donor eggs or donated embryos. The success rates are presented by types of embryos and eggs used in the transfer. This dataset excludes cycles that were considered research—that is, cycles performed to evaluate new procedures.

This dataset assembles all final birth data for females aged 15–19, 15–17, and 18–19 for the United States and each of the 50 states.

Data are based on 100% of birth certificates filed in all 50 states. All the teen birth rates in this dashboard reflect the latest revisions to Census populations (i.e., the intercensal populations) and thus provide a consistent series of accurate rates for the past 25 years. The denominators of the teen birth rates for 1991–1999 have been revised to incorporate the results of the 2000 Census. The denominators of the teen birth rates for 2001–2009 have revised to incorporate the results of the 2010 Census.

This dataset of U.S. mortality trends since 1900 highlights childhood mortality rates by age group for age at death.

Age-adjusted death rates (deaths per 100,000) after 1998 are calculated based on the 2000 U.S. standard population. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years between 2000 and 2010 are revised using updated intercensal population estimates and may differ from rates previously published. Data on age-adjusted death rates prior to 1999 are taken from historical data (see References below).

Age groups for childhood death rates are based on age at death.

SOURCES

CDC/NCHS, National Vital Statistics System, historical data, 1900-1998 (see https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm); CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. National Center for Health Statistics, Data Warehouse. Comparability of cause-of-death between ICD revisions. 2008. Available from: http://www.cdc.gov/nchs/nvss/mortality/comparability_icd.htm.

2. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.

3. Kochanek KD, Murphy SL, Xu JQ, Arias E. Deaths: Final data for 2017. National Vital Statistics Reports; vol 68 no 9. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf.

4. Arias E, Xu JQ. United States life tables, 2017. National Vital Statistics Reports; vol 68 no 7. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_07-508.pdf.

5. National Center for Health Statistics. Historical Data, 1900-1998. 2009. Available from: https://www.cdc.gov/nchs/nvss/mortality_historical_data.htm.

Data on death rates for suicide, by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Vital Statistics System (NVSS); Grove RD, Hetzel AM. Vital statistics rates in the United States, 1940–1960. National Center for Health Statistics. 1968; numerator data from NVSS annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics. 2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

This dataset describes drug poisoning deaths at the U.S. and state level by selected demographic characteristics, and includes age-adjusted death rates for drug poisoning from 1999 to 2015.

Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are defined as having ICD–10 underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent).

Estimates are based on the National Vital Statistics System multiple cause-of-death mortality files (1). Age-adjusted death rates (deaths per 100,000 U.S. standard population for 2000) are calculated using the direct method. Populations used for computing death rates for 2011–2015 are postcensal estimates based on the 2010 U.S. census. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Estimate does not meet standards of reliability or precision. Death rates are flagged as “Unreliable” in the chart when the rate is calculated with a numerator of 20 or less.

Death rates for some states and years may be low due to a high number of unresolved pending cases or misclassification of ICD–10 codes for unintentional poisoning as R99, “Other ill-defined and unspecified causes of mortality” (2). For example, this issue is known to affect New Jersey in 2009 and West Virginia in 2005 and 2009 but also may affect other years and other states. Estimates should be interpreted with caution.

Smoothed county age-adjusted death rates (deaths per 100,000 population) were obtained according to methods described elsewhere (3–5). Briefly, two-stage hierarchical models were used to generate empirical Bayes estimates of county age-adjusted death rates due to drug poisoning for each year during 1999–2015. These annual county-level estimates “borrow strength” across counties to generate stable estimates of death rates where data are sparse due to small population size (3,5). Estimates are unavailable for Broomfield County, Colo., and Denali County, Alaska, before 2003 (6,7). Additionally, Bedford City, Virginia was added to Bedford County in 2015 and no longer appears in the mortality file in 2015. County boundaries are consistent with the vintage 2005-2007 bridged-race population file geographies (6).

NNDSS - Table I. infrequently reported notifiable diseases - 2016. In this Table, provisional* cases of selected† infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed.
Note:

These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

“Symbols and footnotes changed in week #4, please refer to the MMWR publication for the symbols/footnotes for weeks 1, 2, and 3”.

Footnote: -: No reported cases N: Not reportable NA: Not available NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts.

• Case counts for reporting year 2016 are provisional and subject to change. Data for years 2011 through 2015 are finalized. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. † This table does not include cases from the U.S. territories. Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.
  § Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly reports from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Not reportable in all reporting jurisdictions. Data from states where the condition is not reportable are excluded from this table, except for the arboviral diseases and influenza-associated pediatric mortality. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html. †† Office of Management and Budget approval of the NNDSS Revision #0920-0728 on January 21, 2016, authorized CDC to receive data for these conditions. CDC is in the process of soliciting data for these conditions (except Zika virus, congenital infection). CDC and the U.S. states are still modifying the technical infrastructure needed to collect and transmit data for Zika virus congenital infections. §§ Jamestown Canyon virus and Lacrosse virus have replaced California serogroup diseases. ¶¶ Data for Haemophilus influenzae (all ages, all serotypes) are available in Table II. * Please refer to the MMWR publication for weekly updates to the footnote for this condition.
  ††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§ Data for meningococcal disease (all serogroups) are available in Table II. ¶¶¶ Please refer to the MMWR publication for weekly updates to the footnote for this condition. ** Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. †††† Please refer to the MMWR publication for weekly updates to the footnote for this condition. §§§§ All cases reported have occurred in travelers returning from affected areas, with their sexual contacts, or infants infected in ute

More than 450 public health and clinical laboratories located throughout the United States participate in surveillance for severe acute respiratory virus coronavirus type 2 (SARS-CoV-2), the virus that causes COVID-19, through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). The dataset contains a weekly summary of aggregate counts of the total SARS-CoV-2 tests and SARS-CoV-2 detections reported to NREVSS since March 14, 2020. These data are reported weekly on a voluntary basis. Clinical laboratories do not report demographic data through NREVSS. Testing practices may vary regionally, and the number of participating laboratories may change from year to year. Results can be changed for up to 2 years after the initial reporting week. However, discrepancies may be noted and updated at the discretion of the data stewards and key stakeholders.

While NREVSS strives to present the most precise estimates of respiratory viral trends with reporting burden minimized for participating laboratories, there are several inherent limitations to this surveillance system.

NREVSS does not collect patient-specific data or demographic information. Multiple samples may be collected from a single patient, so NREVSS results do not necessarily reflect the number of patients tested, nor do they directly reflect hospitalizations or deaths related to COVID-19.

Participating laboratories vary in size, testing capabilities, and areas served. Some institutions may receive and test samples from sites across a given state or even from multiple states. Without direct knowledge of the population base, NREVSS cannot be used to determine the prevalence or incidence of infection.

For more information on NREVSS and COVID-19 surveillance please visit: https://www.cdc.gov/surveillance/nrevss. These data appear starting May 25, 2023 on the CDC COVID Data Tracker at the following URLs: https://covid.cdc.gov/covid-data-tracker/#trends ; https://covid.cdc.gov/covid-data-tracker/#cases.

NREVSS data are reported at the national and HHS regional levels. The ten (10) U.S. Department of HHS regions are defined here: https://www.hhs.gov/about/agencies/iea/regional-offices/index.html.

The data represent SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) results, which include reverse transcriptase-polymerase chain reaction (RT-PCR) tests from a voluntary, sentinel network of participating laboratories in the United States, including clinical, public health and commercial laboratories (https://www.cdc.gov/surveillance/nrevss/labs/index.html).

These data exclude antigen, antibody, and at-home test results.

All data are provisional and subject to change. Reporting is less complete for the past 1 week, and more complete (>90%) for the period 2 weeks earlier.

There are data from all states across the 10 HHS regions. Because the data are from a sentinel network of laboratories, however, results may vary geographically. The data do not include all test results within a jurisdiction and therefore do not reflect all SARS-CoV-2 NAATs administered in the United States.

Percent positivity is one of the surveillance metrics used to monitor COVID-19 transmission over time and by area. Percent positivity is calculated by dividing the number of positive NAATs by the total number of NAATs administered, then multiplying by 100 [(# of positive NAAT tests / total NAAT tests) x 100].

The data represent laboratory tests performed, not individual (deduplicated) results in people. In the table and upon hovering on the map, the total test counts in the data reflect the latest data reported from NREVSS laboratories and may not match the data presented by various jurisdictions.

On May 11, 2023, CDC discontinued utilizing the COVID electronic laboratory reporting (CELR) platform as the primary laboratory source of COVID-19 results. These data are archived at health.data.gov.

For more information about NREVSS, please see: https://www.cdc.gov/surveillance/nrevss/

The U.S. government has taken unprecedented action to address the public health threat posed by this new coronavirus. To accelerate response efforts, CDC received supplemental funds through five congressional acts: the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Coronavirus Aid, Relief, and Economic Security Act; Paycheck Protection Program and Health Care Enhancement Act; Coronavirus Response and Relief Supplemental Appropriations Act, 2021; and American Rescue Plan Act of 2021. CDC is actively funding state, tribal, local, and territorial public health organizations to meet the challenges of this fast-moving public health threat.

Data on normal weight, overweight, and obesity among adults aged 20 and over by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Health and Nutrition Examination Survey. For more information on the National Health and Nutrition Examination Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

This dataset describes injury mortality in the United States beginning in 1999. Two concepts are included in the circumstances of an injury death: intent of injury and mechanism of injury. Intent of injury describes whether the injury was inflicted purposefully (intentional injury) and, if purposeful, whether the injury was self-inflicted (suicide or self-harm) or inflicted by another person (homicide). Injuries that were not purposefully inflicted are considered unintentional (accidental) injuries. Mechanism of injury describes the source of the energy transfer that resulted in physical or physiological harm to the body. Examples of mechanisms of injury include falls, motor vehicle traffic crashes, burns, poisonings, and drownings (1,2).

Data are based on information from all resident death certificates filed in the 50 states and the District of Columbia. Age-adjusted death rates (per 100,000 standard population) are based on the 2000 U.S. standard population. Populations used for computing death rates for 2011–2015 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for non-census years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Causes of injury death are classified by the International Classification of Diseases, Tenth Revision (ICD–10). Categories of injury intent and injury mechanism generally follow the categories in the external-cause-of-injury mortality matrix (1,2). Cause-of-death statistics are based on the underlying cause of death.

SOURCES

CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. National Center for Health Statistics. ICD–10: External cause of injury mortality matrix.

2. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.

3. Murphy SL, Xu JQ, Kochanek KD, Curtin SC, and Arias E. Deaths: Final data for 2015. National vital statistics reports; vol 66. no. 6. Hyattsville, MD: National Center for Health Statistics. 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf.

4. Miniño AM, Anderson RN, Fingerhut LA, Boudreault MA, Warner M. Deaths: Injuries, 2002. National vital statistics reports; vol 54 no 10. Hyattsville, MD: National Center for Health Statistics. 2006.

CDC monitors invasive bacterial infections that cause bloodstream infections, sepsis, and meningitis in persons living in the community through Active Bacterial Core surveillance (ABCs). ABCs conducts laboratory- and population-based surveillance for invasive pneumococcal disease (IPD). ABCs serotype data are used to measure the impact of vaccine use in the United States on vaccine-type IPD.

This table reports IPD case counts in the ABCs catchment area by serotype for years 1998 through 2022. Cases are grouped into the following mutually exclusive age groups: age https://www.cdc.gov/abcs/methodology/index.html.

Analyze and visualize data using the ABCs Bact Facts Interactive Data Dashboard at https://www.cdc.gov/abcs/bact-facts-interactive-dashboard.

The BEAM (Bacteria, Enterics, Amoeba, and Mycotics) Dashboard is an interactive tool to access and visualize data from the System for Enteric Disease Response, Investigation, and Coordination (SEDRIC). The BEAM Dashboard provides timely data on pathogen trends and serotype details to inform work to prevent illnesses from food and animal contact.

The CDC Content Syndication site at https://tools.cdc.gov/syndication/ allows you to import content from CDC websites directly into your own website or application. These services are provided free of charge from CDC. The data shown in this table represent the weekly top page views from CDC.gov offered by syndication.

This dataset contains model-based county estimates for drug-poisoning mortality.

Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are defined as having ICD–10 underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent).

Estimates are based on the National Vital Statistics System multiple cause-of-death mortality files (1). Age-adjusted death rates (deaths per 100,000 U.S. standard population for 2000) are calculated using the direct method. Populations used for computing death rates for 2011–2016 are postcensal estimates based on the 2010 U.S. census. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Death rates for some states and years may be low due to a high number of unresolved pending cases or misclassification of ICD–10 codes for unintentional poisoning as R99, “Other ill-defined and unspecified causes of mortality” (2). For example, this issue is known to affect New Jersey in 2009 and West Virginia in 2005 and 2009 but also may affect other years and other states. Drug poisoning death rates may be underestimated in those instances.

Smoothed county age-adjusted death rates (deaths per 100,000 population) were obtained according to methods described elsewhere (3–5). Briefly, two-stage hierarchical models were used to generate empirical Bayes estimates of county age-adjusted death rates due to drug poisoning for each year. These annual county-level estimates “borrow strength” across counties to generate stable estimates of death rates where data are sparse due to small population size (3,5). Estimates for 1999-2015 have been updated, and may differ slightly from previously published estimates. Differences are expected to be minimal, and may result from different county boundaries used in this release (see below) and from the inclusion of an additional year of data. Previously published estimates can be found here for comparison.(6) Estimates are unavailable for Broomfield County, Colorado, and Denali County, Alaska, before 2003 (7,8). Additionally, Clifton Forge County, Virginia only appears on the mortality files prior to 2003, while Bedford City, Virginia was added to Bedford County in 2015 and no longer appears in the mortality file in 2015. These counties were therefore merged with adjacent counties where necessary to create a consistent set of geographic units across the time period. County boundaries are largely consistent with the vintage 2005-2007 bridged-race population file geographies, with the modifications noted previously (7,8).

REFERENCES

1. National Center for Health Statistics. National Vital Statistics System: Mortality data. Available from: http://www.cdc.gov/nchs/deaths.htm.

2. CDC. CDC Wonder: Underlying cause of death 1999–2016. Available from: http://wonder.cdc.gov/wonder/help/ucd.html.

3. Rossen LM, Khan D, Warner M. Trends and geographic patterns in drug-poisoning death rates in the U.S., 1999–2009. Am J Prev Med 45(6):e19–25. 2013.

4. Rossen LM, Khan D, Warner M. Hot spots in mortality from drug poisoning in the United States, 2007–2009. Health Place 26:14–20. 2014.

5. Rossen LM, Khan D, Hamilton B, Warner M. Spatiotemporal variation in selected health outcomes from the National Vital Statistics System. Presented at: 2015 National Conference on Health Statistics, August 25, 2015, Bethesda, MD. Available from: http://www.cdc.gov/nchs/ppt/nchs2015/Rossen_Tuesday_WhiteOak_BB3.pdf.

6. Rossen LM, Bastian B, Warner M, and Khan D. NCHS – Drug Poisoning Mortality by County: United States, 1999-2015. Available from: https://data.cdc.gov/NCHS/NCHS-Drug-Poisoning-Mortality-by-County-United-Sta/pbkm-d27e.

7. National Center for Health Statistics. County geog

Weekly Cumulative Doses (in Millions) of Influenza Vaccine Distributed by Flu Season in the United States

• Archived data are available here: https://data.cdc.gov/resource/e5zk-7tx5 • Flu vaccine is produced by private manufacturers, so supply depends on manufacturers. Vaccine manufacturers have projected that they will supply the United States with as many as 173.5 million to 183.5 million doses of influenza vaccines for the 2022-2023 season. • Additional information is available: https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm.

This dataset describes drug poisoning deaths at the U.S. and state level by selected demographic characteristics, and includes age-adjusted death rates for drug poisoning.

Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are defined as having ICD–10 underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent).

Estimates are based on the National Vital Statistics System multiple cause-of-death mortality files (1). Age-adjusted death rates (deaths per 100,000 U.S. standard population for 2000) are calculated using the direct method. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 U.S. census. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Death rates for some states and years may be low due to a high number of unresolved pending cases or misclassification of ICD–10 codes for unintentional poisoning as R99, “Other ill-defined and unspecified causes of mortality” (2). For example, this issue is known to affect New Jersey in 2009 and West Virginia in 2005 and 2009 but also may affect other years and other states. Drug poisoning death rates may be underestimated in those instances.

REFERENCES

1. National Center for Health Statistics. National Vital Statistics System: Mortality data. Available from: http://www.cdc.gov/nchs/deaths.htm.

2. CDC. CDC Wonder: Underlying cause of death 1999–2016. Available from: http://wonder.cdc.gov/wonder/help/ucd.html.

For more information on CDC.gov metrics please see http://www.cdc.gov/metrics/

Interactive Summary Health Statistics for Children provide annual estimates of selected health topics for children under age 18 years based on final data from the National Health Interview Survey.

Weekly COVID-19 Vaccination Coverage, Pregnant Women 18-49 Years Old

• COVID-19 vaccination coverage among pregnant women is assessed through the Vaccine Safety Datalink*

• Data on updated 2023-24 COVID-19 vaccinations among pregnant women was available starting September 23, 2023, and includes doses received starting September 14, 2023.

This dataset represents weekly hospital respiratory data and metrics aggregated to national and state/territory levels reported to CDC’s National Health Safety Network (NHSN) beginning August 2020. Data for reporting dates through April 30, 2024 represent data reported during a previous mandated reporting period as specified by the HHS Secretary. Data for reporting dates May 1, 2024 – October 31, 2024 represent voluntarily reported data in the absence of a mandate. Data for reporting dates beginning November 1, 2024 represent data reported during a current mandated reporting period. All data and metrics capturing information on respiratory syncytial virus (RSV) were voluntarily reported until November 1, 2024. All data included in this dataset represent aggregated counts, and include metrics capturing information specific to hospital capacity, occupancy, hospitalizations, and new hospital admissions with corresponding metrics indicating reporting coverage for a given reporting week. NHSN monitors national and local trends in healthcare system stress and capacity for all acute care and critical access hospitals in the United States.

For more information on the reporting mandate per the Centers for Medicare and Medicaid Services (CMS) requirements, visit: Updates to the Condition of Participation (CoP) Requirements for Hospitals and Critical Access Hospitals (CAHs) To Report Acute Respiratory Illnesses.

For more information regarding NHSN’s collection of these data, including full reporting guidance, visit: NHSN Hospital Respiratory Data.

Source: CDC National Healthcare Safety Network (NHSN). Data source description (updated November 15, 2024): As of October 9, 2024, Hospital Respiratory Data (HRD; formerly Respiratory Pathogen, Hospital Capacity, and Supply data or 'COVID-19 hospital data') are reported to HHS through CDC's National Healthcare Safety Network (NHSN) based on updated requirements from the Centers for Medicare and Medicaid Services (CMS). These data were voluntarily reported to NHSN May 1, 2024 until November 1, 2024, at which time CMS began requiring acute care and critical access hospitals to electronically report information via NHSN about COVID-19, influenza, and RSV, hospital bed census and capacity. Hospital bed capacity and occupancy data for all patients and for patients with COVID-19 or influenza for collection dates prior to May 1, 2024, represent data reported during a previously mandated reporting period as specified by the HHS Secretary, and data for collection dates May 1, 2024 – October 31, 2024 represent data reported voluntarily to NHSN. All RSV data through October 31, 2024 represent voluntarily reported data; as such, all voluntarily reported data included in this dataset represent reporting hospitals only for a given week and might not be complete or representative of all hospitals during the specified reporting periods.NHSN monitors national and local trends in healthcare system stress and capacity for all acute care and critical access hospitals in the United States. Data reported by hospitals to NHSN represent aggregated counts and include metrics capturing information specific to hospital capacity, occupancy, hospitalizations, and admissions. Find more information about reporting to NHSN: https://www.cdc.gov/nhsn/psc/hospital-respiratory-reporting.html.Data quality: While CDC reviews reported data for completeness and errors and corrects those found, some reporting errors might still exist within the data. CDC and partners work with reporters to correct these errors and update the data in subsequent weeks. Data reported as of December

This data visualization presents county-level provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. County-level provisional counts include deaths occurring within the 50 states and the District of Columbia, as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts (see Technical Notes).

The provisional data presented on the dashboard below include reported 12 month-ending provisional counts of death due to drug overdose by the decedent’s county of residence and the month in which death occurred.

Percentages of deaths with a cause of death pending further investigation and a note on historical completeness (e.g. if the percent completeness was under 90% after 6 months) are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts (see Technical Notes). Counts between 1-9 are suppressed in accordance with NCHS confidentiality standards. Provisional data presented on this page will be updated on a quarterly basis as additional records are received.

Technical Notes

Nature and Sources of Data

Provisional drug overdose death counts are based on death records received and processed by the National Center for Health Statistics (NCHS) as of a specified cutoff date. The cutoff date is generally the first Sunday of each month. National provisional estimates include deaths occurring within the 50 states and the District of Columbia. NCHS receives the death records from the state vital registration offices through the Vital Statistics Cooperative Program (VSCP).

The timeliness of provisional mortality surveillance data in the National Vital Statistics System (NVSS) database varies by cause of death and jurisdiction in which the death occurred. The lag time (i.e., the time between when the death occurred and when the data are available for analysis) is longer for drug overdose deaths compared with other causes of death due to the time often needed to investigate these deaths (1). Thus, provisional estimates of drug overdose deaths are reported 6 months after the date of death.

Provisional death counts presented in this data visualization are for “12 month-ending periods,” defined as the number of deaths occurring in the 12 month period ending in the month indicated. For example, the 12 month-ending period in June 2020 would include deaths occurring from July 1, 2019 through June 30, 2020. The 12 month-ending period counts include all seasons of the year and are insensitive to reporting variations by seasonality. These provisional counts of drug overdose deaths and related data quality metrics are provided for public health surveillance and monitoring of emerging trends. Provisional drug overdose death data are often incomplete, and the degree of completeness varies by jurisdiction and 12 month-ending period. Consequently, the numbers of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation.

Cause of Death Classification and Definition of Drug Deaths

Mortality statistics are compiled in accordance with the World Health Organizations (WHO) regulations specifying that WHO member nations classify and code causes of death with the current revision of the International Statistical Classification of Diseases and Related Health Problems (ICD). ICD provides the basic guidance used in virtually all countries to code and classify causes of death. It provides not only disease, injury, and poisoning categories but also the rules used to select the single underlying cause of death for tabulation from the several diagnoses that may be reported on a single death certificate, as well as definitions, tabulation lists, the format of the death certificate, and regul

This data is no longer being updated. New data is being tracked at https://healthdata.gov/National/HHS-Unaccompanied-Children-Program/ehpz-xc9n

This data represents unaccompanied children who are taken into custody by Customs and Border Protection brought to a facility and processed for transfer to the Department of Health and Human Services (HHS) as required by law. HHS holds the child for testing and quarantine, and shelters the child until the child is placed with a sponsor here in the United States.

This file contains COVID-19 death counts and rates by jurisdiction of residence (U.S., HHS Region) and demographic characteristics (sex, age, race and Hispanic origin, and age/race and Hispanic origin). United States death counts and rates include the 50 states, plus the District of Columbia.

Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file.

Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death.

Death counts should not be compared across jurisdictions. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly.

The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.

Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf).

Rate are based on deaths occurring in the specified week and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly) rate prevailed for a full year.

Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).

Note: After May 3, 2024, this dataset will no longer be updated because hospitals are no longer required to report data on COVID-19 and influenza hospital admissions, hospital capacity, or occupancy data to HHS through CDC’s National Healthcare Safety Network (NHSN).

This dataset represents hospitalization data and metrics aggregated to country, HHS region, and state/territory. Hospitalization data are reported to CDC’s National Healthcare Safety Network, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN and included in this dataset represent aggregated counts and include metrics capturing information specific to hospital admissions, and inpatient and ICU bed capacity occupancy.

Data fields for new admissions of pediatric patients with confirmed COVID-19 for ages 0-4 years, 5-11 years, and 12-17 years were not required for reporting until February 2022; therefore, data for the following fields in this dataset begin on March 1, 2022 to account for delays in initial reporting of these fields:

adm_00_04_covid_confirmed avg_adm_00_04_covid_confirmed avg_adm_00_04_covid_confirmed_per_100k adm_05_11_covid_confirmed avg_adm_05_11_covid_confirmed avg_adm_05_11_covid_confirmed_per_100k adm_12_17_covid_confirmed avg_adm_12_17_covid_confirmed avg_adm_12_17_covid_confirmed_per_100k

Updated weekly each Friday at noon, ET.

This data set contains estimated teen birth rates for age group 15–19 (expressed per 1,000 females aged 15–19) by county and year.

DEFINITIONS

Estimated teen birth rate: Model-based estimates of teen birth rates for age group 15–19 (expressed per 1,000 females aged 15–19) for a specific county and year. Estimated county teen birth rates were obtained using the methods described elsewhere (1,2,3,4). These annual county-level teen birth estimates “borrow strength” across counties and years to generate accurate estimates where data are sparse due to small population size (1,2,3,4). The inferential method uses information—including the estimated teen birth rates from neighboring counties across years and the associated explanatory variables—to provide a stable estimate of the county teen birth rate. Median teen birth rate: The middle value of the estimated teen birth rates for the age group 15–19 for counties in a state. Bayesian credible intervals: A range of values within which there is a 95% probability that the actual teen birth rate will fall, based on the observed teen births data and the model.

NOTES

Data on the number of live births for women aged 15–19 years were extracted from the National Center for Health Statistics’ (NCHS) National Vital Statistics System birth data files for 2003–2015 (5).

Population estimates were extracted from the files containing intercensal and postcensal bridged-race population estimates provided by NCHS. For each year, the July population estimates were used, with the exception of the year of the decennial census, 2010, for which the April estimates were used.

Hierarchical Bayesian space–time models were used to generate hierarchical Bayesian estimates of county teen birth rates for each year during 2003–2015 (1,2,3,4).

The Bayesian analogue of the frequentist confidence interval is defined as the Bayesian credible interval. A 100*(1-α)% Bayesian credible interval for an unknown parameter vector θ and observed data vector y is a subset C of parameter space Ф such that 1-α≤P({C│y})=∫p{θ │y}dθ, where integration is performed over the set and is replaced by summation for discrete components of θ. The probability that θ lies in C given the observed data y is at least (1- α) (6).

County borders in Alaska changed, and new counties were formed and others were merged, during 2003–2015. These changes were reflected in the population files but not in the natality files. For this reason, two counties in Alaska were collapsed so that the birth and population counts were comparable. Additionally, Kalawao County, a remote island county in Hawaii, recorded no births, and census estimates indicated a denominator of 0 (i.e., no females between the ages of 15 and 19 years residing in the county from 2003 through 2015). For this reason, Kalawao County was removed from the analysis. Also , Bedford City, Virginia, was added to Bedford County in 2015 and no longer appears in the mortality file in 2015. For consistency, Bedford City was merged with Bedford County, Virginia, for the entire 2003–2015 period. Final analysis was conducted on 3,137 counties for each year from 2003 through 2015. County boundaries are consistent with the vintage 2005–2007 bridged-race population file geographies (7).

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation—Licensure. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to requirements, restrictions and penalties associated with holding a retail license to sell e-cigarettes over-the-counter and through vending machines.

NNDSS - Table I. infrequently reported notifiable diseases - 2015. In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnote:-: No reported cases N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. �� Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. �� Data for the Arboviral disease, Chikungunya, and Hantavirus infection disease, non-Hantavirus Pulmonary Syndrome (HPS), will be displayed in this table after the CDC obtains Office of Management and Budget Paperwork Reduction Act approval to receive data for these conditions. ** Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ��ʉ�� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the arboviral diseases, STD data, TB data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html. ���� Data for H. influenzae (all ages, all serotypes) are available in Table II. ���� Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Please refer to the MMWR publication for weekly updates to the footnote for this condition. * Please refer to the MMWR publication for weekly updates to the footnote for this condition. ��ʉ�ʉ�� Data for meningococcal disease (all serogroups) are available in Table II. ������ Please refer to the MMWR publication for weekly updates to the footnote for this condition. ������ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. ** Please refer to the MMWR publication for weekly updates to the footnote for this condition. See Table II for Dengue Hemorrhagic Fever.

This dataset provides modeled predictions of PM2.5 levels from the EPA's Downscaler model. Data are at the census tract level for 2011-2014. These data are used by the CDC's National Environmental Public Health Tracking Network to generate air quality measures. Census tract-level datasets contain estimates of the mean predicted concentration and associated standard error. Please refer to the metadata attachment for more information.

Learn more about outdoor air quality on the Tracking Network's website: https://ephtracking.cdc.gov/showAirLanding.action.

By using these data, you signify your agreement to comply with the following requirements:

1. Use the data for statistical reporting and analysis only.
2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals.
3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov.
4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating.
5. Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC.
6. Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking.

This dataset contains model-based ZIP Code Tabulation Area (ZCTA) level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population counts, and American Community Survey (ACS) 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. These data can be joined with the Census 2021 ZCTA boundary file in a GIS system to produce maps for 40 measures at the ZCTA level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7

This dataset provides a data dictionary for PLACES and 500 Cities releases. For each measure, the data dictionary provides the measure ID, measure full and short name, measure category ID and name, year of BRFSS data used to generate the estimate by release year, and frequency BRFSS collects data about the measure.

The Research and Development Survey (RANDS) is a platform designed for conducting survey question evaluation and statistical research. RANDS is an ongoing series of surveys from probability-sampled commercial survey panels used for methodological research at the National Center for Health Statistics (NCHS). RANDS estimates are generated using an experimental approach that differs from the survey design approaches generally used by NCHS, including possible biases from different response patterns and sampling frames as well as increased variability from lower sample sizes. Use of the RANDS platform allows NCHS to produce more timely data than would be possible using traditional data collection methods. RANDS is not designed to replace NCHS’ higher quality, core data collections. Below are experimental estimates of telemedicine access and use for three rounds of RANDS during COVID-19. Data collection for the three rounds of RANDS during COVID-19 occurred between June 9, 2020 and July 6, 2020, August 3, 2020 and August 20, 2020, and May 17, 2021 and June 30, 2021. Information needed to interpret these estimates can be found in the Technical Notes. RANDS during COVID-19 included questions about whether providers offered telemedicine (including video and telephone appointments) in the last 2 months—both during and before the pandemic—and about the use of telemedicine in the last 2 months during the pandemic. As a result of the coronavirus pandemic, many local and state governments discouraged people from leaving their homes for nonessential reasons. Although health care is considered an essential activity, telemedicine offers an opportunity for care without the potential or perceived risks of leaving the home. The National Health Interview Survey, conducted by NCHS, added telemedicine questions to its sample adult questionnaire in July 2020. The Household Pulse Survey (https://www.cdc.gov/nchs/covid19/pulse/telemedicine-use.htm), an online survey conducted in response to the COVID-19 pandemic by the Census Bureau in partnership with other federal agencies including NCHS, also reports estimates of telemedicine use during the pandemic (beginning in Phase 3.1, which started on April 14, 2021). The Household Pulse Survey reports telemedicine use in the last 4 weeks among adults and among households with at least one child under age 18 years. The experimental estimates on this page are derived from RANDS during COVID-19 and show the percentage of U.S. adults who have a usual place of care and a provider that offered telemedicine in the past 2 months, who used telemedicine in the past 2 months, or who have a usual place of care and a provider that offered telemedicine prior to the coronavirus pandemic. Technical Notes: https://www.cdc.gov/nchs/covid19/rands/telemedicine.htm#limitations

The National Hospital Ambulatory Medical Care Survey (NHAMCS), conducted by the National Center for Health Statistics (NCHS), collects annual data on visits to emergency departments to describe patterns of utilization and provision of ambulatory care delivery in the United States. Data are collected from nonfederal, general, and short-stay hospitals from all 50 U.S. states and the District of Columbia, and are used to develop nationally representative estimates.

The data include counts and rates of emergency department visits from 2016-2022 for the 10 leading primary diagnoses and reasons for visit, stratified by selected patient and hospital characteristics. Rankings for the 10 leading categories were identified using weighted data from 2022 and were then assessed in prior years.

The 2011 BRFSS data reflects a change in weighting methodology (raking) and the addition of cell phone only respondents. Shifts in observed prevalence from 2010 to 2011 for BRFSS measures will likely reflect the new methods of measuring risk factors, rather than true trends in risk-factor prevalence. A break in trend lines after 2010 is used to reflect this change in methodolgy. Percentages are weighted to population characteristics. Data are not available if it did not meet BRFSS stability requirements.For more information on these requirements, as well as risk factors and calculated variables, see the Technical Documents and Survey Data for a specific year - http://www.cdc.gov/brfss/annual_data/annual_data.htm.Recommended citation: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [appropriate year].

The Coronavirus Disease 2019 (COVID-19) Hospitalization Surveillance Network (COVID-NET) a network that conducts active, population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations among children and adults. COVID-NET, along with the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET) and the Influenza Hospitalization Surveillance Network (FluSurv-NET), comprise the Respiratory Virus Hospitalization Surveillance Network (RESP-NET). The RESP-NET platforms have overlapping surveillance areas and use similar methods to collect data. COVID-NET is CDC’s source for important data on rates of hospitalizations associated with COVID-19. Hospitalization rates show how many people in the surveillance area are hospitalized with COVID-19, compared to the total number of people residing in that area.

Data are preliminary and subject to change as more data become available. Data will be updated weekly.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

This data dictionary provides information about archived demographic trend data for people receiving COVID-19 vaccinations in the United States at the national level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

These data have been archived to provide historical demographic trend data for COVID-19 vaccine recipients prior to CDC converting the Vaccination Demographic Trends site to using data based on the date of vaccine administration. Previously, the Vaccination Demographic Trends site presented trend data by the date the vaccination was reported to CDC.

MMWR Surveillance Summary 66 (No. SS-1):1-8 found that nonmetropolitan areas have significant numbers of potentially excess deaths from the five leading causes of death. These figures accompany this report by presenting information on potentially excess deaths in nonmetropolitan and metropolitan areas at the state level. They also add additional years of data and options for selecting different age ranges and benchmarks.

Potentially excess deaths are defined in MMWR Surveillance Summary 66(No. SS-1):1-8 as deaths that exceed the numbers that would be expected if the death rates of states with the lowest rates (benchmarks) occurred across all states. They are calculated by subtracting expected deaths for specific benchmarks from observed deaths.

Not all potentially excess deaths can be prevented; some areas might have characteristics that predispose them to higher rates of death. However, many potentially excess deaths might represent deaths that could be prevented through improved public health programs that support healthier behaviors and neighborhoods or better access to health care services.

Mortality data for U.S. residents come from the National Vital Statistics System. Estimates based on fewer than 10 observed deaths are not shown and shaded yellow on the map.

Underlying cause of death is based on the International Classification of Diseases, 10th Revision (ICD-10)

Heart disease (I00-I09, I11, I13, and I20–I51) Cancer (C00–C97) Unintentional injury (V01–X59 and Y85–Y86) Chronic lower respiratory disease (J40–J47) Stroke (I60–I69) Locality (nonmetropolitan vs. metropolitan) is based on the Office of Management and Budget’s 2013 county-based classification scheme.

Benchmarks are based on the three states with the lowest age and cause-specific mortality rates.

Potentially excess deaths for each state are calculated by subtracting deaths at the benchmark rates (expected deaths) from observed deaths.

Users can explore three benchmarks:

“2010 Fixed” is a fixed benchmark based on the best performing States in 2010. “2005 Fixed” is a fixed benchmark based on the best performing States in 2005. “Floating” is based on the best performing States in each year so change from year to year.

SOURCES

CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).

REFERENCES

1. Moy E, Garcia MC, Bastian B, Rossen LM, Ingram DD, Faul M, Massetti GM, Thomas CC, Hong Y, Yoon PW, Iademarco MF. Leading Causes of Death in Nonmetropolitan and Metropolitan Areas – United States, 1999-2014. MMWR Surveillance Summary 2017; 66(No. SS-1):1-8.

2. Garcia MC, Faul M, Massetti G, Thomas CC, Hong Y, Bauer UE, Iademarco MF. Reducing Potentially Excess Deaths from the Five Leading Causes of Death in the Rural United States. MMWR Surveillance Summary 2017; 66(No. SS-2):1–7.

Notice: For data on COVID-19 in the United States, please see https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html.

Notice: Data from California published in week 29 for years 2019 and 2020 were incomplete when originally published on July 24, 2020. On August 4, 2020, incomplete case counts were replaced with a "U" indicating case counts are not available for specified time period.

NNDSS - TABLE 1FF. Severe acute respiratory syndrome-associated coronavirus disease to Shigellosis – 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.

Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

• Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).

Weekly RSV Vaccination Coverage, Pregnant Women 18-49 Years Old

• RSV vaccination coverage among pregnant women is assessed through the Vaccine Safety Datalink*

• Data on RSV vaccinations among pregnant women was available starting September 22, 2023, and includes doses received starting September 24, 2023.

2011 to present. BRFSS combined land line and cell phone age-adjusted prevalence data. The BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. Data will be updated annually as it becomes available.

Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf Glossary: https://data.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct

This site provides historical data beginning June 22, 2022, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Primary Series Completion, Booster Dose Eligibility, and Booster Dose Receipt by Age, United States”.

Fully Vaccinated / Completed Primary Series: For surveillance purposes, COVID Data Tracker counts people as being "fully vaccinated" or as having "completed a primary series" if they received two doses on different days (regardless of time interval) of the two-dose mRNA series or received one dose of a single-dose vaccine. When the vaccine manufacturer is not reported, the recipient is considered fully vaccinated with two doses.First Booster Dose:  For surveillance purposes, the count and percentage of people who received a first booster dose includes anyone who is fully vaccinated and has received another dose of COVID-19 vaccine since August 13, 2021. This includes people who received a first booster dose and people who received an additional primary series dose as this metric does not distinguish if the recipient is  immunocompromised and received an additional dose. First booster dose eligibility: CDC counts people as being " eligible for a first booster dose" if it has been at least 5 months since completion of a Pfizer-BioNTech or Moderna primary series or at least 2 months since receipt of a Janssen (Johnson & Johnson) singe-dose vaccine. Second Booster Dose:For surveillance purposes, the count and percentage of people who received a second booster dose includes anyone who is fully vaccinated and has received two subsequent doses of COVID-19 vaccine since August 13, 2021. This includes people who received two booster doses and people who received one additional dose and one booster dose.  The count of people who received a second booster dose and the percentage of people with a first booster who received a second booster dose does not account for whether a person is immunocompromised or time interval since first booster dose. Second booster dose eligibility: CDC counts people as being  "eligible for a second booster dose"  if it has been at least 4 months since receiving a first booster dose. Limitations to counting people with a second booster dose: Due to the aggregate vaccination record reporting method used by Idaho for its residents under the age of 18 years and by Texas for all its residents, CDC counts all 4th doses received by these populations as a second booster dose. This includes immunocompromised individuals who received a three-dose primary series and only one booster dose. This limitation may lead to an undercount of people who received the single-dose J&J/Janssen vaccine as their primary series and two booster doses. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

The U.S. Census Bureau, in collaboration with five federal agencies, launched the Household Pulse Survey to produce data on the social and economic impacts of Covid-19 on American households. The Household Pulse Survey was designed to gauge the impact of the pandemic on employment status, consumer spending, food security, housing, education disruptions, and dimensions of physical and mental wellness.

The survey was designed to meet the goal of accurate and timely weekly estimates. It was conducted by an internet questionnaire, with invitations to participate sent by email and text message. The sample frame is the Census Bureau Master Address File Data. Housing units linked to one or more email addresses or cell phone numbers were randomly selected to participate, and one respondent from each housing unit was selected to respond for him or herself. Estimates are weighted to adjust for nonresponse and to match Census Bureau estimates of the population by age, sex, race and ethnicity, and educational attainment. All estimates shown meet the NCHS Data Presentation Standards for Proportions.

2005-2016. This dataset includes data from the retired BRFSS Vision Module. From 2005-2011 the BRFSS employed a ten question vision module regarding vision impairment, access and utilization of eye care, and self-reported eye diseases. In 2013 and subsequently, one question in the core of BRFSS asks about vision: “Are you blind or do you have serious difficulty seeing, even when wearing glasses?” The latest data for this core question can be found in the Vision and Eye Health Surveillance System (VEHSS). VEHSS is intended to provide population estimates of vision loss function, eye diseases, health disparities, as well as barriers and facilitators to access to vision and eye care. This information can be used for designing, implementing, and evaluating vision and eye health prevention programs. To access the latest BRFSS data, (2013-2017) view the Behavioral Risk Factors – Vision and Eye Health Surveillance dataset (https://chronicdata.cdc.gov/Vision-Eye-Health/Behavioral-Risk-Factors-Vision-and-Eye-Health-Surv/vkwg-yswv).

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when individuals in states and territories were subject to executive orders, administrative orders, resolutions, and proclamations for COVID-19 that require or recommend people stay in their homes. Data consists exclusively of state and territorial orders, many of which apply to specific counties within their respective state or territory; therefore, data is broken down to the county level.

These data are derived from the publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly require or recommend individuals stay at home found by the CDC, COVID-19 Community Intervention and At-Risk Task Force, Monitoring and Evaluation Team & CDC, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program from March 15, 2020 through August 15, 2021. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. These data do not include mandatory business closures, curfews, or limitations on public or private gatherings. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.

National Immunization Survey Adult COVID Module (NIS-ACM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. These data represent trends in vaccination status and intent by demographics.

Following collection of August 2021 survey data, an error in data processing led to incorrect categorization of some survey respondents; some respondents who should have been categorized as MSA: Principal City instead were categorized as MSA: Non-Principal City. Data downloaded during the period September 12, 2021 through September 30, 2021 may have incorrect estimates by MSA status, SVI of county of residence, and political leaning of county of residence.

Provisional counts of deaths in the United States by race and educational attainment. The dataset includes cumulative provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when members of the public in states and territories were subject to state and territorial executive orders, administrative orders, resolutions, and proclamations for COVID-19 that require them to wear masks in public. “Members of the public” are defined as individuals operating in a personal capacity. “In public” is defined to mean either (1) anywhere outside the home or (2) both in retail businesses and in restaurants/food establishments. Data consists exclusively of state and territorial orders, many of which apply to specific counties within their respective state or territory; therefore, data is broken down to the county level.

These data are derived from publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly require individuals to wear masks in public found by the CDC, COVID-19 Community Intervention & Critical Populations Task Force, Monitoring & Evaluation Team, Mitigation Policy Analysis Unit, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program, and Max Gakh, Assistant Professor, School of Public Health, University of Nevada, Las Vegas from April 10, 2020 through July 20, 2021. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. Effective and expiration dates were coded using only the dates provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not include data on counties that have opted out of their state mask mandate pursuant to state law. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.

Vaccination Coverage among Adults (18+ Years)

• Data on adult vaccination coverage from the Behavioral Risk Factor Surveillance System (BRFSS) for the general population at the national, regional, and state levels by age groups.

• Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/index.html

This dataset contains model-based place (incorporated and census-designated places) estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related social needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

Monthly COVID-19 death rates per 100,000 population stratified by age group, race/ethnicity, sex, and region, with race/ethnicity by age group and age group by race/ethnicity double stratification

This data presents national-level provisional maternal mortality rates based on a current flow of mortality and natality data in the National Vital Statistics System. Provisional rates which are an early estimate of the number of maternal deaths per 100,000 live births, are shown as of the date specified and may not include all deaths and births that occurred during a given time period (see Technical Notes).

A maternal death is the death of a woman while pregnant or within 42 days of termination of pregnancy irrespective of the duration and the site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes. In this data visualization, maternal deaths are those deaths with an underlying cause of death assigned to International Statistical Classification of Diseases, 10th Revision (ICD-10) code numbers A34, O00–O95, and O98–O99.

The provisional data include reported 12 month-ending provisional maternal mortality rates overall, by age, and by race and Hispanic origin. Provisional maternal mortality rates presented in this data visualization are for “12-month ending periods,” defined as the number of maternal deaths per 100,000 live births occurring in the 12-month period ending in the month indicated. For example, the 12-month ending period in June 2020 would include deaths and births occurring from July 1, 2019, through June 30, 2020. Evaluation of trends over time should compare estimates from year to year (June 2020 and June 2021), rather than month to month, to avoid overlapping time periods. In the visualization and in the accompanying data file, rates based on death counts less than 20 are suppressed in accordance with current NCHS standards of reliability for rates. Death counts between 1-9 in the data file are suppressed in accordance with National Center for Health Statistics (NCHS) confidentiality standards.

Provisional data presented on this page will be updated on a quarterly basis as additional records are received. Previously released estimates are revised to include data and record updates received since the previous release. As a result, the reliability of estimates for a 12-month period ending with a specific month will improve with each quarterly release and estimates for previous time periods may change as new data and updates are received.

Cumulative provisional counts of deaths sex, race/Hispanic origin, age group, and by select underlying causes of death. The dataset also includes provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death. Includes deaths that occurred between January 1, 2020 to July 28, 2020.

2008-2017. Centers for Disease Control and Prevention (CDC). Office on Smoking and Health (OSH) – Global Tobacco Surveillance System (GTSS) - Global Adult Tobacco Survey (GATS). The Global Adult Tobacco Survey (GATS) is the global standard to systematically monitor adult tobacco use and track key tobacco control indicators. GATS is a nationally representative household survey of adults 15 years of age or older, using a standard protocol. It is intended to generate comparable data within and across countries. GATS enhances countries' capacity to design, implement and evaluate tobacco control interventions.

Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.

This archived public use dataset contains historical case and percent positivity data updated weekly for all available counties and jurisdictions. Each week, the dataset was refreshed to capture any historical updates. Please note, percent positivity data may be incomplete for the most recent time period.

Related data CDC provides the public with two active versions of COVID-19 county-level community transmission level data: this dataset with historical case and percent positivity data for each county from January 22, 2020 (Weekly Historical Changes dataset) and a dataset with the levels as originally posted (Weekly Originally Posted dataset) since October 20, 2022. Please navigate to the Weekly Originally Posted dataset for the Community Transmission Levels published weekly on Thursdays.

Methods for calculating county level of community transmission indicator The County Level of Community Transmission indicator uses two metrics: (1) total new COVID-19 cases per 100,000 persons in the last 7 days and (2) percentage of positive SARS-CoV-2 diagnostic nucleic acid amplification tests (NAAT) in the last 7 days. For each of these metrics, CDC classifies transmission values as low, moderate, substantial, or high (below and here). If the values for each of these two metrics differ (e.g., one indicates moderate and the other low), then the higher of the two should be used for decision-making.

CDC core metrics of and thresholds for community transmission levels of SARS-CoV-2 Total New Case Rate Metric: "New cases per 100,000 persons in the past 7 days" is calculated by adding the number of new cases in the county (or other administrative level) in the last 7 days divided by the population in the county (or other administrative level) and multiplying by 100,000. "New cases per 100,000 persons in the past 7 days" is considered to have transmission level of Low (0-9.99); Moderate (10.00-49.99); Substantial (50.00-99.99); and High (greater than or equal to 100.00).

Test Percent Positivity Metric: "Percentage of positive NAAT in the past 7 days" is calculated by dividing the number of positive tests in the county (or other administrative level) during the last 7 days by the total number of tests resulted over the last 7 days. "Percentage of positive NAAT in the past 7 days" is considered to have transmission level of Low (less than 5.00); Moderate (5.00-7.99); Substantial (8.00-9.99); and High (greater than or equal to 10.00).

The data in this dataset are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.

This dataset is created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access.

Archived data CDC has archived two prior versions of these datasets. Both versions contain the same 7 data elements reflecting community transmission levels for all available counties and jurisdictions; however, the datasets updated daily. The archived datasets can be found here:

<a href="https://data.cdc.gov/Public-Health-Surveillance/United-States-COVID-19-County-Level-of-Community-T

The CDC Botulism Consultation Service, the Alaska Division of Public Health, and the California Department of Public Health provide clinical consultations on suspected cases of all types of botulism except infant botulism. These agencies are the only sources of antitoxin for non-infant botulism in the United States. The California Infant Botulism Treatment and Prevention provides clinical consultations on suspected infant botulism cases; it is the only source of antitoxin for infant botulism in the United States. Together, these clinical consultations provide expert guidance to clinicians and support the collection of epidemiologic and medical information for all suspected botulism cases reported in the United States.

1999-2018. The GYTS is a school-based survey that collects data on students aged 13–15 years using a standardized methodology for constructing the sample frame, selecting schools and classes, and processing data. The GYTS surveillance system is intended to enhance the capacity of countries to design, implement, and evaluate tobacco control and prevention programs. Funding for the GYTS has been provided by the Canadian Public Health Association, National Cancer Institute, United Nations Children Emergency Fund, and the World Health Organization—Tobacco Free Initiative.

This dataset includes breastfeeding data from the National Immunization Survey (NIS). This data is used for DNPAO's Data, Trends, and Maps database, which provides national and state specific data on obesity, nutrition, physical activity, and breastfeeding. For more information about breastfeeding and NIS visit https://www.cdc.gov/breastfeeding/data/nis_data/index.htm.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation—Smokefree Campus. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include state smokefree indoor air laws for smokefree campuses in private and public colleges and schools (K-12).

NNDSS - Table II. Meningococcal to Pertussis - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Data for meningococcal disease, invasive caused by serogroups ACWY, serogroup B, other serogroups, and unknown serogroups are available in Table I.

This file contains the complete set of data reported to 122 Cities Mortality Reposting System. The system was retired as of 10/6/2016. While the system was running each week, the vital statistics offices of 122 cities across the United States reported the total number of death certificates processed and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group (Under 28 days, 28 days - 1 year, 1-14 years, 15-24 years, 25-44 years, 45-64 years, 65-74 years, 75-84 years, and - 85 years). U:Unavailable. - : No reported cases.* Mortality data in this table were voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. Total includes unknown ages. More information on Flu Activity & Surveillance is available at http://www.cdc.gov/flu/weekly/fluactivitysurv.htm.

National Immunization Survey-Adult COVID Module (NIS-ACM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. These data represent trends in vaccination status and intent by week for the national-level view, and by month for the jurisdiction-level view.

NNDSS - Table II. Legionellosis to Malaria - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation—Youth Access. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to restrictions, enforcement and penalties associated with the sale of cigarettes to youth through retail sales and vending machines.

Data on obesity among children and adolescents aged 2-19 years by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Health and Nutrition Examination Survey. For more information on the National Health and Nutrition Examination Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

This file contains the provisional percent of total deaths by week for COVID-19, Influenza, and Respiratory Syncytial Virus for deaths occurring among residents in the United States, by sex, age group, and race and Hispanic origin. Provisional data are based on non-final counts of deaths based on the flow of mortality data in National Vital Statistics System.

Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States

• Archived data are here: https://data.cdc.gov/resource/uxgd-cqqc

• CDC is exploring use of data obtained from IQVIA§ (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices.

• These projected pharmacy estimates include flu vaccinations that were billed for (i.e. claims) or paid by cash. Medical office projected estimates are claims-based only.

• The sampled pharmacies and physician medical offices and the captured volume of transactions represent approximately 92% and 82% of influenza vaccines administered nationally, respectively.

• Vaccinations administered in other settings such as workplaces and community settings are not included in these data.

*National estimates for pharmacies and medical offices include vaccinations administered in 50 states and DC. National estimates for medical office vaccinations do not include doses where geographic information (i.e. which state the dose was administered in) was missing. Pharmacy data are through Friday of each week and medical office data are through Saturday of each week. Week ending dates for prior seasons are aligned with the current season’s week ending dates.

§ 1) King, L. M., Bartoces, M., Fleming-Dutra, K. E., et. al, L. A. (2020). Changes in US outpatient antibiotic prescriptions from 2011–2016external icon. Clinical Infectious Diseases, 70(3), 370-377. 2) McLaughlin, J. M., Swerdlow, D. L., Khan, F., et. Al (2019). Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United Statesexternal icon. Human vaccines & immunotherapeutics, 15(4), 841-849.

National Immunization Survey Child COVID Module (NIS-CCM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. These data represent trends in vaccination status and intent, and other behavioral indicators, by demographics and other characteristics.

NOTE: On October 19, 2021, estimates for 2016–2018 by health insurance status were revised to correct errors. Changes are highlighted and tagged at https://www.cdc.gov/nchs/data/hus/2019/012-508.pdf

Data on health conditions among children under age 18, by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Health Interview Survey, Family Core and Sample Child questionnaires. For more information on the National Health Interview Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

Note: After May 3, 2024, this dataset will no longer be updated because hospitals are no longer required to report data on COVID-19 hospital admissions, hospital capacity, or occupancy data to HHS through CDC’s National Healthcare Safety Network (NHSN). The related CDC COVID Data Tracker site was revised or retired on May 10, 2023.

This dataset represents weekly COVID-19 hospitalization data and metrics aggregated to national, state/territory, and regional levels. COVID-19 hospitalization data are reported to CDC’s National Healthcare Safety Network, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN and included in this dataset represent aggregated counts and include metrics capturing information specific to COVID-19 hospital admissions, and inpatient and ICU bed capacity occupancy.

Reporting information:As of December 15, 2022, COVID-19 hospital data are required to be reported to NHSN, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN represent aggregated counts and include metrics capturing information specific to hospital capacity, occupancy, hospitalizations, and admissions. Prior to December 15, 2022, hospitals reported data directly to the U.S. Department of Health and Human Services (HHS) or via a state submission for collection in the HHS Unified Hospital Data Surveillance System (UHDSS).While CDC reviews these data for errors and corrects those found, some reporting errors might still exist within the data. To minimize errors and inconsistencies in data reported, CDC removes outliers before calculating the metrics. CDC and partners work with reporters to correct these errors and update the data in subsequent weeks.Many hospital subtypes, including acute care and critical access hospitals, as well as Veterans Administration, Defense Health Agency, and Indian Health Service hospitals, are included in the metric calculations provided in this report. Psychiatric, rehabilitation, and religious non-medical hospital types are excluded from calculations.Data are aggregated and displayed for hospitals with the same Centers for Medicare and Medicaid Services (CMS) Certification Number (CCN), which are assigned by CMS to counties based on the CMS Provider of Services files.Full details on COVID-19 hospital data reporting guidance can be found here: https://www.hhs.gov/sites/default/files/covid-19-faqs-hospitals-hospital-laboratory-acute-care-facility-data-reporting.pdf

Metric details:Time Period: timeseries data will update weekly on Mondays as soon as they are reviewed and verified, usually before 8 pm ET. Updates will occur the following day when reporting coincides with a federal holiday. Note: Weekly updates might be delayed due to delays in reporting. All data are provisional. Because these provisional counts are subject to change, including updates to data reported previously, adjustments can occur. Data may be updated since original publication due to delays in reporting (to account for data received after a given Thursday publication) or data quality corrections.New COVID-19 Hospital Admissions (count): Number of new admissions of patients with laboratory-confirmed COVID-19 in the previous week (including both adult and pediatric admissions) in the entire jurisdiction.New COVID-19 Hospital Admissions (7-Day Average): 7-day average of new admissions of patients with laboratory-confirmed COVID-19 in the previous week (including both adult and pediatric admissions) in the entire jurisdiction.Cumulative COVID-19 Hospital Admissions: Cumulative total number of admissions of patients with labo

NNDSS - Table II. Varicella to West Nile virus disease - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNet Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I. �� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the Arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/document/SRCA_FINAL_REPORT_2006-2012_final.xlsx.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

Monthly Nirsevimab Receipt and Intent Among Females Aged 18-49 Years Who Have a Baby <8 Months, Are Currently Pregnant, or Are Trying to Get Pregnant.

• Using data from the National Immunization Survey-Adult COVID Module (NIS-ACM), monthly estimates of receipt and intent for baby’s receipt of nirsevimab reported by females aged 18-49 years with infants under the age of 8 months, females aged 18-49 years who are currently pregnant, and females aged 18-49 years who are currently trying to get pregnant.

• The NIS-ACM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older.

The Coronavirus Disease 2019 (COVID-19) Hospitalization Surveillance Network (COVID-NET) a network that conducts active, population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations among children and adults. COVID-NET, along with the Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET) and the Influenza Hospitalization Surveillance Network (FluSurv-NET), comprise the Respiratory Virus Hospitalization Surveillance Network (RESP-NET). The RESP-NET platforms have overlapping surveillance areas and use similar methods to collect data. COVID-NET is CDC’s source for important data on rates of hospitalizations associated with COVID-19. Hospitalization rates show how many people in the surveillance area are hospitalized with COVID-19, compared to the total number of people residing in that area.

Data are preliminary and subject to change as more data become available. Data will be updated weekly.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

The weekly respiratory virus vaccination data come from the National Immunization Survey-Adult COVID Module (NIS-ACM), National Immunization Survey-Child COVID Module (NIS-CCM), and the National Immunization Survey-Flu (NIS-Flu). The NIS-ACM provides data on Influenza (flu), COVID-19, and RSV vaccination for adults aged ≥18 years in the United States. The NIS-CCM provides data on COVID-19 vaccination for children aged 6 months-17 years in the United States. The NIS-Flu provides data on Influenza vaccination for children aged 6 months-17 years in the United States National Immunization Survey data are collected by telephone interview using a random-digit-dialed sample of cellular telephone numbers stratified by state, the District of Columbia, five local jurisdictions (Bexar County TX, Chicago IL, Houston TX, New York City NY, and Philadelphia County PA), and Guam, Puerto Rico, and the United States Virgin Islands. Data are weighted to represent the non-institutionalized United States population and mitigate possible bias that can result from incomplete sample frame (exclusion of households with no phone service or only landline telephones) or non-response. All responses are self-reported, or reported by a parent for children 6 months-17 years. For more information about the surveys, see https://www.cdc.gov/vaccines/imz-managers/nis/about.html#current-surveys. Estimates should be interpreted with caution when there is a small sample size or wide confidence interval. 

NNDSS - Table II. Hepatitis (viral, acute) C - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Based on the CSTE Position Statement 15-ID-03: Revision of the Case Definition of Hepatitis C for National Notification, acute hepatitis C is now reported by case classification status.

NNDSS - Table 1D. Arboviral diseases, Western equine encephalitis virus disease to Babesiosis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.

Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.

• Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).

2011-2022. The ASTDD Synopses of State Oral Health Programs contain information useful in tracking states’ efforts to improve oral health and contributions to progress toward the national targets for Healthy People objectives for oral health. A subset of the information collected from the most recent five years is provided on the Oral Health Data website. For more information, see http://www.cdc.gov/oralhealthdata/overview/synopses/index.html

1991-2016. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Funding Data, Appropriations (1991-2016) and Expenditures (2008-2016). Appropriations data show public funds allocated to/by a particular state for tobacco prevention and control. They are not necessarily expended. Appropriations are from four major funding sources, Federal, state, Robert Wood Johnson Foundation (RWJF), and the American Legacy Foundation (Legacy). Expenditures are amounts spent by state tobacco control programs on tobacco prevention and control. Expenditure data are available by CDC Best Practices Program Components (State and Community Interventions, Health Communication Interventions, Cessation Interventions, Surveillance and Evaluation, and Administration and Management). Expenditures from 2008 to 2014 are compared against 2007 CDC Best Practices Recommendations; expenditures from 2015 and forward are compared against 2014 CDC Best Practices Recommendations.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation—Tax. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include state excise taxes on e-cigarettes and tax stamps.

The U.S. Census Bureau, in collaboration with five federal agencies, launched the Household Pulse Survey to produce data on the social and economic impacts of Covid-19 on American households. The Household Pulse Survey was designed to gauge the impact of the pandemic on employment status, consumer spending, food security, housing, education disruptions, and dimensions of physical and mental wellness.

The survey was designed to meet the goal of accurate and timely weekly estimates. It was conducted by an internet questionnaire, with invitations to participate sent by email and text message. The sample frame is the Census Bureau Master Address File Data. Housing units linked to one or more email addresses or cell phone numbers were randomly selected to participate, and one respondent from each housing unit was selected to respond for him or herself. Estimates are weighted to adjust for nonresponse and to match Census Bureau estimates of the population by age, sex, race and ethnicity, and educational attainment. All estimates shown meet the NCHS Data Presentation Standards for Proportions.

1995-2010. BRFSS land line only prevalence data. BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. Data will be updated annually as it becomes available. Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf Glossary: https://chronicdata.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct/data

NNDSS - Table II. Mumps to Rabies, animal - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

Percent of tests positive for a pathogen is one of the surveillance metrics used to monitor respiratory pathogen transmission over time. The percent of tests positive is calculated by dividing the number of positive tests by the total number of tests administered, then multiplying by 100 [(# of positive tests/total tests) x 100]. These data include percent of tests positive values for the detection of severe acute respiratory virus coronavirus type 2 (SARS-CoV-2), the virus that causes COVID-19 and Respiratory syncytial virus (RSV) reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS), a sentinel network of laboratories located through the US, includes clinical, public health and commercial laboratories; additional information available at: https://www.cdc.gov/surveillance/nrevss/index.html. Influenza results include clinical laboratory test results from NREVSS and influenza collaborating laboratories; more details about influenza virologic surveillance are available here: https://www.cdc.gov/flu/weekly/overview.html.

Data represent calculations based on laboratory tests performed, not individual people tested. RSV and COVID-19 are limited to nucleic acid amplification tests (NAATs), also listed as polymerase chain reaction tests (PCR). Participating laboratories report weekly to CDC the total number of RSV tests performed that week and the number of those tests that were positive. The RSV trend graphs display the national average of the weekly % test positivity for the current, previous, and following weeks in accordance with the recommendations for assessing RSV trends by percent (https://academic.oup.com/jid/article/216/3/345/3860464).

All data are provisional and subject to change.

This dataset provides data at the county level for the contiguous United States. It includes monthly Palmer Drought Severity Index (PDSI) data from 1895-2016 provided by the Cooperative Institute for Climate and Satellites - North Carolina. Please refer to the metadata attachment for more information.

Learn more about drought on the Tracking Network's website: https://ephtracking.cdc.gov/showDroughtLanding.

By using these data, you signify your agreement to comply with the following requirements:

1. Use the data for statistical reporting and analysis only.
2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals.
3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov.
4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating.
5. Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC.
6. Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking.

Problems or Questions? Email trackingsupport@cdc.gov.

2002-2010. BRFSS SMART County Prevalence land line only data. The Selected Metropolitan Area Risk Trends (SMART) project uses the Behavioral Risk Factor Surveillance System (BRFSS) to analyze the data of selected counties with 500 or more respondents. BRFSS data can be used to identify emerging health problems, establish and track health objectives, and develop and evaluate public health policies and programs. BRFSS is a continuous, state-based surveillance system that collects information about modifiable risk factors for chronic diseases and other leading causes of death. Data will be updated annually as it becomes available. Detailed information on sampling methodology and quality assurance can be found on the BRFSS website (http://www.cdc.gov/brfss). Methodology: http://www.cdc.gov/brfss/factsheets/pdf/DBS_BRFSS_survey.pdf Glossary: https://chronicdata.cdc.gov/Behavioral-Risk-Factors/Behavioral-Risk-Factor-Surveillance-System-BRFSS-H/iuq5-y9ct/data

This dataset provides modeled predictions of PM2.5 levels from the EPA's Downscaler model. Data are at the census tract level for 2016-2020. These data are used by the CDC's National Environmental Public Health Tracking Network to generate air quality measures. Census tract-level datasets contain estimates of the mean predicted concentration and associated standard error. Please refer to the metadata attachment for more information. Learn more about outdoor air quality on the Tracking Network's website: https://ephtracking.cdc.gov/showAirLanding.action. By using these data, you signify your agreement to comply with the following requirements: 1. Use the data for statistical reporting and analysis only. 2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals. 3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov. 4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating. 5. Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC. 6. Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking.

To rapidly monitor recent changes in the use of telemedicine, the National Center for Health Statistics (NCHS) and the Health Resources and Services Administration’s Maternal and Child Health Bureau (HRSA MCHB) partnered with the Census Bureau on an experimental data system called the Household Pulse Survey. This 20-minute online survey was designed to complement the ability of the federal statistical system to rapidly respond and provide relevant information about the impact of the coronavirus pandemic in the U.S.

The U.S. Census Bureau, in collaboration with five federal agencies, launched the Household Pulse Survey to produce data on the social and economic impacts of the COVID-19 pandemic on American households. The Household Pulse Survey was designed to gauge the impact of the pandemic on employment status, consumer spending, food security, housing, education disruptions, and dimensions of physical and mental wellness.

The survey was designed to meet the goal of accurate and timely estimates. It was conducted by an internet questionnaire, with invitations to participate sent by email and text message. The sample frame is the Census Bureau Master Address File Data. Housing units linked to one or more email addresses or cell phone numbers were randomly selected to participate, and one respondent from each housing unit was selected to respond for him or herself. Estimates are weighted to adjust for nonresponse and to match Census Bureau estimates of the population by age, sex, race and ethnicity, and educational attainment. All estimates shown meet the NCHS Data Presentation Standards for Proportions.

This file contains the provisional percent of total deaths by week for COVID-19, Influenza, and Respiratory Syncytial Virus for deaths occurring among residents in the United States. Provisional data are based on non-final counts of deaths based on the flow of mortality data in National Vital Statistics System.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

This data represents the age-adjusted prevalence of high total cholesterol, hypertension, and obesity among US adults aged 20 and over between 1999-2000 to 2017-2018.

Notes:

• All estimates are age adjusted by the direct method to the U.S. Census 2000 population using age groups 20–39, 40–59, and 60 and over.

Definitions

Hypertension: Systolic blood pressure greater than or equal to 130 mmHg or diastolic blood pressure greater than or equal to 80 mmHg, or currently taking medication to lower high blood pressure

High total cholesterol: Serum total cholesterol greater than or equal to 240 mg/dL.

Obesity: Body mass index (BMI, weight in kilograms divided by height in meters squared) greater than or equal to 30.

Data Source and Methods

Data from the National Health and Nutrition Examination Surveys (NHANES) for the years 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010, 2011–2012, 2013–2014, 2015–2016, and 2017–2018 were used for these analyses.

NHANES is a cross-sectional survey designed to monitor the health and nutritional status of the civilian noninstitutionalized U.S. population. The survey consists of interviews conducted in participants’ homes and standardized physical examinations, including a blood draw, conducted in mobile examination centers.

2000-2018. Water Fluoridation Statistics is a biennial report of the percentage and number of people receiving fluoridated water from 2000 through 2018, originally published at http://www.cdc.gov/fluoridation/statistics/index.htm. For more information, see: http://www.cdc.gov/oralhealthdata/overview/fluoridation_indicators.html

NNDSS - Table II. Salmonellosis to Shigellosis - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

$ Includes E. coli O157:H7, Shiga toxin-positive, serogroup non-O157, and Shiga toxin-positive, not serogrouped.

Data for School year-end 1994 through year-end 2020. State oral health surveys are the data sources for these indicators. States periodically conduct independent screening surveys of a probability sample designed to be representative of all third-grade students in the state. Some states also conduct surveys of students in other grades in school, or of Head Start program enrollees. This surveillance activity is voluntary. States submit their data to the Association of State and Territorial Dental Directors (ASTDD), where the survey design and data collected are reviewed for quality and against the criteria for inclusion in NOHSS, before being sent to CDC for inclusion in Oral Health Data. For more information, see: http://www.cdc.gov/oralhealthdata/overview/childIndicators/

This dataset includes data on policy and environmental supports for physical activity, diet, and breastfeeding. This data is used for DNPAO's Data, Trends, and Maps database, which provides national and state specific data on obesity, nutrition, physical activity, and breastfeeding.

This site provides historical data related to COVID-19 booster dose eligibility presented on two CDC COVID Data Tracker sites: Vaccinations in the US and Vaccination Equity.  Data are updated weekly on Thursdays.Some COVID-19 vaccine recipients are eligible to receive booster doses,  and criteria for booster eligibility may change over time. Data and footnotes will be updated to align with the current recommendations.  CDC counts people as having “received a booster dose” if they are fully vaccinated and received another dose of any COVID-19 vaccine on or after August 13, 2021. This does not distinguish whether the recipient is immunocompromised and received an additional doseData Limitations: The booster eligibility metric excludes fully vaccinated recipients who have an “Other” primary series vaccine type.  Booster eligibility counts and percentages exclude vaccine administrations reported by Texas as the primary series cannot be linked to booster dose in the aggregate data submitted by Texas. Footnotes:CDC counts people as being “eligible to get a booster dose<

Provisional death counts of diabetes, coronavirus disease 2019 (COVID-19) and other select causes of death, by month, sex, and age.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

Note: Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This table summarizes COVID-19 case and death data submitted to CDC as case reports for the line-level dataset. Case and death counts are stratified according to sex, age, and race and ethnicity at regional and national levels. Data for US territories are included in case and death counts, but not population counts. Weekly cumulative counts with five or fewer cases or deaths are not reported to protect confidentiality of patients. Records with unknown or missing sex, age, or race and ethnicity and of multiple, non-Hispanic race and ethnicity are included in case and death totals. COVID-19 case and death data are provisional and are subject to change. Visualization of COVID-19 case and death rate trends by demographic variables may be viewed on COVID Data Tracker (https://covid.cdc.gov/covid-data-tracker/#demographicsovertime).

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Deaths involving COVID-19 reported to NCHS by week and county Social Vulnerability Index (SVI) in the United States. SVI scores are from CDC/ASTDR's Geospatial Research, Analysis & Service Program 2018 database. These scores range from 0 to 1, and categorized as low (0-0.333), moderate (0.334-0.666) or high (0.667-1).

More information on SVI can be found here: https://www.atsdr.cdc.gov/placeandhealth/svi/index.html

NNDSS - Table II. Cryptosporidiosis to Dengue Hemorrhagic Fever - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Dengue Fever includes cases that meet criteria for Dengue Fever with hemorrhage, other clinical, and unknown case classifications. �� DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

U.S. Department of Health and Human Services (HHS). Centers for Disease Control and Prevention (CDC). Healthy People 2020 Tobacco Use Objectives. Healthy People 2020. Healthy People 2020 provides a framework for action to reduce tobacco use to the point that it is no longer a public health problem for the Nation. This dataset includes information related to the Healthy People 2020 Tobacco Use objectives, operational definitions, baselines, and targets. Baseline years may vary by objective. Targets represented correspond to the year 2020.

This dataset provides model-based provisional estimates of the weekly numbers of drug overdose, suicide, and transportation-related deaths using “nowcasting” methods to account for the normal lag between the occurrence and reporting of these deaths. Estimates less than 10 are suppressed. These early model-based provisional estimates were generated using a multi-stage hierarchical Bayesian modeling process to generate smoothed estimates of the weekly numbers of death, accounting for reporting lags. These estimates are based on several assumptions about how the reporting lags have changed in recent months across different jurisdictions, and the resulting estimates differ from other sources of provisional mortality data. For now, these estimates should be considered highly uncertain until further evaluations can be done to determine the validity of these assumptions about timeliness. The true patterns in reporting lags will not be known until data are finalized, typically 11–12 months after the end of the calendar year. Importantly, these estimates are not a replacement for monthly provisional drug overdose death counts, or quarterly provisional mortality estimates. For more detail about the nowcasting methods and models, see:

Rossen LM, Hedegaard H, Warner M, Ahmad FB, Sutton PD. Early provisional estimates of drug overdose, suicide, and transportation-related deaths: Nowcasting methods to account for reporting lags. Vital Statistics Rapid Release; no 11. Hyattsville, MD: National Center for Health Statistics. February 2021. DOI: https://doi.org/10.15620/ cdc:101132

Interactive Summary Health Statistics for Adults provide annual estimates of selected health topics for adults aged 18 years and over based on final data from the National Health Interview Survey. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

Cumulative provisional counts of deaths sex, race/Hispanic origin, age group, and by select underlying causes of death. The dataset also includes provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death. Includes deaths that occurred between January 1, 2020 to July 4, 2020.

This dataset has been archived and will no longer be updated as of 10/16/2024. For updated data, please refer to the ILINet State Activity Indicator Map.

Information on outpatient visits to health care providers for respiratory illness referred to as influenza-like illness (ILI) is collected through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet). ILINet consists of outpatient healthcare providers in all 50 states, Puerto Rico, the District of Columbia, and the U.S. Virgin Islands. More than 100 million patient visits were reported during the 2022-23 season. Each week, more than 3,000 outpatient health care providers around the country report to CDC the number of patient visits for ILI by age group (0-4 years, 5-24 years, 25-49 years, 50-64 years, and ≥65 years) and the total number of visits for any reason. A subset of providers also reports total visits by age group. For this system, ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and a cough and/or a sore throat. Activity levels are based on the percent of outpatient visits due to ILI in a jurisdiction compared to the average percent of ILI visits that occur during weeks with little or no influenza virus circulation (non-influenza weeks) in that jurisdiction. The number of sites reporting each week is variable; therefore, baselines are adjusted each week based on which sites within each jurisdiction provide data. To perform this adjustment, provider level baseline ILI ratios are calculated for those that have a sufficient reporting history. Providers that do not have the required reporting history to calculate a provider-specific baseline are assigned the baseline ratio for their practice type. The jurisdiction level baseline is then calculated using a weighted sum of the baseline ratios for each contributing provider.

The activity levels compare the mean reported percent of visits due to ILI during the current week to the mean reported percent of visits due to ILI during non-influenza weeks. The 13 activity levels correspond to the number of standard deviations below, at, or above the mean for the current week compared with the mean during non-influenza weeks. Activity levels are classified as minimal (levels 1-3), low (levels 4-5), moderate (levels 6-7), high (levels 8-10), and very high (levels 11-13). An activity level of 1 corresponds to an ILI percentage below the mean, level 2 corresponds to an ILI percentage less than 1 standard deviation above the mean, level 3 corresponds to an ILI percentage more than 1 but less than 2 standard deviations above the mean, and so on, with an activity level of 10 corresponding to an ILI percentage 8 to 11 standard deviations above the mean. The very high levels correspond to an ILI percentage 12 to 15 standard deviations above the mean for level 11, 16 to 19 standard deviations above the mean for level 12, and 20 or more standard deviations above the mean for level 13.

Disclaimers:

The ILI Activity Indicator map reflects the intensity of ILI activity, not the extent of geographic spread of ILI, within a jurisdiction. Therefore, outbreaks occurring in a single area could cause the entire jurisdiction to display high or very high activity levels. In addition, data collected in ILINet may disproportionally represent certain populations within a jurisdiction, and therefore, may not accurately depict the full picture of respiratory illness activity for the entire jurisdiction. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being more complete.

More information is available on FluView Interactive.

NNDSS - Table II. Babesiosis to Coccidioidomycosis - 2014.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting year 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

NNDSS - Table II. West Nile virus disease - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Updated weekly from the Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases (ArboNET Surveillance). Data for Jamestown Canyon virus, La Crosse virus, Chikungunya virus, Eastern equine encephalitis virus, Powassan virus, St. Louis virus, and Western equine encephalitis virus diseases are available in Table I.

¶ Not reportable in all states. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/downloads.html.

NNDSS - Table II. Babesiosis to Campylobacteriosis - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation – Smokefree Indoor Air. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to state legislation on smokefree indoor air in private worksites, restaurants, and bars.

NNDSS - Table II. Hepatitis (viral, acute) A & B - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

The National Hospital Care Survey (NHCS) collects data on patient care in hospital-based settings to describe patterns of health care delivery and utilization in the United States. Settings currently include inpatient and emergency departments (ED). From this collection, the NHCS contributes data that may inform emerging national health threats such as the current opioid public health emergency. The 2022 - 2024 NHCS are not yet fully operational so it is important to note that the data presented here are preliminary and not nationally representative.

The data are from 32 hospitals submitting inpatient and 27 hospitals submitting ED Uniform Bill (UB)-04 administrative claims from December 1, 2022–November 30, 2024. Even though the data are not nationally representative, they can provide insight into the use of opioids and other overdose drugs. The NHCS data is submitted from various types of hospitals (e.g., general/acute, children’s, etc.) and can show results from a variety of indicators related to drug use, such as overall drug use, comorbidities, and drug and polydrug overdose. NHCS data can also be used to report on patient conditions within the hospital over time.

National Immunization Survey Child COVID Module (NIS-CCM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. These data represent trends in vaccination status and intent, and other behavioral indicators, by demographics and other characteristics.

CDC is planning a major relaunch of CDC.gov on May 15th, followed by subsequent monthly batches of sites restructuring their CDC.gov content into the fall of 2024.

Because this restructuring includes merged or changed content, CDC will be updating all URLs to a new standard naming structure. About 70% of these updates will occur during the May 15th launch, but another 30% of our content and URLs will be restructured on a rolling schedule.

This data set contains the mapping information from old URLs to new URLs. Before May 15th, 2024, this dataset will only include one row of data to preview the fields in the dataset. After May 15th it will contain all content URLs that changed as part of the relaunch of CDC.gov. After launch, we will continue to add additional mappings typically around the 15th of each month for any for sites updated in each monthly batch.

NNDSS - Table II. Giardiasis to Haemophilus influenza - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Data for Haemophilus influenzae (age <5 for serotype b, nontypeable, non-b serotype, and unknown serotype) are available in Table I.

Provisional estimates of infant mortality (deaths of infants under 1 year per 1,000 live births), neonatal mortality (deaths of infants aged 0-27 days per 1,000 live births), postneonatal mortality (deaths of infants aged 28 days through 11 months per 1,000 live births), and death rates for the five leading causes of infant death.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Summary dataset provides a full snapshot of clinic services and profile, patient characteristics, and ART success rates. It is worth noting that patient medical characteristics, such as age, diagnosis, and ovarian reserve, affect ART treatment’s success. Comparison of success rates across clinics may not be meaningful because of differences in patient populations and ART treatment methods. The success rates displayed in this dataset do not reflect any one patient’s chance of success. Patients should consult with a doctor to understand their chance of success based on their own characteristics.

Source: Behavioral Risk Factor Surveillance System (BRFSS), 2012 & 2014.

1. Centers for Disease Control and Prevention (CDC). Best Practices for Comprehensive Tobacco Control Programs. Funding. CDC's Best Practices for Comprehensive Tobacco Control Programs is an evidence-based guide to help states plan and establish effective tobacco control programs to prevent and reduce tobacco use. Data are reported at total and per capita funding levels. Data include recommended, upper, and lower total funding levels for state programs, in addition to funding breakdowns by intervention areas such as: State and Community Interventions, Health Communication Interventions, Cessation Interventions, Surveillance and Evaluation, and Administration and Management.

NNDSS - Table II. Salmonellosis to Shigellosis - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Includes E. coli O157:H7; Shiga toxin positive, serogroup non-O157; and Shiga toxin positive, not serogrouped.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

NNDSS - Table II. Lyme disease to Meningococcal - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. § Data for meningococcal disease, invasive caused by serogroups ACWY; serogroup B; other serogroup; and unknown serogroup are available in Table I.

NNDSS - Table II. Tetanus to Varicella - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

1999-2024. National Association of Attorneys General (NAAG). Policy—Tobacco Settlement Payments. The National Association of Attorneys General (NAAG) provides Tobacco Settlement Revenue data for 46 states participating in the Master Settlement Agreement (MSA) with the four largest tobacco companies in the United States. Data are reported on an annual basis. Four states (Florida, Minnesota, Mississippi, and Texas) provide the STATE System their Tobacco Settlement Revenue data independently.

This dataset represents preliminary estimates of cumulative U.S. COVID-19 disease burden for the 2024-2025 period, including illnesses, outpatient visits, hospitalizations, and deaths. The weekly COVID-19-associated burden estimates are preliminary and based on continuously collected surveillance data from patients hospitalized with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. The data come from the Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET), a surveillance platform that captures data from hospitals that serve about 10% of the U.S. population. Each week CDC estimates a range (i.e., lower estimate and an upper estimate) of COVID-19 -associated burden that have occurred since October 1, 2024.

Note: Data are preliminary and subject to change as more data become available. Rates for recent COVID-19-associated hospital admissions are subject to reporting delays; as new data are received each week, previous rates are updated accordingly.

References Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS One. 2015;10(3):e0118369. https://doi.org/10.1371/journal.pone.0118369  Rolfes, MA, Foppa, IM, Garg, S, et al. Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness. Influenza Other Respi Viruses. 2018; 12: 132– 137. https://doi.org/10.1111/irv.12486Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of influenza cases averted by vaccination in the United States. Vaccine. 2018;36(48):7331-7337. doi:10.1016/j.vaccine.2018.10.026 Collier SA, Deng L, Adam EA, Benedict KM, Beshearse EM, Blackstock AJ, Bruce BB, Derado G, Edens C, Fullerton KE, Gargano JW, Geissler AL, Hall AJ, Havelaar AH, Hill VR, Hoekstra RM, Reddy SC, Scallan E, Stokes EK, Yoder JS, Beach MJ. Estimate of Burden and Direct Healthcare Cost of Infectious Waterborne Disease in the United States. Emerg Infect Dis. 2021 Jan;27(1):140-149. doi: 10.3201/eid2701.190676. PMID: 33350905; PMCID: PMC7774540.Reed C, Kim IK, Singleton JA,  et al. Estimated influenza illnesses and hospitalizations averted by vaccination–United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6349a2.htm Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the Prevalence of Pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15(12):2004-2007. https://dx.doi.org/10.3201/eid1512.091413  Devine O, Pham H, Gunnels B, et al. Extrapolating Sentinel Surveillance Information to Estimate National COVID-19 Hospital Admission Rates: A Bayesian Modeling Approach. Influenza and Other Respiratory Viruses. https://onlinelibrary.wiley.com/doi/10.1111/irv.70026. Volume18, Issue10. October 2024.COVID-NET | COVID-19 | CDC https://www.cdc.gov/covid/hcp/clinical-care/systematic-review-process.html  Excess natural-cause deaths in California by cause and setting: March 2020 through February 2021 | PNAS Nexus | Oxford Academic (oup.com)Kruschke, J. K. 2011. Doing Bayesian data analysis: a tutorial with R and BUGS. Elsevier, Amsterdam, Section 3.3.5.

This dataset provides modeled predictions of ozone levels from the EPA's Downscaler model. Data are at the census tract level for 2011-2014. These data are used by the CDC's National Environmental Public Health Tracking Network to generate air quality measures. Census tract-level datasets contain estimates of the mean predicted concentration and associated standard error. Please refer to the metadata attachment for more information.

Learn more about outdoor air quality on the Tracking Network's website: https://ephtracking.cdc.gov/showAirLanding.action.

By using these data, you signify your agreement to comply with the following requirements:

1. Use the data for statistical reporting and analysis only.
2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals.
3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov.
4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating.

NNDSS - Table II. Chlamydia to Coccidioidomycosis - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

VEHSS Composite Prevalence Estimates 2017, 2019, 2021, 2022. This dataset contains estimates of the prevalence of visual acuity loss and major eye diseases generated using a Bayesian meta-analytic modeling approach that combines information from multiple data sources to produce comprehensive estimates of prevalence by age, race, and gender at the national, state and county levels. These composite prevalence estimates are the primary surveillance measures developed by the Centers for Disease Control and Prevention’s Vision & Eye Health Surveillance System (VEHSS).

For more information about these estimates including summary tables and maps, methods, and links to related publications visit https://www.cdc.gov/visionhealth/vehss/estimates/index.html To view this data in the VEHSS interactive data visualization application, visit https://ddt-vehss.cdc.gov/ and search for “VEHSS Composite Prevalence Estimate”.

Visual Acuity Loss: Visual acuity loss prevalence estimates represent best-corrected visual acuity in the better-seeing eye and are included in rows where Category=’Measured Visual Acuity’. Rows with Subgroup = ‘Any vision loss' represents any impairment or blindness of 20/40 or worse; rows with Subgroup = 'US-defined blindness' refers to the subset of vision loss that is 20/200 or worse.

Age Related Macular Degeneration: The age-related macular degeneration (AMD) estimates represent AMD as measured with retinal imaging examination, and are included in rows where Category = ‘Age Related Macular Degeneration’. The Subgroup ‘Vision threatening AMD’ includes patients with geographic atrophy, wet-form AMD, or choroidal neovascularization in either eye. The Subgroup ‘Non-vision threatening AMD’ includes patients with early or intermediate dry-form AMD defined as retinal pigment epithelium abnormalities or drusen ≥125 µm in the worse-affected eye, and do not have vision threatening AMD.

Diabetic Retinopathy: The diabetic retinopathy (DR) estimates represent DR as measured with retinal imaging examination, and are included in rows where Category=’Diabetic Eye Diseases’. The Subgroup ‘Vision threatening DR’ includes patients with severe non-proliferative DR, proliferative DR, and diabetic macular edema. The Subgroup ‘Non-vision threatening DR’ is defined as patients with mild-moderate non-proliferative DR or unspecified DR, and do not have vision threatening DR.

Glaucoma: The glaucoma estimates represent glaucoma as measured with retinal imaging examination and are included in rows where Category=’Glaucoma’. The Subgroup ‘Vision affecting glaucoma’ includes people with glaucoma and abnormal visual field. The Subgroup ‘Non-vision affecting glaucoma’ is defined as people with glaucoma without an abnormal visual field.

Age Groups: The VEHSS Composite Prevalence Estimates are available by major age groups (All ages, ages 0-17, 18-39, 40-64, 65-84, 85+) and detailed (5-year) age groups, which are indicated by the text “by detailed age groups” in the ‘Indicator’ field.

Prevalence Data Type: These estimates are also available as crude (Data_Value_Type = ‘Crude Prevalence’) or adjusted data (Data_Value_Type=’Adjusted Prevalence). Crude Prevalence is the estimate of the actual number and percentage of people living with each condition. Adjusted Prevalence estimates are adjusted to match the national population by age, race/ethnicity, and gender. Adjusted prevalence estimates can be used to help identify disparities in prevalence between geographic areas that are not explained by differences in demographic characteristics.

Data Sources: Data sources for VEHSS Composite Prevalence Estimates include the National Health and Nutrition Examination Survey (NHANES), the American Community Survey (ACS), the National Survey of Children’s Health (NSCH), the Behavioral Risk Factor Surveillance System (BRFSS), Medicare Fee-For-Service claims, the Transformed Medicaid Statistical Information System, MarketScan commercial insurance

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when bars in states and territories were subject to closing and reopening requirements through executive orders, administrative orders, resolutions, and proclamations for COVID-19. Data can be used to determine when bars in states and territories were subject to closing and reopening requirements through executive orders, administrative orders, resolutions, and proclamations for COVID-19. Data consists exclusively of state and territorial orders, many of which apply to specific counties within their respective state or territory; therefore, data is broken down to the county level.

These data are derived from publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly close or reopen bars found by the CDC, COVID-19 Community Intervention & Critical Populations Task Force, Monitoring & Evaluation Team, Mitigation Policy Analysis Unit, and the CDC, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program from March 11, 2020 through August 15, 2021. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. Effective and expiration dates were coded using only the date provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.

The Research and Development Survey (RANDS) is a platform designed for conducting survey question evaluation and statistical research. RANDS is an ongoing series of surveys from probability-sampled commercial survey panels used for methodological research at the National Center for Health Statistics (NCHS). RANDS estimates are generated using an experimental approach that differs from the survey design approaches generally used by NCHS, including possible biases from different response patterns and sampling frames as well as increased variability from lower sample sizes. Use of the RANDS platform allows NCHS to produce more timely data than would be possible using traditional data collection methods. RANDS is not designed to replace NCHS’ higher quality, core data collections. Below are experimental estimates of loss of work due to illness with coronavirus for three rounds of RANDS during COVID-19. Data collection for the three rounds of RANDS during COVID-19 occurred between June 9, 2020 and July 6, 2020, August 3, 2020 and August 20, 2020, and May 17, 2021 and June 30, 2021. Information needed to interpret these estimates can be found in the Technical Notes. RANDS during COVID-19 included a question about the inability to work due to being sick or having a family member sick with COVID-19. The National Health Interview Survey, conducted by NCHS, is the source for high-quality data to monitor work-loss days and work limitations in the United States. For example, in 2018, 42.7% of adults aged 18 and over missed at least 1 day of work in the previous year due to illness or injury and 9.3% of adults aged 18 to 69 were limited in their ability to work or unable to work due to physical, mental, or emotional problems. The experimental estimates on this page are derived from RANDS during COVID-19 and show the percentage of U.S. adults who did not work for pay at a job or business, at any point, in the previous week because either they or someone in their family was sick with COVID-19. Technical Notes: https://www.cdc.gov/nchs/covid19/rands/work.htm#limitations

This dataset documents rates and trends in heart disease and stroke mortality. Specifically, this report presents county (or county equivalent) estimates of heart disease and stroke death rates in 2000-2019 and trends during two intervals (2000-2010, 2010-2019) by age group (ages 35–64 years, ages 65 years and older), race/ethnicity (non-Hispanic American Indian/Alaska Native, non-Hispanic Asian/Pacific Islander, non-Hispanic Black, Hispanic, non-Hispanic White), and sex (women, men). The rates and trends were estimated using a Bayesian spatiotemporal model and a smoothed over space, time, and demographic group. Rates are age-standardized in 10-year age groups using the 2010 US population. Data source: National Vital Statistics System.

2013-2022. This dataset is a de-identified summary table of vision and eye health data indicators from BRFSS, stratified by all available combinations of age group, race/ethnicity, gender, risk factor and state. BRFSS is a system of telephone surveys conducted by CDC that collect state data about U.S. residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services. BRFSS completes more than 400,000 adult interviews each year across 50 states, the District of Columbia, and three U.S. territories. BRFSS data for VEHSS includes one question from the core component related to Visual Function. Data were suppressed following NCHS standards. Data will be updated as it becomes available. Detailed information on VEHSS BRFSS analyses can be found on the VEHSS BRFSS webpage (link). General information about BRFSS can be found on the BRFSS website (https://www.cdc.gov/brfss). The VEHSS BRFSS dataset was last updated in November 2019.

1995-2025. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation—Preemption. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to statutory state preemption of more stringent local laws on advertising, smokefree indoor air, youth access and licensure.

Provisional deaths involving COVID-19 reported to NCHS by MMWR week, race and Hispanic origin, and age group. Deaths occurred in the United States.

Age groups: 0-4, 5-11, 12-17, 18-29, 30-39, 40-49, 50-64, 65-74, and 75+ years

Deaths by educational attainment, race, sex, and age group for deaths occurring in the United States. Data are final for 2019 and provisional for 2020. The dataset includes annual counts of death for total deaths and for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

Provisional counts of deaths by the month the deaths occurred, by age group and race/ethnicity, for select underlying causes of death for 2020-2021. Final data is provided for 2019. The dataset also includes monthly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

This dataset provides modeled predictions of particulate matter (PM2.5) levels from the EPA's Downscaler model. These data are used by the CDC's National Environmental Public Health Tracking Network to generate air quality measures. Data are at the county levels for 2001-2014. The dataset includes the maximum, median, mean, and population-weighted mean concentration. Please refer to the metadata attachment for more information.

Learn more about outdoor air quality on the Tracking Network's website: https://ephtracking.cdc.gov/showAirLanding.action.

By using these data, you signify your agreement to comply with the following requirements:

1. Use the data for statistical reporting and analysis only.
2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals.
3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov.
4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating.
5. Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC.
6. Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking.

Problems or Questions? Email trackingsupport@cdc.gov.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

This site provides historical data beginning June 14, 2023, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States" site titled “US COVID-19 Vaccine Doses Delivered by Vaccine Type”

Definition for Distributed: Cumulative number of COVID-19 updated vaccine doses distributed in the United States. CDC is no longer reporting metrics for Johnson & Johnson, and the original Pfizer and Moderna vaccines.

Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

The NCHS National Post-acute and Long-term Care Study (NPALS) collects data on post-acute and long-term care providers every two years. The goal is to monitor post-acute and long-term care settings with reliable, accurate, relevant, and timely statistical information to support and inform policy, research, and practice. These data tables provide an overview of the geographic, organizational, staffing, service provision, and user characteristics of paid, regulated long-term and post-acute care providers in the United States. The settings include adult day services centers, home health agencies, hospices, inpatient rehabilitation facilities, long-term care hospitals, and nursing homes.

NNDSS - Table II. Spotted Fever Rickettsiosis to Syphilis - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.

��� Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsiosis. Rocky Mountain spotted fever (RMSF) caused by Rickettsia rickettsii, is the most common and well-known spotted fever.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

NNDSS - Table II. Rabies, animal to Rubella, congenital syndrome - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

NNDSS - Table II. Ehrlichiosis/Anaplasmosis - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Please refer to the MMWR publication for weekly updates to the footnote for this condition.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.

Weekly Cumulative Influenza Vaccination Coverage, Children 6 months through 17 years, United States

• Archived data are available here: https://data.cdc.gov/resource/vfj2-bfuw • Influenza vaccination coverage among children is assessed through the National Immunization Survey-Flu (NIS-Flu) annually, providing weekly influenza vaccination coverage estimates for children 6 months–17 years based upon parental report. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html) o NIS-Flu is a national random-digit-dialed cellular telephone survey of households conducted during the flu season (October-June). • Final estimates for prior seasons and other flu vaccination data are available at CDC’s FluVaxView: https://www.cdc.gov/flu/fluvaxview/index.htm.

National Immunization Survey-Adult COVID Module (NIS-ACM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. Trends in behavioral indicators represent the percent of unvaccinated people responding to each of the indicators by intent status and by week for the national-level view, and by month for the jurisdiction-level view.

The Research and Development Survey (RANDS) is a platform designed for conducting survey question evaluation and statistical research. RANDS is an ongoing series of surveys from probability-sampled commercial survey panels used for methodological research at the National Center for Health Statistics (NCHS). RANDS estimates are generated using an experimental approach that differs from the survey design approaches generally used by NCHS, including possible biases from different response patterns and sampling frames as well as increased variability from lower sample sizes. Use of the RANDS platform allows NCHS to produce more timely data than would be possible using traditional data collection methods. RANDS is not designed to replace NCHS’ higher quality, core data collections. Below are experimental estimates of reduced access to healthcare for three rounds of RANDS during COVID-19. Data collection for the three rounds of RANDS during COVID-19 occurred between June 9, 2020 and July 6, 2020, August 3, 2020 and August 20, 2020, and May 17, 2021 and June 30, 2021. Information needed to interpret these estimates can be found in the Technical Notes. RANDS during COVID-19 included questions about unmet care in the last 2 months during the coronavirus pandemic. Unmet needs for health care are often the result of cost-related barriers. The National Health Interview Survey, conducted by NCHS, is the source for high-quality data to monitor cost-related health care access problems in the United States. For example, in 2018, 7.3% of persons of all ages reported delaying medical care due to cost and 4.8% reported needing medical care but not getting it due to cost in the past year. However, cost is not the only reason someone might delay or not receive needed medical care. As a result of the coronavirus pandemic, people also may not get needed medical care due to cancelled appointments, cutbacks in transportation options, fear of going to the emergency room, or an altruistic desire to not be a burden on the health care system, among other reasons. The Household Pulse Survey (https://www.cdc.gov/nchs/covid19/pulse/reduced-access-to-care.htm), an online survey conducted in response to the COVID-19 pandemic by the Census Bureau in partnership with other federal agencies including NCHS, also reports estimates of reduced access to care during the pandemic (beginning in Phase 1, which started on April 23, 2020). The Household Pulse Survey reports the percentage of adults who delayed medical care in the last 4 weeks or who needed medical care at any time in the last 4 weeks for something other than coronavirus but did not get it because of the pandemic. The experimental estimates on this page are derived from RANDS during COVID-19 and show the percentage of U.S. adults who were unable to receive medical care (including urgent care, surgery, screening tests, ongoing treatment, regular checkups, prescriptions, dental care, vision care, and hearing care) in the last 2 months. Technical Notes: https://www.cdc.gov/nchs/covid19/rands/reduced-access-to-care.htm#limitations

NNDSS - Table II. Lyme disease to Meningococcal - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. �� Data for meningococcal disease, invasive caused by serogroups ACWY; serogroup B; other serogroup; and unknown serogroup are available in Table I.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

NNDSS - Table II. Chlamydia to Coccidioidomycosis - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.

NNDSS - Table IV. Tuberculosis - 2016.This Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States will exclude counts from US territories. Footnote: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Min: Minimum. Max: Maximum. * Case counts for reporting year 2015 and 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf Data for TB are displayed quarterly.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

Community-Based Survey of Supports for Healthy Eating and Active Living (CBS HEAL) is a CDC survey of a nationally representative sample of U.S. municipalities to better understand existing community-level policies and practices that support healthy eating and active living. The survey collects information about policies such as nutrition standards, incentives for healthy food retail, bike/pedestrian-friendly design, and Complete Streets. About 2,000 municipalities respond to the survey. Participating municipalities receive a report that allows them to compare their policies and practices with other municipalities of similar geography, population size, and urban status.

The CBS HEAL survey was first administered in 2014 and was administered again in 2021. Data is provided in multiple formats for download including as a SAS file. A methods report and a SAS program for formatting the data are also provided.

This dataset includes live births, birth rates, and fertility rates by race of mother in the United States since 1960.

Data availability varies by race and ethnicity groups. All birth data by race before 1980 are based on race of the child. Since 1980, birth data by race are based on race of the mother. For race, data are available for Black and White births since 1960, and for American Indians/Alaska Native and Asian/Pacific Islander births since 1980. Data on Hispanic origin are available since 1989. Teen birth rates for specific racial and ethnic categories are also available since 1989. From 2003 through 2015, the birth data by race were based on the “bridged” race categories (5). Starting in 2016, the race categories for reporting birth data changed; the new race and Hispanic origin categories are: Non-Hispanic, Single Race White; Non-Hispanic, Single Race Black; Non-Hispanic, Single Race American Indian/Alaska Native; Non-Hispanic, Single Race Asian; and, Non-Hispanic, Single Race Native Hawaiian/Pacific Islander (5,6). Birth data by the prior, “bridged” race (and Hispanic origin) categories are included through 2018 for comparison.

SOURCES

NCHS, National Vital Statistics System, birth data (see https://www.cdc.gov/nchs/births.htm); public-use data files (see https://www.cdc.gov/nchs/data_access/VitalStatsOnline.htm); and CDC WONDER (see http://wonder.cdc.gov/).

REFERENCES

1. National Office of Vital Statistics. Vital Statistics of the United States, 1950, Volume I. 1954. Available from: https://www.cdc.gov/nchs/data/vsus/vsus_1950_1.pdf.

2. Hetzel AM. U.S. vital statistics system: major activities and developments, 1950-95. National Center for Health Statistics. 1997. Available from: https://www.cdc.gov/nchs/data/misc/usvss.pdf.

3. National Center for Health Statistics. Vital Statistics of the United States, 1967, Volume I–Natality. 1969. Available from: https://www.cdc.gov/nchs/data/vsus/nat67_1.pdf.

4. Martin JA, Hamilton BE, Osterman MJK, et al. Births: Final data for 2015. National vital statistics reports; vol 66 no 1. Hyattsville, MD: National Center for Health Statistics. 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_01.pdf.

5. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: Final data for 2016. National Vital Statistics Reports; vol 67 no 1. Hyattsville, MD: National Center for Health Statistics. 2018. Available from: https://www.cdc.gov/nvsr/nvsr67/nvsr67_01.pdf.

6. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Births: Final data for 2018. National vital statistics reports; vol 68 no 13. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_13.pdf.

This dataset includes teen birth rates for females by age group, race, and Hispanic origin in the United States since 1960.

Data availability varies by race and ethnicity groups. All birth data by race before 1980 are based on race of the child. Since 1980, birth data by race are based on race of the mother. For race, data are available for Black and White births since 1960, and for American Indians/Alaska Native and Asian/Pacific Islander births since 1980. Data on Hispanic origin are available since 1989. Teen birth rates for specific racial and ethnic categories are also available since 1989. From 2003 through 2015, the birth data by race were based on the “bridged” race categories (5). Starting in 2016, the race categories for reporting birth data changed; the new race and Hispanic origin categories are: Non-Hispanic, Single Race White; Non-Hispanic, Single Race Black; Non-Hispanic, Single Race American Indian/Alaska Native; Non-Hispanic, Single Race Asian; and, Non-Hispanic, Single Race Native Hawaiian/Pacific Islander (5,6). Birth data by the prior, “bridged” race (and Hispanic origin) categories are included through 2018 for comparison.

National data on births by Hispanic origin exclude data for Louisiana, New Hampshire, and Oklahoma in 1989; New Hampshire and Oklahoma in 1990; and New Hampshire in 1991 and 1992. Birth and fertility rates for the Central and South American population includes other and unknown Hispanic. Information on reporting Hispanic origin is detailed in the Technical Appendix for the 1999 public-use natality data file (see ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/Nat1999doc.pdf).

State, territorial, and county executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when individuals in states, territories, and counties were subject to executive orders, administrative orders, resolutions, and proclamations for COVID-19 that require or recommend people stay in their homes.

These data are derived from the publicly available state, territorial, and county executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly require or recommend individuals stay at home found by the CDC, COVID-19 Community Intervention and At-Risk Task Force, Monitoring and Evaluation Team & CDC, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program from March 15 through May 5, 2020. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. These data do not include mandatory business closures, curfews, or limitations on public or private gatherings. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.

This dataset contains model-based place (incorporated and census designated places) estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia —at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population estimates, and American Community Survey (ACS) 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. These data can be joined with the 2020 Census place boundary file in a GIS system to produce maps for 40 measures at the place level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7

Provisional count of deaths involving coronavirus disease 2019 (COVID-19) by United States county of occurrence, from January 1, 2020 through December 31, 2020.

NNDSS - Table II. Hepatitis (viral, acute) - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

2018 to 2020, 3-year average. Rates are age-standardized. County rates are spatially smoothed. The data can be viewed by sex and race/ethnicity. Data source: National Vital Statistics System. Additional data, maps, and methodology can be viewed on the Interactive Atlas of Heart Disease and Stroke https://www.cdc.gov/heart-disease-stroke-atlas/about/index.html

1999-2008; 2005-2008. This dataset is a de-identified summary table of vision and eye health data indicators from NHANES, stratified by all available combinations of age group, race/ethnicity, gender, and risk factor. NHANES is a program of studies conducted by the National Center for Health Statistics at CDC designed to assess the health and nutritional status of adults and children in the U.S, and combines interviews and physical examinations. NHANES stopped collecting vision and eye health data in 2008. Approximate sample size is 5,000 persons per year. NHANES data for VEHSS includes questions and examinations related to Visual Function, Vision Exam Measures, Eye Health Conditions, Service Utilization, and Examination Measures. Data were suppressed for cell sizes less than 30 persons, or where the relative standard error more than 30% of the mean. Detailed information on VEHSS NHANES analyses can be found on the VEHSS NHANES webpage (https://www.cdc.gov/visionhealth/vehss/data/national-surveys/national-health-and-nutrition-examination-survey.html). Additional information about NHANES can be found on the NHANES website (https://www.cdc.gov/nchs/nhanes/index.htm). The VEHSS NHANES dataset was last updated in June 2018.

Count and percent of total COVID-19 deaths since January 1, 2020, by age group, race/ethnicity, and sex

Interactive Quarterly Early Release Estimates provide health statistics based on data from the 2019-2022 National Health Interview Survey (NHIS) for selected health topics for adults aged 18 years and over. All estimates are unadjusted percentages based on preliminary data files and are released prior to final data editing and final weighting to provide access to the most recent information from the NHIS. Estimates presented here are based on quarterly data. Estimates based on half-year data, with groupings by demographic characteristics, are available in the Interactive Biannual Early Release Estimates. Estimates based on the 1997–2018 NHIS can be found in Previous Early Release Reports on Key Health Indicators.

This dataset provides data at the county level for the contiguous United States. It includes daily Ozone Monitoring Instrument (OMI) Population-Weighted Ultraviolet (UV) irradiance data from October 2004-2015 provided by the Environmental Remote Sensing group at the Rollins School of Public Health at Emory University. Please refer to the metadata attachment for more information.

These data are used by the CDC's National Environmental Public Health Tracking Network to generate sunlight and UV measures. Learn more about sunlight and UV on the Tracking Network's website: https://ephtracking.cdc.gov/showUVLanding.

By using these data, you signify your agreement to comply with the following requirements:

1. Use the data for statistical reporting and analysis only.
2. Do not attempt to learn the identity of any person included in the data and do not combine these data with other data for the purpose of matching records to identify individuals.
3. Do not disclose of or make use of the identity of any person or establishment discovered inadvertently and report the discovery to: trackingsupport@cdc.gov.
4. Do not imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources and CDC unless the data user and data source are formally collaborating.
5. Acknowledge, in all reports or presentations based on these data, the original source of the data and CDC.
6. Suggested citation: Centers for Disease Control and Prevention. National Environmental Public Health Tracking Network. Web. Accessed: insert date. www.cdc.gov/ephtracking.

Problems or Questions? Email trackingsupport@cdc.gov.

Interactive Biannual Early Release Estimates provide health statistics based on data from the 2019-2021 National Health Interview Survey (NHIS) for selected health topics for adults aged 18 years and over. All estimates are unadjusted percentages based on preliminary data files and are released prior to final data editing and final weighting to provide access to the most recent information from the NHIS. Estimates can be grouped by demographic characteristics (such as age, race and Hispanic origin, or sex). Estimates based on 2019-2020 NHIS quarterly data are available in Interactive Quarterly Early Release Estimates. Estimates based on the 1997–2018 NHIS can be found in Previous Early Release Reports on Key Health Indicators.

This dataset contains county-level non-medical factor measures from the American Community Survey 5-year data for the entire United States—50 states and the District of Columbia. Data were downloaded from data.census.gov using Census API and processed by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. These measures complement existing PLACES measures, including PLACES non-medical factor measures (e.g., health insurance, routine check-up). These data can be used together with PLACES data to identify which health and non-medical factor issues overlap in a community to help inform public health planning.

To access spatial data, please use the ArcGIS Online service: https://cdcarcgis.maps.arcgis.com/home/item.html?id=d51009ea78b54635be95c6ec9955ec17.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when restaurants in states and territories were subject to closing and reopening requirements through executive orders, administrative orders, resolutions, and proclamations for COVID-19. Data can be used to determine when restaurants in states and territories were subject to closing and reopening requirements through executive orders, administrative orders, resolutions, and proclamations for COVID-19. Data consists exclusively of state and territorial orders, many of which apply to specific counties within their respective state or territory; therefore, data is broken down to the county level.

These data are derived from publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly close or reopen restaurants found by the CDC, COVID-19 Community Intervention & Critical Populations Task Force, Monitoring & Evaluation Team, Mitigation Policy Analysis Unit, and the CDC, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program from March 11, 2020 through August 15, 2021. These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. Effective and expiration dates were coded using only the date provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.

1. Centers for Disease Control and Prevention (CDC). Best Practices for Comprehensive Tobacco Control Programs. Funding. CDC's Best Practices for Comprehensive Tobacco Control Programs is an evidence-based guide to help states plan and establish effective tobacco control programs to prevent and reduce tobacco use. These data update Best Practices for Comprehensive Tobacco Control Programs—2007. Data are reported at total and per capita funding levels. Data include recommended and minimum total funding levels for state programs, in addition to funding breakdowns by intervention areas such as: State and Community Interventions, Mass-Reach Health Communication Interventions, Cessation Interventions, Surveillance and Evaluation, and Infrastructure, Administration, and Management.

This dataset represents preliminary weekly hospital respiratory data and metrics aggregated to national and state/territory levels reported to CDC’s National Health Safety Network (NHSN) beginning August 2020. This dataset updates weekly on Wednesdays with preliminary data reported to NHSN for the previous reporting week (Sunday – Saturday).

Data for reporting dates through April 30, 2024 represent data reported during a previous mandated reporting period as specified by the HHS Secretary. Data for reporting dates May 1, 2024 – October 31, 2024 represent voluntarily reported data in the absence of a mandate. Data for reporting dates beginning November 1, 2024 represent data reported during a current mandated reporting period. All data and metrics capturing information on respiratory syncytial virus (RSV) were voluntarily reported until November 1, 2024. All data included in this dataset represent aggregated counts, and include metrics capturing information specific to hospital capacity, occupancy, hospitalizations, and new hospital admissions with corresponding metrics indicating reporting coverage for a given reporting week. NHSN monitors national and local trends in healthcare system stress and capacity for all acute care and critical access hospitals in the United States.

For more information on the reporting mandate per the Centers for Medicare and Medicaid Services (CMS) requirements, visit: Updates to the Condition of Participation (CoP) Requirements for Hospitals and Critical Access Hospitals (CAHs) To Report Acute Respiratory Illnesses.

For more information regarding NHSN’s collection of these data, including full reporting guidance, visit: NHSN Hospital Respiratory Data.

For data that is considered final for a given reporting week (Sunday – Saturday), and reflects that which is used in NHSN HRD dashboards for publication each Friday, visit: https://data.cdc.gov/Public-Health-Surveillance/Weekly-Hospital-Respiratory-Data-HRD-Metrics-by-Ju/ua7e-t2fy/about_data.

Source: CDC National Healthcare Safety Network (NHSN). Data source description (updated November 15, 2024): As of October 9, 2024, Hospital Respiratory Data (HRD; formerly Respiratory Pathogen, Hospital Capacity, and Supply data or 'COVID-19 hospital data') are reported to HHS through CDC's National Healthcare Safety Network (NHSN) based on updated requirements from the Centers for Medicare and Medicaid Services (CMS). These data were voluntarily reported to NHSN May 1, 2024 until November 1, 2024, at which time CMS began requiring acute care and critical access hospitals to electronically report information via NHSN about COVID-19, influenza, and RSV, hospital bed census and capacity. Hospital bed capacity and occupancy data for all patients and for patients with COVID-19 or influenza for collection dates prior to May 1, 2024, represent data reported during a previously mandated reporting

Data on delay or nonreceipt of needed medical care, nonreceipt of needed prescription drugs, or nonreceipt of needed dental care during the past 12 months due to cost by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Health Interview Survey, Family Core, Sample Child, and Sample Adult questionnaires. Data for level of difficulty are from the 2010 Quality of Life, 2011-2017 Functioning and Disability, and 2018 Sample Adult questionnaires. For more information on the National Health Interview Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

Household Pulse Survey (HPS): HPS is a rapid-response survey of adults ages ≥18 years led by the U.S. Census Bureau, in partnership with seven other federal statistical agencies, to measure household experiences during the COVID-19 pandemic. Detailed information on probability sampling using the U.S. Census Bureau’s Master Address File, questionnaires, response rates, and bias assessment is available on the Census Bureau website (https://www.census.gov/data/experimental-data-products/household-pulse-survey.html).

Data from adults age ≥18 years are collected by 20-minute online survey from randomly sampled households stratified by state and the top 15 metropolitan statistical areas (MSAs). Data are weighted to represent total persons age 18 and older living within households and to mitigate possible bias that can result from non-responses and incomplete survey frame. Data from adults age ≥18 years are collected by 20-minute online survey from randomly sampled households stratified by state and the top 15 metropolitan statistical areas (MSAs). For more information on this survey, see https://www.census.gov/programs-surveys/household-pulse-survey.html.

Data are weighted to represent total persons age 18 and older living within households and to mitigate possible bias that can result from non-responses and incomplete survey frame. Responses in the Household Pulse Survey (https://www.census.gov/programs-surveys/household-pulse-survey.html) are self-reported. Estimates of vaccination coverage may differ from vaccine administration data reported at COVID-19 Vaccinations in the United States (https://covid.cdc.gov/covid-data-tracker/#vaccinations).

Deaths involving coronavirus disease 2019 (COVID-19) by month of death, region, age, place of death, and race and Hispanic origin: May-August 2020.

All birth data by race before 1980 are based on race of the child; starting in 1980, birth data by race are based on race of the mother. Birth data are used to calculate infant mortality rate.

https://www.cdc.gov/nchs/data-visualization/mortality-trends/

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

2001-2011. The GSPS was initiated in 2000 to collect information on tobacco use, knowledge and attitudes of school personnel toward tobacco, existence and effectiveness of tobacco control policies in schools, and training and materials available for implementing tobacco prevention and control interventions.

Provisional death counts of malignant neoplasms (cancer) by month and year, and other selected demographics, for 2020-2021. Data are based on death certificates for U.S. residents.

Data on infant, neonatal, postneonatal, fetal, and perinatal mortality rates by selected characteristics of the mother. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time.

SOURCE: NCHS, National Vital Statistics System, public-use Linked Birth/Infant Death Data Set, public-use Fetal Death File, and public-use Birth File. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.

Data on hypertension in adults age 20 and older in the United States, by selected characteristics. Data are from Health, United States. SOURCE: National Center for Health Statistics, National Health and Nutrition Examination Survey. Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.

2014, 2013. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census tract-level data in GIS-friendly format can be joined with census tract spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-Boundaries/x7zy-2xmx) in a geographic information system (GIS) to produce maps of 27 measures at the census tract level.

Deaths involving coronavirus disease 2019 (COVID-19) and pneumonia reported to NCHS by jurisdiction of occurrence, place of death, and age group.

Note: The cumulative case count for some counties (with small population) is higher than expected due to the inclusion of non-permanent residents in COVID-19 case counts.

Reporting of Aggregate Case and Death Count data was discontinued on May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. Although these data will continue to be publicly available, this dataset will no longer be updated.

Aggregate Data Collection Process Since the beginning of the COVID-19 pandemic, data were reported through a robust process with the following steps:Aggregate county-level counts were obtained indirectly, via automated overnight web collection, or directly, via a data submission process.If more than one official county data source existed, CDC used a comprehensive data selection process comparing each official county data source to retrieve the highest case and death counts, unless otherwise specified by the state.A CDC data team reviewed counts for congruency prior to integration. CDC routinely compiled these data and post the finalized information on COVID Data Tracker.Cases and deaths are based on date of report and not on the date of symptom onset. CDC calculates rates in this data by using population estimates provided by the US Census Bureau Population Estimates Program (2019 Vintage).COVID-19 aggregate case and death data were organized in a time series that includes cumulative number of cases and deaths as reported by a jurisdiction on a given date. New case and death counts were calculated as the week-to-week change in reported cumulative cases and deaths (i.e., newly reported cases and deaths = cumulative number of cases/deaths reported this week minus the cumulative total reported the week before.

This process was collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provided the most up-to-date numbers on cases and deaths by report date. Throughout data collection, CDC retrospectively updated counts to correct known data quality issues. CDC also worked with jurisdictions after the end of the public health emergency declaration to finalize county data. Source: The weekly archived dataset is based on county-level aggregate count dataConfirmed/Probable Cases/Death breakdown: Cumulative cases and deaths for each county are included. Total reported cases include probable and confirmed cases.Time Series Frequency: The weekly archived dataset contains weekly time series data (i.e., one record per week per county)

Important note: The counts reflected during a given time period in this dataset may not match the counts reflected for the same time period in the daily archived dataset noted above. Discrepancies may exist due to differences between county and state COVID-19 case surveillance and reconciliation efforts.

The surveillance case definition for COVID-19, a nationally notifiable disease, was first described in a position statement from the Council for State and Territorial Epidemiologists, which was later revised. However, there is some variation in how jurisdictions implement these case classifications. More information on how CDC collects COVID-19 case surveillance data can be found at FAQ: COVID-19 Data and Surveillance.

Confirmed and Probable Counts In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, counts of confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions report

This dataset contains model-based census tract level estimates for the PLACES 2022 release in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2020 or 2019 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2022 release uses 2020 BRFSS data for 25 measures and 2019 BRFSS data for 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, and cholesterol screening) that the survey collects data on every other year. These data can be joined with the census tract 2015 boundary file in a GIS system to produce maps for 29 measures at the census tract level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software. https://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7

NNDSS - Table II. Mumps to Rabies, animal - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

1. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.

Source for 2012 national data: National Occupant Protection Use Survey (NOPUS), 2012. Source for 2012 state data: State Observational Survey of Seat Belt Use, 2012. Source for 2014 national data: National Highway Traffic Safety Administration's (NHTSA) National Occupant Protection Use Survey (NOPUS), 2014. Source for 2014 state data: National Highway Traffic Safety Administration's (NHTSA) State Observation of Seat Belt Use, 2014

Data on visits to physician offices, hospital outpatient departments and hospital emergency departments by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. Note that the data file available here has more recent years of data than what is shown in the PDF or Excel version. Data for 2017 physician office visits are not available.

SOURCE: NCHS, National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey. For more information on the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, see the corresponding Appendix entries at https://www.cdc.gov/nchs/data/hus/hus17_appendix.pdf.

NNDSS - Table IV. Tuberculosis - 2014.This Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States will exclude counts from US territories. Footnote:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. Min: Minimum. Max: Maximum. * Case counts for reporting year 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf Updated reports to the National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention. Data for TB are displayed quarterly.

Weekly COVID-19 Vaccination Coverage and intent among adults 18 Years and Older by Demographic Characteristics and Jurisdiction • Weekly estimates of COVID-19 vaccination coverage and intent among adults 18 years and older are calculated using data from the National Immunization Survey–Adult COVID Module (NIS–ACM) (https://www.cdc.gov/nis/about/).

Weekly comparisons to previous season should take into account differences between seasons in vaccine availability dates. 2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 COVID-19 vaccines were first available at the end of August 2024.

This dataset contains model-based place (incorporated and census-designated places) level estimates for the PLACES 2022 release. PLACES covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 29 measures: 13 for health outcomes, 9 for preventive services use, 4 for chronic disease-related health risk behaviors, and 3 for health status. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2020 or 2019 data, Census Bureau 2010 population data, and American Community Survey 2015–2019 estimates. The 2022 release uses 2020 BRFSS data for 25 measures and 2019 BRFSS data for 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, and cholesterol screening) that the survey collects data on every other year. More information about the methodology can be found at www.cdc.gov/places.

These data represent prevalence estimates of select chronic conditions from the National Health and Nutrition Examination Survey (NHANES).

NNDSS - Table II. Invasive Pneumococcal Diseases, All Ages - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available.

Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.

§ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.

The BEAM (Bacteria, Enterics, Amoeba, and Mycotics) Dashboard is an interactive tool to access and visualize data from the System for Enteric Disease Response, Investigation, and Coordination (SEDRIC). The BEAM Dashboard provides timely data on pathogen trends and serotype details to inform work to prevent illnesses from food and animal contact.

This dataset contains forecasted weekly numbers of reported COVID-19 incident cases, incident deaths, and cumulative deaths in the United States, previously reported on COVID Data Tracker (https://covid.cdc.gov/covid-data-tracker/#datatracker-home). These forecasts were generated using mathematical models by CDC partners in the COVID-19 Forecast Hub (https://covid19forecasthub.org/doc/ensemble/). A CDC ensemble model was produced every week using the submitted models from that week at the national, and state/territory level.

This dataset is intended to mirror the observed and forecasted data, previously available for download on the CDC’s COVID Data Tracker. Mortality forecasts for both new and cumulative reported COVID-19 deaths were produced at the state and territory level and national level. Forecasts of new reported COVID-19 cases were produced at the county, state/territory, and national level. Please note that this dataset is not complete for every model, date, location or combination thereof. Specifically, county level submissions for COVID-19 incident cases were accepted, but not required, and are missing or incomplete for many models and dates. State and territory-level forecasts are more complete, but not all models submitted forecasts for all locations, dates, and targets (new reported deaths, new reported cases, and cumulative reported deaths). Forecasts for COVID-19 incident cases were discontinued in February 2022. Forecasts for COVID-19 cumulative and incident deaths were discontinued in March 2023.

In 2020, the National Center for Health Statistics (NCHS) partnered with the Census Bureau on an experimental data system called the Household Pulse Survey. This survey was designed to complement the ability of the federal statistical system to rapidly respond and provide relevant information about how emergent issues are impacting American households. Beginning in Phase 4.0 (on January 9, 2024), questions on social support, loneliness, and social isolation were added to the survey. These questions have been included on other nationally representative surveys. Briefly, the question on social support was included on the National Health Interview Survey (NHIS) from July 2020-December 2021 and was added to the 2024 NHIS. The question on loneliness was added to the 2024 NHIS. The questions on social isolation are adapted from the Berkman-Syme Social Network Index and were included on an earlier cycle of the National Health and Nutrition Examination Survey. For more information, please visit: https://www.cdc.gov/nchs/covid19/pulse/lack-socialconnection.htm

Provisional count of deaths involving coronavirus disease 2019 (COVID-19) in the United States by week of death and by hospital referral region (HRR). HRR is determined by county of occurrence. Weekly weighted counts of deaths from all causes and due to COVID-19 are provided by HRR overall and for decedents 65 years and older. The weighted counts by HRRs are based on published methods for aggregating county-level data to HRRs. More detail about aggregating to HRRs from counties can be found in the following: https://github.com/Dartmouth-DAC/covid-19-hrr-mapping https://dartmouthatlas.org/covid-19/hrr-mapping/

NNDSS - Table II. Mumps to Rabies, animal - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.

Death counts by age and sex for years 2015-2020. Data for 2015-2019 are final. Data for 2020 are provisional.

Weekly Cumulative Influenza Vaccination Coverage, by Flu Season and Race/Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years, United States

• Influenza vaccination coverage among Medicare fee-for-service beneficiaries aged ≥65 years is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS).

• Weekly influenza vaccination coverage estimates were calculated using Kaplan-Meier survival analysis, based on beneficiaries enrolled as of August 1, 2019 and followed through May 31, 2020 for 2019-20 flu season; and enrolled as of August 1, 2020 and followed through May 31, 2021 for 2020-21 flu season; and enrolled as of Aug 1, 2021 and followed through May 28, 2022 for the 2021-22 flu season.

• Additional information about data source is available https://www2.ccwdata.org/web/guest/home/.

The Overview of Health Disparities analysis is a component of the Healthy People 2020 (HP2020) Final Review. The analysis included 611 objectives in HP2020. This file contains summary level information used for the evaluation of changes in disparities during HP2020, including calculations for the disparities measures and the disparities change categories for all objectives and population characteristics in the analysis. See Technical Notes for the Healthy People 2020 Overview of Health Disparities (https://www.cdc.gov/nchs/healthy_people/hp2020/health-disparities-technical-notes.htm) for additional information and criteria for objectives, data years, and population characteristics included in the analysis and statistical formulas and definitions for the disparities measures.

Data for additional years during the HP2020 tracking period that are not included in the Overview of Health Disparities are available on the HP2020 website (https://www.healthypeople.gov/2020/).

Note that “rate” as used may refer to a statistical rate expressed per unit population or a proportion, depending on how the HP2020 objective was defined.

NNDSS - Table II. Babesiosis to Campylobacteriosis - 2016. In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.

Note: These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting.

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

• Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.

1997-2018. Substance Abuse and Mental Health Services Administration (SAMHSA). Synar Reports: Youth Tobacco Sales. Policy – Youth Tobacco Sales. SAMHSA’s Synar Report on Youth Tobacco Sales presents findings on compliance of the Synar Amendment aimed at decreasing youth access to tobacco, and reviews progress in enforcing State youth tobacco access laws and in reducing the percentage of retailers selling tobacco products to minors.

Approximately 600 public health and clinical laboratories located throughout the United States, participate in surveillance for respiratory syncytial virus (RSV) through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). The dataset contains a weekly summary of the total RSV tests and RSV detections reported to NREVSS. These data are reported on a voluntary basis. Clinical laboratories do not report demographic data through NREVSS. Testing practices and the number of participating laboratories may change from year to year. Results can be changed two years after the initial reporting week. However, discrepancies may be noted and updated at the discretion of the data stewards and key stakeholders.

Data are collected from collaborating university and community hospital laboratories, select states and county public health laboratories, and commercial laboratories. This information is submitted and updated on a weekly basis.

While NREVSS strives to present the most precise national, regional and state respiratory viral trends with the least amount of burden possible for participating laboratories, there are a number of inherent limitations to this surveillance system.

NREVSS does not collect patient-data or demographic information. Multiple samples may be collected from a single patient, so NREVSS results do not necessarily reflect the number of patients tested nor does it reflect hospitalizations or deaths related to a particular virus.

Participating laboratories vary in size, testing capabilities, and areas served. Some institutions may receive and test samples from sites across a given state or even from multiple states. Without direct knowledge of the population base, NREVSS cannot be used to determine the prevalence or incidence of infection.

For more information on RSV surveillance and research please visit: https://www.cdc.gov/surveillance/nrevss and https://www.cdc.gov/rsv/research/us-surveillance.html

This dataset describes drug poisoning deaths at the U.S. and state level by selected demographic characteristics, and includes age-adjusted death rates for drug poisoning.

Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are defined as having ICD–10 underlying cause-of-death codes X40–X44 (unintentional), X60–X64 (suicide), X85 (homicide), or Y10–Y14 (undetermined intent).

Estimates are based on the National Vital Statistics System multiple cause-of-death mortality files (1). Age-adjusted death rates (deaths per 100,000 U.S. standard population for 2000) are calculated using the direct method. Populations used for computing death rates for 2011–2017 are postcensal estimates based on the 2010 U.S. census. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for noncensus years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.

Death rates for some states and years may be low due to a high number of unresolved pending cases or misclassification of ICD–10 codes for unintentional poisoning as R99, “Other ill-defined and unspecified causes of mortality” (2). For example, this issue is known to affect New Jersey in 2009 and West Virginia in 2005 and 2009 but also may affect other years and other states. Drug poisoning death rates may be underestimated in those instances.

REFERENCES

1. National Center for Health Statistics. National Vital Statistics System: Mortality data. Available from: http://www.cdc.gov/nchs/deaths.htm.

2. CDC. CDC Wonder: Underlying cause of death 1999–2016. Available from: http://wonder.cdc.gov/wonder/help/ucd.html.

NNDSS - Table I. infrequently reported notifiable diseases - 2018. In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. This tables excludes U.S. territories.

Notice: The case counts for Haemophilus influenzae, invasive disease Nontypeable" and "Non-b serotype" were switched for 2018 weeks 1-52.

Note: These are provisional cases of selected national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia are collated and published weekly on the NNDSS Data and Statistic web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.